,Drug_1,drug2,Level_of_interaction,Quality_of_interaction,Summary,Description
0,Glecaprevir/Pibrentasvir,Abacavir,No Interaction Expected,NA,"Coadministration has not been studied with abacavir alone but based on metabolism and clearance a clinically significant interaction is unlikely. Abacavir is metabolised by alcohol dehydrogenase and UGT, which is not expected to be affected by glecaprevir/pibrentasvir, and is renally cleared.  Glecaprevir/pibrentasvir and abacavir was evaluated as part of a Phase 1 study with Triumeq (abacavir/dolutegravir/lamivudine) and showed no clinically significant interactions.","Drug-drug interaction studies were performed with abacavir and showed no clinically significant interactions with Maviret.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.No dose adjustment is required when Mavyret is coadministered with abacavir. Coadministration of abacavir (as abacavir/dolutegravir/lamivudine, 500/50/300 mg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 12 subjects. There was no change abacavir Cmax or AUC, but Cmin increased by 31%.Mavyret Prescribing Information, AbbVie Inc., June 2019.The pharmacokinetics of glecaprevir/pibrentasvir (300/120 mg once daily) coadministered with abacavir/dolutegravir/lamivudine (600/50/300 mg once daily) was studied in 24 healthy subjects. Cmax and AUC for glecaprevir and pibrentasvir decreased by 25-28%, but there was no impact on Cmax and AUC for abacavir, dolutegravir or lamivudine. No dose adjustment is required when glecaprevir/pibrentasvir are coadministered with abacavir, dolutegravir and lamivudine.Glecaprevir and pibrentasvir interactions with combination antiretroviral regimens. Kosloski MP, Dutta S, Viani RM, et al. Conference on Retroviruses and Opportunistic Infections, Seattle, February 2017, abstract 413."
1,Glecaprevir/Pibrentasvir,Abiraterone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Abiraterone has multiple metabolic pathways and is an inhibitor of CYP2D6. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and data from ketoconazole have shown a negligible effect of CYP3A4 inhibitors on abiraterone.,(See Summary)
2,Glecaprevir/Pibrentasvir,Acalabrutinib,Potential Interaction,NA,Coadministration has not been studied. Acalabrutinib is a CYP3A4 and P-gp substrate. Acalabrutinib concentrations may increase due to mild inhibition of CYP3A4 and inhibition of P-gp by glecaprevir/pibrentasvir which may result in increased toxicity. On treatment monitoring is recommended.,(See Summary)
3,Glecaprevir/Pibrentasvir,Acamprosate,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as acamprosate does not undergo significant metabolism.,(See Summary)
4,Glecaprevir/Pibrentasvir,Acarbose,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. After ingestion of acarbose the majority of active unchanged drug remains in the lumen of the gastrointestinal tract to exert its pharmacological effect and is metabolised by intestinal enzymes and by the gut microflora.,(See Summary)
5,Glecaprevir/Pibrentasvir,Acebutolol,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Acebutolol is mainly excreted in the urine as the diacetol metabolite, which is not mediated by CYP450.",(See Summary)
6,Glecaprevir/Pibrentasvir,Aceclofenac,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aceclofenac is metabolised by CYP2C9 which is not affected by glecaprevir/pibrentasvir.,(See Summary)
7,Glecaprevir/Pibrentasvir,Acenocoumarol,Potential Interaction,NA,"Coadministration has not been studied. Acenocoumarol is metabolised by CYP2C9 (major) and CYP1A2. Glecaprevir/pibrentasvir is a mild inhibitor of CYP1A2 and clinically significant interactions are unlikely. However, as acenocoumarol has a narrow therapeutic index and concentrations may increase, close monitoring of INR and other adverse effects is recommended.","Coadministration has not been studied. As liver function may change during treatment with Maviret, a close monitoring of International Normalised Ratio (INR) values is recommended with vitamin K antagonists.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019."
8,Glecaprevir/Pibrentasvir,Acetazolamide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as acetazolamide is excreted unchanged in urine.,(See Summary)
9,Glecaprevir/Pibrentasvir,Aciclovir,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aciclovir is eliminated primarily unchanged in the urine via glomerular filtration and active renal secretion. It is transported by OCT3 which is not expected to be affected by glecaprevir/pibrentasvir,(See Summary)
10,Glecaprevir/Pibrentasvir,Acitretin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Acitretin undergoes isomerisation and glucuronidation which are not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
11,Glecaprevir/Pibrentasvir,Activated charcoal,Potential Weak Interaction,NA,"Coadministration has not been studied. Activated charcoal absorbs substances in the stomach and intestines and may decrease absorption of orally administered medications. If coadministration is required, administration of activated charcoal and glecaprevir/pibrentasvir should be separated by 4 hours. [Note: this interaction is not specific for glecaprevir/pibrentasvir, but for any medication taken with activated charcoal.]",(See Summary)
12,Glecaprevir/Pibrentasvir,Adefovir,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glecaprevir/pibrentasvir is metabolised by and is a weak inhibitor of CYP3A4. The potential for hepatically metabolised interactions with adefovir is low. Adefovir is largely excreted unchanged via renal glomerular filtration and active renal secretion by OAT1, which are not expected to be affected by glecaprevir/pibrentasvir. ",(See Summary)
13,Glecaprevir/Pibrentasvir,Agomelatine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Agomelatine is metabolized predominantly by CYP1A2 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP1A2 and is unlikely to affect the exposure of agomelatine to any clinically significant extent. [Note, agomelatine is contraindicated in hepatic impairment as increases in exposure of 140-fold have been seen in cirrhotic patients.]",(See Summary)
14,Glecaprevir/Pibrentasvir,Albendazole,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Albendazole is metabolized in part by CYP3A4, but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of albendazole to any clinically significant extent.",(See Summary)
15,Glecaprevir/Pibrentasvir,Albiglutide,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Albiglutide is a protein for which the expected metabolic pathway is degradation to small peptides and individual amino acids by ubiquitous proteolytic enzymes. However, as albiglutide slows gastric emptying it is advisable to take glecaprevir/pibrentasvir at least 1 hour before an albiglutide injection. [Note: this interaction is not specific for glecaprevir/pibrentasvir, but for any medication taken with albiglutide.]",(See Summary)
16,Glecaprevir/Pibrentasvir,Alemtuzumab,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as alemtuzumab is a protein for which the expected metabolic pathway is degradation to small peptides and individual amino acids by widely distributed proteolytic enzymes.,(See Summary)
17,Glecaprevir/Pibrentasvir,Alendronic acid,No Interaction Expected,NA,"Coadministration has not been studied but alendronate can be administered with glecaprevir/pibrentasvir and no dose alteration is required. Alendronate is not metabolised and is cleared from the plasma by uptake into bone and elimination via renal excretion. Although no pharmacokinetic interaction is expected, alendronate should be separated from food or other medicinal products and therefore should be separated from glecaprevir/pibrentasvir administration. [Note: this interaction is not specific for glecaprevir/pibrentasvir, but for any medication taken with alendronic acid.]",(See Summary)
18,Glecaprevir/Pibrentasvir,Alfentanil,Potential Interaction,NA,"Coadministration has not been studied. Concentrations of alfentanil may increase due to mild CYP3A4 inhibition by glecaprevir/pibrentasvir. Due to the narrow therapeutic index of alfentanil, patients should be monitored closely for adverse effects including respiratory depression. Dose reduction may be required.",(See Summary)
19,Glecaprevir/Pibrentasvir,Alfuzosin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alfuzosin is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of alfuzosin to any clinically significant extent.,(See Summary)
20,Glecaprevir/Pibrentasvir,Aliskiren,Do Not Coadminister,NA,Coadministration has not been studied. Aliskiren is a substrate of P-gp and concentrations may increase due to inhibition of P-gp by glecaprevir/pibrentasvir. Concomitant use with aliskiren is not recommended.,(See Summary)
21,Glecaprevir/Pibrentasvir,Allopurinol,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as allopurinol is metabolised by xanthine oxidase. [Note, the European SmPC and US Prescribing Information for allopurinol recommend a reduced dose in hepatic impairment.]",(See Summary)
22,Glecaprevir/Pibrentasvir,Almotriptan,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro studies indicate a minor role for CYP3A4 and CYP2D6 in the metabolism of almotriptan. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of almotriptan to any clinically significant extent.,(See Summary)
23,Glecaprevir/Pibrentasvir,Aloe vera,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aloe vera is only a weak inhibitor of CYPs in vitro and therefore is unlikely to cause clinically significant interactions. It does not inhibit P-gp and there is no evidence to suggest it impacts UGTs.,(See Summary)
24,Glecaprevir/Pibrentasvir,Alogliptin ,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alogliptin does not undergo extensive metabolism and is excreted mainly unchanged in the urine and metabolism by CYPs is minimal. No transporter interactions have been described.,(See Summary)
25,Glecaprevir/Pibrentasvir,Alprazolam,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alprazolam is mainly metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of alprazolam to any clinically significant extent.,(See Summary)
26,Glecaprevir/Pibrentasvir,Aluminium hydroxide,No Interaction Expected,NA,Antacids can be administered with glecaprevir/pibrentasvir and no dose alteration is required. ,(See Summary)
27,Glecaprevir/Pibrentasvir,Alverine citrate,No Interaction Expected,NA,"Coadministration has not been studied but based on limited understanding of metabolism and clearance a clinically significant interaction is unlikely. However as alverine citrate affects gastric motility, an effect on the absorption of glecaprevir/pibrentasvir cannot be ruled out. Doses of glecaprevir/pibrentasvir and alverine should be separated by 4 hours if possible. [Note: this interaction is not specific for glecaprevir/pibrentasvir, but for any medication taken with alverine citrate.]",(See Summary)
28,Glecaprevir/Pibrentasvir,Amantadine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amantadine is only metabolized to a minor extent (principally N-acetylation) and is largely excreted unchanged in urine.,(See Summary)
29,Glecaprevir/Pibrentasvir,Ambrisentan,Potential Interaction,NA,"Coadministration has not been studied. Ambrisentan is a substrate for P-gp and is glucuronidated by several UGT isoenzymes, and also undergoes oxidative metabolism mainly by CYP3A4 (and to a lesser extent by CYP3A5 and CYP2C19). Ambrisentan concentrations may increase due to inhibition of P-gp by glecaprevir/pibrentasvir. ",(See Summary)
30,Glecaprevir/Pibrentasvir,Amikacin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as amikacin is largely excreted unchanged renally via glomerular filtration.,(See Summary)
31,Glecaprevir/Pibrentasvir,Amiloride,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amiloride is not metabolized by the liver but is excreted unchanged by the kidneys, with approximately 50% of an oral dose excreted in urine. ",(See Summary)
32,Glecaprevir/Pibrentasvir,Amiodarone,Potential Interaction,NA,"Coadministration has not been studied. Concentrations of amiodarone may increase due to inhibition of P-gp and weak inhibition of CYP3A4 by glecaprevir/pibrentasvir. As amiodarone has a narrow therapeutic index and unpredictable therapeutic levels, monitor patients closely for signs and symptoms of toxicity. Use with caution and consider therapeutic drug monitoring and/or ECGs during treatment.",(See Summary)
33,Glecaprevir/Pibrentasvir,Amisulpride,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amisulpride is largely excreted unchanged in urine and undergoes relatively little metabolism.,(See Summary)
34,Glecaprevir/Pibrentasvir,Amitriptyline,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amitriptyline is metabolised predominantly by CYP2D6 and CYP2C19 which are not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
35,Glecaprevir/Pibrentasvir,Amlodipine,No Interaction Expected,NA,"Coadministration has not been studied. Amlodipine is metabolized by CYP3A4 and is a mild inhibitor of CYP3A4. Glecaprevir/pibrentasvir are metabolised by CYP3A4 and transported by P-gp. Although amlodipine may increase glecaprevir/pibrentasvir concentrations, this is unlikely to be of clinical significance. Increased concentrations of amlodipine may be seen by weak inhibition of CYP3A4 by glecaprevir/pibrentasvir but this is also unlikely to be clinically significant.","Drug-drug interaction studies were performed with amlodipine and showed no clinically significant interactions with Maviret.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.No dose adjustment is required when Mavyret is coadministered with amlodipine.Mavyret Prescribing Information, AbbVie Inc., June 2019."
36,Glecaprevir/Pibrentasvir,Amobarbital,Do Not Coadminister,NA,Coadministration has not been studied and is not recommended. Amobarbital induces CYP3A4 and P-gp and could decrease concentrations of glecaprevir/pibrentasvir. This may result in loss of efficacy and potential virological failure.,(See Summary)
37,Glecaprevir/Pibrentasvir,Amodiaquine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amodiaquine is metabolised by CYP2C8 which is not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
38,Glecaprevir/Pibrentasvir,Amoxicillin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amoxicillin is renally excreted unchanged by glomerular filtration and tubular secretion.,(See Summary)
39,Glecaprevir/Pibrentasvir,Amphetamine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amphetamine is metabolised by CYP2D6 which is not expected to be affected by glecaprevir/pibrentasvir. ,(See Summary)
40,Glecaprevir/Pibrentasvir,Amphotericin B,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as amphotericin B is mainly excreted in the urine.,(See Summary)
41,Glecaprevir/Pibrentasvir,Ampicillin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ampicillin is renally excreted unchanged by glomerular filtration and tubular secretion.,(See Summary)
42,Glecaprevir/Pibrentasvir,Anagrelide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Angarelide is metabolised by CYP1A2 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP1A2 and is unlikely to affect the exposure of anagrelide to any clinically significant extent.,(See Summary)
43,Glecaprevir/Pibrentasvir,Anastrozole,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Anastrozole is metabolized by multiple enzyme pathways and a clinically significant interaction is not expected.,(See Summary)
44,Glecaprevir/Pibrentasvir,Anidulafungin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as anidulafungin is not hepatically metabolized and there are no known transporter interactions.,(See Summary)
45,Glecaprevir/Pibrentasvir,Antacids,No Interaction Expected,NA,Antacids can be administered with glecaprevir/pibrentasvir and no dose alteration is required. ,(See Summary)
46,Glecaprevir/Pibrentasvir,Apixaban,Potential Interaction,NA,"Coadministration has not been studied. Apixaban is metabolized mainly by CYP3A4/5 (with minor contributions from CYPs 1A2, 2C8, 2C9, 2C19, and 2J2) and is a substrate of P-gp and BCRP. Concentrations of apixaban may increase due to strong inhibition of P-gp by glecaprevir/pibrentasvir, and inhibition of BCRP. Use with caution. Close monitoring for increased apixaban side effects is recommended. ",(See Summary)
47,Glecaprevir/Pibrentasvir,Aprepitant,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aprepitant is a substrate, a moderate inhibitor, and an inducer of CYP3A4. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and no significant effect on aprepitant is likely. During treatment with aprepitant, CYP3A4 is inhibited although this is unlikely to have a clinically significant effect on glecaprevir/pibrentasvir due to the large therapeutic safety margins. Note, following cessation of aprepitant, glecaprevir/pibrentasvir concentrations may decrease due to short-term mild induction of CYP2C9, CYP3A4 and glucuronidation, though any effect should be transient.",(See Summary)
48,Glecaprevir/Pibrentasvir,Aripiprazole,Potential Interaction,NA,"Coadministration has not been studied. Aripiprazole is metabolised by CYP3A4 and concentrations may increase due to weak inhibition of CYP3A4 by glecaprevir/pibrentasvir. As aripiprazole has a narrow therapeutic index and unpredictable therapeutic levels, monitor patients closely for signs and symptoms of toxicity.",(See Summary)
49,Glecaprevir/Pibrentasvir,Artemether,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Artemether is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of artemether to any clinically significant extent.,(See Summary)
50,Glecaprevir/Pibrentasvir,Artemisinin,No Interaction Expected,NA,"Coadministration has not been studied. Artemisinins undergo rapid metabolism via several CYP450 (CYPs 3A4, 2A6, 2B6). The active metabolite (dihydroartemisinin, which has greater potency than the parent drug) is further metabolized via UGTs 1A9 and 2B7 and has been shown to induce CYP3A4. This is unlikely to have a clinically significant effect on glecaprevir/pibrentasvir due to the large therapeutic safety margins.",(See Summary)
51,Glecaprevir/Pibrentasvir,Artesunate,No Interaction Expected,NA,Coadministration has not been studied. Dihydroartemisinin (the active metabolite of artesunate) is further metabolised via UGTs 1A9 and 2B7 and has been shown to induce CYP3A4. This is unlikely to have a clinically significant effect on glecaprevir/pibrentasvir due to the large therapeutic safety margins.,(See Summary)
52,Glecaprevir/Pibrentasvir,Ascorbic acid (Vitamin C),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ascorbic acid is largely hydrolysed to salicylic acid followed by conjugation with either glycine or glucuronic acid.,(See Summary)
53,Glecaprevir/Pibrentasvir,Asenapine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Asenapine is metabolized by glucuronidation (UGT1A4) and oxidative metabolism (mainly CYP1A2, with minor contributions from CYP3A4 and CYP2D6). As asenapine is metabolised by multiple pathways, a clinically significant effect is unlikely.",(See Summary)
54,Glecaprevir/Pibrentasvir,Aspirin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as aspirin is metabolised by deacetylation and UGT2B7 conjugation.,(See Summary)
55,Glecaprevir/Pibrentasvir,Astemizole,Potential Interaction,NA,"Coadministration has not been studied. Astemizole is metabolised by CYP3A4 and glecaprevir/pibrentasvir is only a weak inhibitor CYP3A4. Although clinically significant interaction is unlikely, use with caution as astemizole has a narrow therapeutic index and has been discontinued in many countries.",(See Summary)
56,Glecaprevir/Pibrentasvir,Atazanavir alone,Do Not Coadminister,NA,"Coadministration has not been studied and is contraindicated. Coadministration of glecaprevir/pibrentasvir with OATP1B inhibitors, such as atazanavir, is contraindicated due to increased risk of ALT elevations. Coadministration of atazanavir/ritonavir (300/100 mg once daily) and glecaprevir/pibrentasvir increased glecaprevir Cmax, AUC and Cmin by at least 4.06-fold, 6.53-fold and 14.3-fold, respectively. Pibrentasvir Cmax, AUC and Cmin increased by at least 29%, 64% and 129%, respectively (n=12).","Coadministration of atazanavir/ritonavir (300/100 mg once daily) and glecaprevir/pibrentasvir increased glecaprevir Cmax, AUC and Cmin by at least 4.06-fold, 6.53-fold and 14.3-fold, respectively. Pibrentasvir Cmax, AUC and Cmin increased by at least 29%, 64% and 129%, respectively. (Effect of atazanavir and ritonavir on the first dose of glecaprevir and pibrentasvir is reported.) Co-administration with atazanavir is contraindicated due to the risk of ALT elevations.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Mavyret is contraindicated with atazanavir. Coadministration of atazanavir/ritonavir (300/100 mg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 12 subjects. Glecaprevir Cmax, AUC and Cmin increased by at least 4.06-fold, 6.53-fold and 14.3-fold, respectively. Pibrentasvir Cmax, AUC and Cmin increased by at least 29%, 64% and 129%, respectively. (Effect of atazanavir and ritonavir on the first dose of glecaprevir and pibrentasvir is reported.) Mavyret Prescribing Information, AbbVie Inc., June 2019."
57,Glecaprevir/Pibrentasvir,Atazanavir/cobicistat,Do Not Coadminister,NA,"Coadministration has not been studied and is contraindicated. Concomitant use of glecaprevir/pibrentasvir with OATP1B inhibitors, such as atazanavir, is contraindicated due to increased risk of ALT elevations. Coadministration of atazanavir/ritonavir (300/100 mg once daily) and glecaprevir/pibrentasvir increased glecaprevir Cmax, AUC and Cmin by at least 4.06-fold, 6.53-fold and 14.3-fold, respectively. Pibrentasvir Cmax, AUC and Cmin increased by at least 29%, 64% and 129%, respectively (n=12).","Coadministration of atazanavir/ritonavir (300/100 mg once daily) and glecaprevir/pibrentasvir increased glecaprevir Cmax, AUC and Cmin by at least 4.06-fold, 6.53-fold and 14.3-fold, respectively. Pibrentasvir Cmax, AUC and Cmin increased by at least 29%, 64% and 129%, respectively. (Effect of atazanavir and ritonavir on the first dose of glecaprevir and pibrentasvir is reported.) Co-administration with atazanavir is contraindicated due to the risk of ALT elevations.Co-administration of Maviret with medicinal products that inhibit P-gp and BCRP (e.g. cobicistat) may slow elimination of glecaprevir and pibrentasvir and thereby increase plasma exposure of the antivirals.Coadministration of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide with glecaprevir/pibrentasvir was studied. Glecaprevir Cmax, AUC and Cmin increased by 150%, 205% and 358%, respectively. Pibrentasvir Cmax was unchanged but AUC and Cmin increased by 57% and 89%, respectively. The mechanism is P-gp, BCRP and OATP inhibition by cobicistat and OATP inhibition by elvitegravir.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Mavyret is contraindicated with atazanavir. Coadministration of atazanavir/ritonavir (300/100 mg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 12 subjects. Glecaprevir Cmax, AUC and Cmin increased by at least 4.06-fold, 6.53-fold and 14.3-fold, respectively. Pibrentasvir Cmax, AUC and Cmin increased by at least 29%, 64% and 129%, respectively. (Effect of atazanavir and ritonavir on the first dose of glecaprevir and pibrentasvir is reported.) Coadministration is contraindicated due to increased risk of ALT elevations.Mavyret Prescribing Information, AbbVie Inc., June 2019."
58,Glecaprevir/Pibrentasvir,Atazanavir + ritonavir,Do Not Coadminister,NA,"Coadministration of glecaprevir/pibrentasvir with OATP1B inhibitors, such as atazanavir, is contraindicated due to increased risk of ALT elevations. Coadministration of atazanavir/ritonavir (300/100 mg once daily) and glecaprevir/pibrentasvir increased glecaprevir Cmax, AUC and Cmin by at least 4.06-fold, 6.53-fold and 14.3-fold, respectively. Pibrentasvir Cmax, AUC and Cmin increased by at least 29%, 64% and 129%, respectively (n=12).","Coadministration of atazanavir/ritonavir (300/100 mg once daily) and glecaprevir/pibrentasvir increased glecaprevir Cmax, AUC and Cmin by at least 4.06-fold, 6.53-fold and 14.3-fold, respectively. Pibrentasvir Cmax, AUC and Cmin increased by at least 29%, 64% and 129%, respectively. (Effect of atazanavir and ritonavir on the first dose of glecaprevir and pibrentasvir is reported.) Co-administration with atazanavir is contraindicated due to the risk of ALT elevations.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Mavyret is contraindicated with atazanavir. Coadministration of atazanavir/ritonavir (300/100 mg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 12 subjects. Glecaprevir Cmax, AUC and Cmin increased by at least 4.06-fold, 6.53-fold and 14.3-fold, respectively. Pibrentasvir Cmax, AUC and Cmin increased by at least 29%, 64% and 129%, respectively. (Effect of atazanavir and ritonavir on the first dose of glecaprevir and pibrentasvir is reported.) Coadministration is contraindicated due to increased risk of ALT elevations.Mavyret Prescribing Information, AbbVie Inc., June 2019."
59,Glecaprevir/Pibrentasvir,Atenolol,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Atenolol is mainly eliminated unchanged in the kidney, predominantly by glomerular filtration with some involvement of OAT1 which is not affected by glecaprevir/pibrentasvir.",(See Summary)
60,Glecaprevir/Pibrentasvir,Atomoxetine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Atomoxetine is metabolised by CYP2D6 which is not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
61,Glecaprevir/Pibrentasvir,Atorvastatin,Do Not Coadminister,NA,"Coadministration of glecaprevir/pibrentasvir and atorvastatin (10 mg single dose) increased atorvastatin AUC by 8.28-fold and increased Cmax by 22-fold. Coadministration is not recommended due to increased levels of atorvastatin, caused by inhibition of OATP1B1, P-gp and BCRP by glecaprevir/pibrentasvir.","Concomitant use with atorvastatin is contraindicated. Co-administration with Maviret may increase plasma concentrations of medicinal products that are substrates of OATP1B1/3 (e.g. atorvastatin).Coadministration of atorvastatin (10 mg once daily) and glecaprevir/pibrentasvir increased atorvastatin Cmax and AUC by 22-fold and 8.28-fold due to inhibition of OATP1B1/3, P-gp, BCRP and CYP3A. Co-administration with atorvastatin is contraindicated.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Coadministration of atorvastatin (10 mg once daily) and glecaprevir/pibrentasvir (400/120 mg once daily) was studied in 11 subjects. Atorvastatin Cmax and AUC increased by 22-fold and 8.28-fold. Increased statin concentrations may increase the risk of myopathy, including rhabdomyolysis. Coadministration with this statin is not recommended.Mavyret Prescribing Information, AbbVie Inc., June 2019."
62,Glecaprevir/Pibrentasvir,Atovaquone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as atovaquone is mainly eliminated unchanged in the faeces.,(See Summary)
63,Glecaprevir/Pibrentasvir,Atropine,No Interaction Expected,NA,"Coadministration has not been studied. Atropine metabolism has not been well described but is thought to be by oxidation and conjugation to inactive metabolites and up to 50% is excreted unchanged by the kidneys. A clinically significant interaction is unlikely; however, atropine may alter the absorption of glecaprevir/pibrentasvir by possibly delaying gastric emptying but the clinical significance of this is unknown.",(See Summary)
64,Glecaprevir/Pibrentasvir,Avelumab,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Avelumab is primarily metabolised through catabolic pathways and drug-drug interactions are not expected.,(See Summary)
65,Glecaprevir/Pibrentasvir,Axitinib,Potential Weak Interaction,NA,Coadministration has not been studied. Axitinib is metabolised by CYP3A4. Glecaprevir is a mild inhibitor of CYP3A4 and therefore could potentially increase axitinib exposure. The clinical relevance of this interaction is unknown. No a priori dosage adjustment is recommended for axitinib.,(See Summary)
66,Glecaprevir/Pibrentasvir,Azathioprine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. (Note, azathioprine interacts with ribavirin and if ribavirin is part of the regimen it is important to refer to the product information for ribavirin and azathioprine.)",(See Summary)
67,Glecaprevir/Pibrentasvir,Azilsartan,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Azilsartan is predominantly metabolised by CYP2C9 which is not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
68,Glecaprevir/Pibrentasvir,Azithromycin,No Interaction Expected,NA,"Coadministration has not been studied. Data suggest that azithromycin may be a substrate for P-gp and concentrations may increase due to inhibition of P-gp by glecaprevir/pibrentasvir. However, this is unlikely to be clinically significant due to azithromycin’s wide therapeutic index.",(See Summary)
69,Glecaprevir/Pibrentasvir,Aztreonam,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Aztreonam is only minimally metabolised and is eliminated mainly unchanged in the urine.,(See Summary)
70,Glecaprevir/Pibrentasvir,Baclofen,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Baclofen is mainly excreted in the urine or deaminated.,(See Summary)
71,Glecaprevir/Pibrentasvir,Basiliximab,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Basiliximab is an immunoglobulin and no metabolic drug-drug interactions are expected. Extensive studies have been carried out with concomitant medication showing no adverse effects.,(See Summary)
72,Glecaprevir/Pibrentasvir,Beclometasone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Beclomethasone is metabolised by hydrolysis to beclomethasone 17-monopropionate in vivo although it is a substrate of CYP3A4 in vitro. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of beclometasone to any clinically significant extent.,(See Summary)
73,Glecaprevir/Pibrentasvir,Bedaquiline,Potential Interaction,NA,"Coadministration has not been studied. Bedaquiline is metabolized by CYP3A4 and concentrations may increase due to weak inhibition of CYP3A4 by glecaprevir/pibrentasvir. Caution is advised due to the narrow therapeutic index of bedaquiline and risk of serious adverse effects. If coadministration is required, more frequent ECG monitoring and monitoring of transaminases is recommended.",(See Summary)
74,Glecaprevir/Pibrentasvir,Benazepril,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as benazepril is glucuronidated and renally cleared.,(See Summary)
75,Glecaprevir/Pibrentasvir,Bendroflumethiazide,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bendroflumethiazide is mainly eliminated by hepatic metabolism, although the exact pathway is not known. It is unlikely that CYP enzymes are involved in this process and no transporter interactions have been described.",(See Summary)
76,Glecaprevir/Pibrentasvir,Benralizumab,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Benralizumab is a humanised IgG1 monoclonal antibody that is degraded by proteolytic enzymes widely distributed in the body and not restricted to hepatic tissue.",(See Summary)
77,Glecaprevir/Pibrentasvir,Benztropine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Benztropine is primarily metabolised by CYP2D6 which is not affected by glecaprevir/pibrentasvir.,(See Summary)
78,Glecaprevir/Pibrentasvir,Benzylpenicillin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as benzylpenicillin is mainly excreted in the urine.,(See Summary)
79,Glecaprevir/Pibrentasvir,Bepridil,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bepridil is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of bepridil to any clinically significant extent.,(See Summary)
80,Glecaprevir/Pibrentasvir,Betahistine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Betahistine undergoes nearly complete metabolism by monoamine oxidase. Based on in-vitro data, no inhibition of cytochrome P450 enzymes by betahistine is expected.",(See Summary)
81,Glecaprevir/Pibrentasvir,Betamethasone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Betamethasone is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of betamethasone to any clinically significant extent.,(See Summary)
82,Glecaprevir/Pibrentasvir,Bevacizumab,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bevacizumab biotransformation involves proteolytic catabolism throughout the body, including endothelial cells, and does not rely primarily on elimination through the kidneys and liver.",(See Summary)
83,Glecaprevir/Pibrentasvir,Bezafibrate,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bezafibrate is metabolised by hydroxylation, glucuronidation and renal elimination (~50%). Due to the involvement of multiple metabolic pathways and renal elimination, a clinically significant interaction is not expected with glecaprevir/pibrentasvir. [Note, the European SmPC for bezafibrate contraindicates its use in significant hepatic disease.]",(See Summary)
84,Glecaprevir/Pibrentasvir,Bictegravir/ Emtricitabine/Tenofovir alafenamide (BIC/FTC/TAF),Potential Weak Interaction,NA,"Coadministration has not been studied. Bictegravir is a substrate of P-gp and concentrations may increase, but to a modest extent, as glecaprevir/pibrentasvir inhibits P-gp. Coadministration of bictegravir with darunavir/cobicistat (a strong CYP3A4 and P-gp inhibitor) increased bictegravir exposure by 74%. This increase is unlikely to be clinically significant; available dose exposure data, as well as data from phase 2 and phase 3 studies (48 weeks treatment), have shown a good safety profile with up to a 2.4 fold increase in bictegravir AUC. Studies performed with emtricitabine or tenofovir alafenamide showed no clinically significant interactions with glecaprevir/pibrentasvir. Note, the European product label for Biktarvy (bictegravir/FTVC/TAF) indicates that coadministration of glecaprevir may increase bictegravir plasma concentrations and recommends caution.","Drug-drug interaction studies were performed with tenofovir alafenamide and showed no clinically significant interactions with Maviret.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.No dose adjustment is required when Mavyret is coadministered with emtricitabine and tenofovir alafenamide.Mavyret Prescribing Information, AbbVie Inc., June 2019."
85,Glecaprevir/Pibrentasvir,Bilastine,Potential Weak Interaction,NA,Coadministration has not been studied but may increase concentrations of bilastine due to inhibition of P-gp by glecaprevir/pibrentasvir. No a priori dose modification is recommended but monitoring for signs and symptoms of increased bilastine exposure is recommended.,(See Summary)
86,Glecaprevir/Pibrentasvir,Bimatoprost,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. No interactions are anticipated since although the drug is metabolised, the systemic concentrations of bimatoprost are extremely low (less than 0.2 ng/ml) following ocular dosing with bimatoprost.",(See Summary)
87,Glecaprevir/Pibrentasvir,Biperiden,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Although limited human data suggest biperiden undergoes hydroxylation in the liver there are no known or documented interactions with other drugs that have an effect on metabolism or transport. ,(See Summary)
88,Glecaprevir/Pibrentasvir,Bisacodyl,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Absorption of bisacodyl from the GI tract is minimal and the small amount absorbed is excreted in the urine as the glucuronide. However, bisacodyl increases colonic mass movements and may affect absorption of glecaprevir/pibrentasvir. The potential interaction can be resolved by giving bisacodyl at least 4 hours after glecaprevir/pibrentasvir. [Note: this interaction is not specific for glecaprevir/pibrentasvir, but for any medication taken with bisacodyl.]",(See Summary)
89,Glecaprevir/Pibrentasvir,Bisoprolol,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bisoprolol is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of bisoprolol to any clinically significant extent. [Note, the European product label for bisoprolol recommends a maximum of 10 mg in severe hepatic impairment whereas the US Prescribing Information recommends an initial 2.5 mg in hepatic impairment with caution in further dose titration.]",(See Summary)
90,Glecaprevir/Pibrentasvir,Black cohosh (Actaea racemosa),No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Black cohosh does not appear to be involved in drug metabolism to a clinically significant effect. Standardized black cohosh supplements, when taken at recommended doses, pose little risk for herb-drug interactions.",(See Summary)
91,Glecaprevir/Pibrentasvir,Blinatumomab,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. An indirect effect of blinatumomab on CYPs may occur due to transient release of cytokines during the first days of therapy which can inhibit CYP450 metabolism however, a clinically relevant interaction is unlikely. The metabolic pathway of blinatumomab has not been characterised. Like other protein therapeutics, blinatumomab is expected to be degraded into small peptides and amino acids via catabolic pathways.",(See Summary)
92,Glecaprevir/Pibrentasvir,Bortezomib,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bortezomib is metabolized by and is a weak inhibitor of CYPs 1A2, 2C9, 2C19, 2D6 and 3A4. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of bortezomib to any clinically significant extent.",(See Summary)
93,Glecaprevir/Pibrentasvir,Bosentan,Do Not Coadminister,NA,"Coadministration is not recommended. Coadministration of glecaprevir/pibrentasvir with bosentan, a moderate CYP3A inducer, may decrease concentrations of glecaprevir/pibrentasvir, leading to reduced therapeutic effect.",(See Summary)
94,Glecaprevir/Pibrentasvir,Bosutinib,Potential Interaction,NA,Coadministration has not been studied. Bosutinib is metabolised principally by CYP3A4 and concentrations may increase as glecaprevir is a weak inhibitor of CYP3A4. This may result in adverse effects. Use with caution.,(See Summary)
95,Glecaprevir/Pibrentasvir,Brentuximab vedotin,Potential Weak Interaction,NA,"Coadministration has not been studied. Brentuximab vedotin releases the active species MMAE within the tumour cell; MMAE is a substrate of CYP3A4 and possibly CYP2D6 and a weak inhibitor of CYP3A4. Glecaprevir is a mild inhibitor of CYP3A4 and may increase concentrations of MMAE and the incidence of neutropenia, but this is unlikely to be clinically relevant. No a priori dose adjustment is recommended but patients should be monitored for adverse reactions.",(See Summary)
96,Glecaprevir/Pibrentasvir,Brinzolamide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Brinzolamide is metabolised by CYP3A4 which is not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
97,Glecaprevir/Pibrentasvir,Brivudine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Brivudine is an analog of thymidine and is incorporated into viral DNA. The metabolism of brivudine is poorly described but to date there is no evidence of CYP or transporter involvement.,(See Summary)
98,Glecaprevir/Pibrentasvir,Brodalumab,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Brodalumab is degraded into small peptides. Brodalumab may modulate serum levels of some cytokines and may modestly increase the exposure of CYP450 substrates such as glecaprevir/pibrentasvir. However, based on data with midazolam (AUC increased by 24%), this is unlikely to be clinically significant.",(See Summary)
99,Glecaprevir/Pibrentasvir,Bromazepam,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bromazepam is a substrate of CYP1A2 and CYP2D6 which are not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
100,Glecaprevir/Pibrentasvir,Bromocriptine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bromocriptine is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of bromocriptine to any clinically significant extent.,(See Summary)
101,Glecaprevir/Pibrentasvir,Bromperidol,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bromperidol is a metabolized by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of bromperidol to any clinically significant extent.,(See Summary)
102,Glecaprevir/Pibrentasvir,Budesonide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Budesonide is metabolised via CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of budesonide to any clinically significant extent.,(See Summary)
103,Glecaprevir/Pibrentasvir,Bumetanide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bumetanide is mainly excreted in the urine and is not transported by OATP.,(See Summary)
104,Glecaprevir/Pibrentasvir,Bupivacaine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bupivacaine is metabolised by UGT, CYPs 1A2 and 3A4, and amide hydrolysis which are not expected to be affected by glecaprevir/pibrentasvir.",(See Summary)
105,Glecaprevir/Pibrentasvir,Buprenorphine,No Interaction Expected,NA,"Coadministration of glecaprevir/pibrentasvir (300/120 mg once daily) and buprenorphine/naloxone was studied in 12 subjects on individualized regimens of buprenorphine/naloxone. Dose normalized Cmax, AUC and C24 were slightly increased for buprenorphine (8%, 17% and 24%) and norbuprenorphine (25%, 30% and 21%). Naloxone dose-normalised Cmax and AUC were minimally affected (12% change or less). These changes were not considered clinically significant. Exposures of glecaprevir and pibrentasvir were similar to the observed values in previous studies. No dose adjustment is required.","Drug-drug interaction studies were performed with buprenorphine and showed no clinically significant interactions with Maviret.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.No dose adjustment is required when Mavyret is coadministered with buprenorphine.Mavyret Prescribing Information, AbbVie Inc., June 2019.Coadministration of glecaprevir/pibrentasvir (300/120 mg once daily) and buprenorphine/naloxone was studied in 12 subjects on individualized regimens of buprenorphine/naloxone. Dose normalized Cmax, AUC and C24 were slightly increased for buprenorphine (8%, 17% and 24%) and norbuprenorphine (25%, 30% and 21%). Naloxone dose-normalised Cmax and AUC were minimally affected (12% change or less). Exposures of glecaprevir and pibrentasvir were similar to the observed values in previous studies. Pharmacodynamics of the buprenorphine/naloxone regimen were not significantly impacted. No dose adjustments are required for coadministration of glecaprevir/pibrentasvir with buprenorphine/naloxone. Absence of significant drug-drug interactions between next generation direct acting antivirals ABT-493 and ABT530 and methadone or buprenorphine/naloxone in subjects on opioid maintenance therapy. Kosloski MP, Dutta S, Zhao W, et al. Hepatol, 2015, 62 (1, Suppl); 569A (AASLD The Liver Meeting, Abstract 723)."
106,Glecaprevir/Pibrentasvir,Bupropion,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bupropion is metabolised by CYP2B6 which is not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
107,Glecaprevir/Pibrentasvir,Buspirone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Buspirone is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of buspirone to any clinically significant extent.,(See Summary)
108,Glecaprevir/Pibrentasvir,Calcitonin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Calcitonin is metabolised primarily via proteolysis in the kidney and to date no clinically significant interactions have been published that would be of concern.,(See Summary)
109,Glecaprevir/Pibrentasvir,Calcium carbimide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Calcium carbimide is a prodrug requiring catalase and hydrogen peroxide to generate the active metabolite. Calcium carbimide is an inhibitor of ALDH but this enzyme is not involved in the metabolism of glecaprevir/pibrentasvir.,(See Summary)
110,Glecaprevir/Pibrentasvir,Calcium resonium,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as calcium resonium is not absorbed.,(See Summary)
111,Glecaprevir/Pibrentasvir,Canagliflozin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Canagliflozin is primarily metabolised by UGTs 1A9 and 2B4 which are not affected by glecaprevir/pibrentasvir. Canagliflozin is a substrate and inhibitor of P-gp. Canagliflozin concentrations may increase due to inhibition of P-gp by glecaprevir/pibrentasvir but this is unlikely to be of clinical significance.,(See Summary)
112,Glecaprevir/Pibrentasvir,Candesartan,Potential Weak Interaction,NA,"Coadministration has not been studied. Although candesartan inhibits OATP1B1 in vitro there is no human data. Data shows that candesartan is a P-gp inhibitor however repeated oral dosing of candesartan did not alter steady state pharmacokinetics of digoxin (a probe P-gp substrate) in healthy volunteers and an interaction with glecaprevir/pibrentasvir is unlikely. However, monitoring for ALT elevations may be required. [Note, use of candesartan in severe hepatic impairment is contraindicated in the European SmPC; the US Prescribing Information recommends caution in moderate hepatic impairment.]",(See Summary)
113,Glecaprevir/Pibrentasvir,Cannabis,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tetrahydrocannabinol (THC, the psychoactive component of cannabis) is metabolised by CYP2C9 and CYP3A4. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of cannabis to any clinically significant extent.",(See Summary)
114,Glecaprevir/Pibrentasvir,Capecitabine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Capecitabine is metabolised by CYP2C9 which is not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
115,Glecaprevir/Pibrentasvir,Capreomycin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as capreomycin is mainly excreted in the urine.,(See Summary)
116,Glecaprevir/Pibrentasvir,Captopril,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Captopril is metabolised by sulfation and approximately 40-50% is excreted in the urine.,(See Summary)
117,Glecaprevir/Pibrentasvir,Carbamazepine,Do Not Coadminister,NA,Coadministration is not recommended. Carbamazepine is expected to significantly decrease glecaprevir/pibrentasvir concentrations due to induction of CYP34 by carbamazepine. This may lead to reduced therapeutic effect. Coadministration of glecaprevir/pibrentasvir (single dose) and carbamazepine (200 mg twice daily) decreased glecaprevir Cmax and AUC by 67% and 66% and decreased pibrentasvir Cmax and AUC by 50% and 51%.,"Concomitant use with strong P-gp and CYP3A inducers (e.g., carbamazepine) is contraindicated. Medicinal products that are strong P-gp and CYP3A inducers (e.g., carbamazepine) could significantly decrease glecaprevir or pibrentasvir plasma concentrations and may lead to the reduced therapeutic effect of Maviret or loss of virologic response. Co-administration of such medicinal products with Maviret is contraindicated. Coadministration of carbamazepine (200 mg twice daily) and glecaprevir/pibrentasvir decreased glecaprevir Cmax and AUC by 67% and 66%; pibrentasvir Cmax and AUC decreased by 50% and 51%. This was due to the induction of P-gp/CYP3A. Co-administration may lead to the reduced therapeutic effect of Maviret and is contraindicated.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Carbamazepine may significantly decrease plasma concentrations of glecaprevir and pibrentasvir, leading to the reduced therapeutic effect of Mavyret. The use of this agent with Mavyret is not recommended. Coadministration of carbamazepine (200 mg twice daily) and glecaprevir/pibrentasvir (300/120 mg single dose) was studied in 10 subjects. Glecaprevir Cmax and AUC decreased by 67% and 66%; pibrentasvir Cmax and AUC decreased by 50% and 51%. Mavyret Prescribing Information, AbbVie Inc., June 2019."
118,Glecaprevir/Pibrentasvir,Carbidopa,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Carbidopa is partly metabolized and partly eliminated unchanged (30% of the total urinary excretion).,(See Summary)
119,Glecaprevir/Pibrentasvir,Carbimazole,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Carbimazole is a pro-drug which undergoes rapid and virtually complete metabolism to the active metabolite, thiamazole (methimazole). There is little evidence of marked interactions with this drug.",(See Summary)
120,Glecaprevir/Pibrentasvir,Carboplatin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Carboplatin is excreted primarily by renal glomerular filtration. In vitro studies have shown that carboplatin does not significantly inhibit cytochrome P450 metabolic enzymes.,(See Summary)
121,Glecaprevir/Pibrentasvir,Carisoprodol,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Carisoprodol is metabolised by CYP2C19 which is not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
122,Glecaprevir/Pibrentasvir,Carvedilol,Potential Interaction,NA,"Coadministration has not been studied. Carvedilol is a substrate and an inhibitor of P-gp. Concentrations of both carvedilol and glecaprevir/pibrentasvir may increase. Due to the potential increase in carvedilol concentrations, close monitoring for side effects including heart rate and blood pressure is recommended. [Note, the US Prescribing Information contraindicates carvedilol in patients with severe liver impairment and the European SmPC contraindicates it in patients with hepatic dysfunction.]",(See Summary)
123,Glecaprevir/Pibrentasvir,Caspofungin,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Caspofungin undergoes spontaneous chemical degradation and non-CYP medicated metabolism. [Note, no dose adjustment is required in patients with normal hepatic function but a dose reduction of caspofungin daily dose to 35 mg is recommended for adults with moderate hepatic impairment. There is no clinical experience in adults with severe hepatic impairment.]",(See Summary)
124,Glecaprevir/Pibrentasvir,Cat's claw (Uncaria tomentosa),No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cat’s claw is an inhibitor of CYP3A4, any increase of glecaprevir/pibrentasvir levels via this enzyme are unlikely to be clinically significant. Mild CYP3A4 inhibition of glecaprevir is unlikely to affect cat’s claw.",(See Summary)
125,Glecaprevir/Pibrentasvir,Cefaclor,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefaclor is predominantly eliminated unchanged by the kidneys.,(See Summary)
126,Glecaprevir/Pibrentasvir,Cefadroxil,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefadroxil is not metabolised and is predominantly eliminated unchanged by the kidneys.,(See Summary)
127,Glecaprevir/Pibrentasvir,Cefalexin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefalexin is predominantly eliminated unchanged renally by glomerular filtration and tubular secretion via OAT1 and MATE1 which are not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
128,Glecaprevir/Pibrentasvir,Cefazolin,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefazolin is predominantly excreted unchanged in the urine, mainly by glomerular filtration with some renal tubular secretion.",(See Summary)
129,Glecaprevir/Pibrentasvir,Cefixime,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as cefixime is mainly excreted in urine.,(See Summary)
130,Glecaprevir/Pibrentasvir,Cefotaxime,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro studies indicate that OATs participate in the renal elimination of cefotaxime but OAT1 and OAT3 are not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
131,Glecaprevir/Pibrentasvir,Cefradine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefradine is not metabolised and is predominantly eliminated unchanged by the kidneys.,(See Summary)
132,Glecaprevir/Pibrentasvir,Ceftaroline,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ceftaroline is not metabolised by CYP enzymes and is primarily eliminated by the kidneys.,(See Summary)
133,Glecaprevir/Pibrentasvir,Ceftazidime,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as ceftazidime is excreted predominantly by renal glomerular filtration.,(See Summary)
134,Glecaprevir/Pibrentasvir,Ceftriaxone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ceftriaxone is eliminated mainly as unchanged drug with approximately 60% of the dose being excreted in the urine predominantly by glomerular filtration and the remainder via biliary excretion.,(See Summary)
135,Glecaprevir/Pibrentasvir,Cefuroxime,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as cefuroxime is not metabolised and is excreted unchanged by the kidneys.,(See Summary)
136,Glecaprevir/Pibrentasvir,Celecoxib,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Celecoxib is a substrate of CYP2C9 which is not expected to be affected by glecaprevir/pibrentasvir. [Note, use in patients with severe liver impairment is contraindicated in the European SPC and not recommended in the US Prescribing Information. In patients with moderate liver impairment (serum albumin 25-35 g/L, Child-Pugh Class B), celecoxib treatment should be started at half the recommended dose.]",(See Summary)
137,Glecaprevir/Pibrentasvir,Celiprolol,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as celiprolol is mainly excreted unchanged in urine and faeces.,(See Summary)
138,Glecaprevir/Pibrentasvir,Cetirizine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cetirizine is metabolised only to a limited extent and is eliminated unchanged in the urine through both glomerular filtration and tubular secretion.,(See Summary)
139,Glecaprevir/Pibrentasvir,Cetuximab,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Like other protein therapeutics, cetuximab is expected to be degraded into small peptides and amino acids via catabolic pathways.",(See Summary)
140,Glecaprevir/Pibrentasvir,Chlorambucil,No Interaction Expected,NA,Coadministration has not been studied but a clinically significant interaction is considered unlikely. Very little has been described about chlorambucil metabolism in humans but CYP450 enzymes are not involved.,(See Summary)
141,Glecaprevir/Pibrentasvir,Chloramphenicol,No Interaction Expected,NA,Coadministration has not been studied. Chloramphenicol is metabolised by CYP3A4 and is an inhibitor of CYPs 2C19 and 3A4. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of chloramphenicol to any clinically significant extent. Inhibition of CYP3A4 by chloramphenicol is unlikely to have a clinically significant effect on glecaprevir/pibrentasvir due to the large therapeutic safety margins.,(See Summary)
142,Glecaprevir/Pibrentasvir,Chloroquine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chloroquine is rapidly metabolised by CYPs 2C8, 3A4 and 2D6 to the pharmacologically active desethylchloroquine and bisdesethylchloroquine and is also renally eliminated. These pathways are not expected to be affected by glecaprevir/pibrentasvir. Note, the European SPC and US Prescribing Information for chloroquine both recommend caution in impaired hepatic function.",(See Summary)
143,Glecaprevir/Pibrentasvir,Chlorothiazide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlorothiazide is not metabolised and is eliminated rapidly by renal excretion.,(See Summary)
144,Glecaprevir/Pibrentasvir,Chlorphenamine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlorphenamine is predominantly metabolized by CYP2D6 which is not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
145,Glecaprevir/Pibrentasvir,Chlorpromazine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlorpromazine is metabolised predominantly by CYP2D6 which is not expected to be affected by glecaprevir/pibrentasvir. [Note, the European SmPC for chlorpromazine advises that its use should be avoided in patients with hepatic dysfunction.]",(See Summary)
146,Glecaprevir/Pibrentasvir,Chlorprothixene,No Interaction Expected,NA,"Co-administration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlorprothixene is metabolised by CYP2D6 which is not affected by glecaprevir/pibrentasvir. [Note, although no interaction is anticipated, ECG monitoring is mandatory prior to treatment with chlorprothixene.]",(See Summary)
147,Glecaprevir/Pibrentasvir,Chlortalidone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as chlortalidone is mainly excreted in urine.,(See Summary)
148,Glecaprevir/Pibrentasvir,Ciclesonide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ciclesonide is metabolised by CYP3A4 and CYP2D6 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of ciclesonide to any clinically significant extent.,(See Summary)
149,Glecaprevir/Pibrentasvir,Ciclosporin (Cyclosporine),Potential Interaction,NA,"Concomitant use of glecaprevir/pibrentasvir with ciclosporin requires close monitoring of doses as concentrations of glecaprevir/pibrentasvir may increase due to inhibition of OATP1B. Coadministration of glecaprevir/pibrentasvir and ciclosporin (100 mg) increased glecaprevir/pibrentasvir concentrations within acceptable parameters (glecaprevir Cmax, AUC and Cmin by 30%, 37% and 34%, respectively; no change in pibrentasvir Cmax and AUC, but Cmin increased by 26%). However at higher doses of ciclosporin (400 mg), glecaprevir concentrations increased significantly (Cmax 4.51-fold, AUC 5.08-fold). Glecaprevir/pibrentasvir is not recommended for use in patients requiring stable ciclosporin doses >100 mg per day.","Co-administration of Maviret with medicinal products that inhibit P-gp and BCRP (e.g. ciclosporin) may slow elimination of glecaprevir and pibrentasvir and thereby increase plasma exposure of the antivirals. Medicinal products that inhibit OATP1B1/3 (e.g. ciclosporin) increase systemic concentrations of glecaprevir. Coadministration of ciclosporin (100 mg single dose) and glecaprevir/pibrentasvir increased glecaprevir Cmax, AUC and Cmin by 30%, 37% and 34%, respectively; there was no change in pibrentasvir Cmax and AUC, but Cmin increased by 26%. Coadministration of ciclosporin (400 mg single dose) increased glecaprevir Cmax and AUC by 4.51-fold and 5.08-fold; there was no change in pibrentasvir Cmax but AUC increased by 93%. HCV-infected transplant recipients received ciclosporin dose of 100 mg or less per day had glecaprevir concentrations 4-fold higher than those not receiving ciclosporin. Maviret is not recommended for use in patients requiring stable ciclosporin doses >100 mg per day. If the combination is unavoidable, use can be considered if the benefit outweighs the risk with close clinical monitoring.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Mavyret is not recommended for use in patients requiring stable cyclosporine doses >100 mg per day. Coadministration of cyclosporine (100 mg single dose) and glecaprevir/pibrentasvir (300/120 mg once daily) increased glecaprevir Cmax, AUC and Cmin by 30%, 37% and 34%, respectively; there was no change in pibrentasvir Cmax and AUC, but Cmin increased by 26% (n=12). Coadministration of cyclosporine (400 mg single dose) and glecaprevir/pibrentasvir (300/120 mg single dose) was studied in 11 subjects/ Glecaprevir Cmax and AUC increased by 4.51-fold and 5.08-fold; there was no change in pibrentasvir Cmax but AUC increased by 93%.Mavyret Prescribing Information, AbbVie Inc., June 2019.Coadministration of glecaprevir/pibrentasvir (300/120 mg once daily) and ciclosporin (100 mg single dose) was studied in 12 healthy subjects. Ciclosporin Cmax, AUC and C23 were minimally affected (14% or less difference). Glecaprevir Cmax, AUC and C24 values were slightly increased (30%, 37% and 34%) as were those for pibrentasvir (11%, 22% and 26%). No dose adjustment is required for glecaprevir/pibrentasvir and ciclosporin.Drug-drug interactions between next generation direct acting antivirals ABT-493 and ABT-530 with cyclosporine or tacrolimus in healthy subjects. Kosloski MP, Dutta S, Zhao W, et al. Hepatol, 2015, 62 (1, Suppl); 561A (AASLD The Liver Meeting, Abstract 710)."
150,Glecaprevir/Pibrentasvir,Cidofovir,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cidofovir is eliminated renally via glomerular filtration and active renal secretion by OAT1 and OAT3 which are not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
151,Glecaprevir/Pibrentasvir,Cilazapril,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cilazapril is metabolised by esterases to the active cilazaprilat which is excreted unchanged in urine. [Note, in patients with cirrhosis, a maximum dose of 0.5 mg/day is recommended as significant hypotension may occur.]",(See Summary)
152,Glecaprevir/Pibrentasvir,Cilostazol,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cilostazol is extensively metabolised by CYP3A4 and CYP2C19. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of cilostazol to any clinically significant extent.,(See Summary)
153,Glecaprevir/Pibrentasvir,Cimetidine,Potential Weak Interaction,NA,"Coadministration has not been studied but may result in decreased concentrations of glecaprevir. Coadministration with the proton pump inhibitor omeprazole (40 mg once daily) decreased glecaprevir AUC by ~50%. A reduction in glecaprevir exposure is possible with cimetidine, however, this is unlikely to be clinically significant.",(See Summary)
154,Glecaprevir/Pibrentasvir,Ciprofloxacin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ciprofloxacin is primarily renally eliminated unchanged by glomerular filtration and tubular secretion by OAT3. These pathways are not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
155,Glecaprevir/Pibrentasvir,Cisapride,Potential Interaction,NA,Coadministration has not been studied. Cisapride is metabolised by CYP3A4 and glecaprevir/pibrentasvir is a weak inhibitor of CYP3A4 and clinically significant interaction cannot be ruled out. Use with caution and close monitoring due to cisapride’s narrow therapeutic index.,(See Summary)
156,Glecaprevir/Pibrentasvir,Cisatracurium,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cisatracurium undergoes mainly (80% of overall elimination) spontaneous degradation in plasma and tissues at physiological pH and temperature (Hofmann elimination).,(See Summary)
157,Glecaprevir/Pibrentasvir,Cisplatin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cisplatin is eliminated renally by OCT2 and MATE1 but glecaprevir/pibrentasvir is not expected to inhibit these transporters,(See Summary)
158,Glecaprevir/Pibrentasvir,Citalopram,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Citalopram is metabolized by CYPs 2C19 (38%), 2D6 (31%) and 3A4 (31%). Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect these pathways to any clinically significant extent.",(See Summary)
159,Glecaprevir/Pibrentasvir,Clarithromycin,Potential Weak Interaction,NA,"Coadministration has not been studied. Clarithromycin is a substrate and inhibitor of both CYP3A4 and P-gp; glecaprevir is an inhibitor of P-gp and a mild inhibitor of CYP3A4. Coadministration could increase glecaprevir, pibrentasvir and clarithromycin concentrations due to CYP3A4 and P-gp inhibition. Any increase in glecaprevir or pibrentasvir is likely to be within the upper clinical bounds and not clinically significant. The significance of increased clarithromycin concentrations is unknown and monitoring may be required.",(See Summary)
160,Glecaprevir/Pibrentasvir,Clavulanic acid,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Clavulanic acid is extensively metabolized (likely by a non-CYP mediated pathway) and excreted in the urine by glomerular filtration. ,(See Summary)
161,Glecaprevir/Pibrentasvir,Clevidipine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clevidipine is rapidly metabolised by hydrolysis of the ester linkage and does not undergo CYP metabolism.,(See Summary)
162,Glecaprevir/Pibrentasvir,Clindamycin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clindamycin is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of clindamycin to any clinically significant extent.,(See Summary)
163,Glecaprevir/Pibrentasvir,Clobazam,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clobazam is metabolised primarily by CYP3A4 and to a lesser extent by CYP2C19. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of clobazam to any clinically significant extent. Clobazam is a weak CYP3A4 inducer and could potentially decrease glecaprevir exposure to a very limited extent. However, this is unlikely to be clinically relevant.",(See Summary)
164,Glecaprevir/Pibrentasvir,Clobetasol (topical),No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Following topical application to most areas of normal skin, only minimal amounts of the drug reach the dermis and subsequently the systemic circulation. Although clobetasol is a substrate of CYP3A4, glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of clobetasol to any clinically significant extent.",(See Summary)
165,Glecaprevir/Pibrentasvir,Clobetasone (topical),No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Following topical application to most areas of normal skin, only minimal amounts of the drug reach the dermis and subsequently the systemic circulation. Although clobetasone is a substrate of CYP3A4, glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of clobetasone to any clinically significant extent.",(See Summary)
166,Glecaprevir/Pibrentasvir,Clodronate,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Clodronate is not metabolised and is primarily excreted unchanged by the kidney. However, if administered orally, clodronate should be taken more than two hours after and one hour before any other oral drugs. [Note: this interaction is not specific for glecaprevir/pibrentasvir, but for any oral medication taken with clodronate.]",(See Summary)
167,Glecaprevir/Pibrentasvir,Clomifene,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Studies suggest clomifene is metabolised by CYP3A4, CYP2D6 and UGTs. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of clomifene to any clinically significant extent.",(See Summary)
168,Glecaprevir/Pibrentasvir,Clomipramine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clomipramine is metabolised mainly by CYP2D6 which is not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
169,Glecaprevir/Pibrentasvir,Clonazepam,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clonazepam is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of clonazepam to any clinically significant extent.,(See Summary)
170,Glecaprevir/Pibrentasvir,Clonidine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as 70% of clonidine is excreted in the urine, largely in the form of unchanged parent drug.",(See Summary)
171,Glecaprevir/Pibrentasvir,Clopidogrel,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clopidogrel is a prodrug that is converted to its active metabolites by CYPs 2C19, 3A4, 2B6, and 1A2. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of clopidogrel to any clinically significant extent. Based on a preliminary drug interaction study with the probe CYP2C19 substrate, omeprazole, no clinically significant interaction is expected when glecaprevir/pibrentasvir is co-administered with CYP2C19 substrates. [Note, the European SmPC for clopidogrel contraindicates it use in severe hepatic impairment but the US Prescribing Information states no dose alteration.]",(See Summary)
172,Glecaprevir/Pibrentasvir,Clorazepate,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clorazepate is rapidly converted to nordiazepam which is then metabolized to oxazepam by CYP3A4. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of clorazepate to any clinically significant extent.,(See Summary)
173,Glecaprevir/Pibrentasvir,Clotiapine,Potential Weak Interaction,NA,"Coadministration has not been studied. The metabolism of clotiapine has not been well characterised but is likely to involve CYP450 enzymes. Clotiapine concentrations may increase due to mild inhibition of CYP3A4 by glecaprevir/pibrentasvir but the clinical significance is unclear. No a priori dose modification is recommended but, in the absence of data, monitoring may be required. A clinically significant effect on glecaprevir/pibrentasvir is unlikely.",(See Summary)
174,Glecaprevir/Pibrentasvir,Cloxacillin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cloxacillin is metabolised to a limited extent and the unchanged drug and metabolites are excreted in the urine by glomerular filtration and renal tubular secretion. The transporters that facilitate this have not been described.,(See Summary)
175,Glecaprevir/Pibrentasvir,Clozapine,Potential Interaction,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clozapine is metabolised by CYP1A2 and CYP3A4. Glecaprevir/pibrentasvir is only a weak inhibitor of CYPs 3A4 and 1A2 and interactions via these enzymes are not deemed clinically significant in the product labels. However, as clozapine is associated with significant toxicities, and in the absence of further data, close monitoring is recommended.",(See Summary)
176,Glecaprevir/Pibrentasvir,Cocaine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cocaine is metabolised via multiple pathways including serum and hepatic cholinesterases, spontaneous hydrolysis, hepatic carboxyesterase and CYP3A4 to norcocaine. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of cocaine to any clinically significant extent.",(See Summary)
177,Glecaprevir/Pibrentasvir,Codeine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Codeine is metabolised by CYP2D6 and CYP3A4. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of codeine to any clinically significant extent.,(See Summary)
178,Glecaprevir/Pibrentasvir,Colchicine,Potential Interaction,NA,"Coadministration has not been studied but may increase colchicine concentrations due to inhibition of P-gp by glecaprevir/pibrentasvir. As colchicine has a narrow therapeutic window, consider alternatives. If coadministration is necessary, dose reduction should be considered in patients with normal hepatic function and coadministration should be used with caution in those with hepatic or renal impairment. ",(See Summary)
179,Glecaprevir/Pibrentasvir,Colecalciferol (Vitamin D),No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Although colecalciferol levels may increase due to weak inhibition of CYP3A4 by glecaprevir/pibrentasvir, this is unlikely to be clinically significant.",(See Summary)
180,Glecaprevir/Pibrentasvir,Colestyramine,Potential Weak Interaction,NA,"Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine. [Note: this interaction is not specific for glecaprevir/pibrentasvir, but for any medication taken with colestyramine.]",(See Summary)
181,Glecaprevir/Pibrentasvir,Conivaptan,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Conivaptan is a substrate and inhibitor of CYP3A4. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of conivaptan to any clinically significant extent. Inhibition of CYP3A4 by conivaptan is unlikely to have a clinically significant effect on glecaprevir/pibrentasvir due to the large therapeutic safety margins.,(See Summary)
182,Glecaprevir/Pibrentasvir,Cyanocobalamin (Vitamin B12),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cyanocobalamin undergoes enterohepatic recycling and is excreted almost entirely in the urine.,(See Summary)
183,Glecaprevir/Pibrentasvir,Cyclizine,No Interaction Expected,NA,"Co-administration has not been studied but based on limited data for the metabolism and clearance of cyclizine, a clinically significant interaction is unlikely. Cyclizine undergoes hepatic metabolism which may include CYP2D6.",(See Summary)
184,Glecaprevir/Pibrentasvir,Cyclobenzaprine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cyclobenzaprine undergoes a complex metabolic process involving glucuronidation and several CYP enzymes including CYPs 3A4 and 1A2. Glecaprevir/pibrentasvir is only a weak inhibitor of CYPs 3A4 and 1A2 and is unlikely to affect the exposure of cyclobenzaprine to any clinically significant extent.,(See Summary)
185,Glecaprevir/Pibrentasvir,Cytisine,No Interaction Expected,NA,Coadministration has not been studied and the pharmacokinetics of cytisine is poorly described. There are no reports of drug interactions or CYP involvement. Based on limited data for metabolism and clearance a clinically significant interaction is unlikely.,(See Summary)
186,Glecaprevir/Pibrentasvir,Dabigatran,Do Not Coadminister,NA,"Coadministration increased dabigatran exposure due to P-gp inhibition by glecaprevir/pibrentasvir. Coadministration of dabigatran (150 mg single dose) and glecaprevir/pibrentasvir increased dabigatran Cmax and AUC by 2.05-fold and 2.38-fold. Coadministration is contraindicated in the European SPC for glecaprevir/pibrentasvir. However, the US Prescribing Information for glecaprevir/pibrentasvir refers to the dabigatran Prescribing Information which suggests no dose adjustment is needed in subjects with normal renal function, but to reduce dabigatran to 75 mg twice daily in subjects with creatinine clearance 30-50 mL/min (or avoid use) and does not recommend coadministration in subjects with creatinine clearance <30 mL/min.","Concomitant use with dabigatran etexilate is contraindicated. Co-administration with Maviret may increase plasma concentrations of medicinal products that are substrates of P-gp (e.g. dabigatran etexilate). Coadministration of dabigatran (150 mg single dose) and glecaprevir/pibrentasvir increased dabigatran Cmax and AUC by 2.05-fold and 2.38-fold due to inhibition of P-gp.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Coadministration of dabigatran (150 mg single dose) and glecaprevir/pibrentasvir (300/120 mg once daily) increased dabigatran Cmax and AUC by 2.05-fold and 2.38-fold (n=11). If Mavyret and dabigatran etexilate are coadministered, refer to the dabigatran etexilate prescribing information for dabigatran etexilate dose modifications in combination with P-gp inhibitors in the setting of renal impairment.Mavyret Prescribing Information, AbbVie Inc., June 2019."
187,Glecaprevir/Pibrentasvir,Daclatasvir,Do Not Coadminister,NA,Glecaprevir/pibrentasvir is a complete regimen. There are no data to support the coadministration with another NS5A agent such as daclatasvir.,(See Summary)
188,Glecaprevir/Pibrentasvir,Dalteparin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as dalteparin is mainly excreted unchanged by the kidney.,(See Summary)
189,Glecaprevir/Pibrentasvir,Danaparoid,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Danaparoid is renally excreted and no hepatic involvement was shown in animal studies.,(See Summary)
190,Glecaprevir/Pibrentasvir,Dantron,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dantron is absorbed from the small intestine and acts at the large intestine. ,(See Summary)
191,Glecaprevir/Pibrentasvir,Dapagliflozin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dapagliflozin is metabolised by UGT1A9 which is not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
192,Glecaprevir/Pibrentasvir,Dapsone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metabolism of dapsone is largely by N-acetylation and multiple CYP enzymes have been described.,(See Summary)
193,Glecaprevir/Pibrentasvir,Daratumumab,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Like other protein therapeutics, daratumumab is expected to be degraded into small peptides and amino acids via catabolic pathways and is not anticipated to alter drug-metabolising enzymes.",(See Summary)
194,Glecaprevir/Pibrentasvir,Darbepoetin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Darbepoetin is not hepatically metabolized and to date no clinically significant interactions have been published that would be of concern.,(See Summary)
195,Glecaprevir/Pibrentasvir,Darunavir/cobicistat,Do Not Coadminister,NA,"Coadministration with darunavir/cobicistat has not been studied and is not recommended as it may substantially increase glecaprevir exposure. Medicinal products that inhibit OATP1B1/3 (e.g. darunavir) increase systemic concentrations of glecaprevir. Coadministration of darunavir/ritonavir (800/100 mg) increased glecaprevir AUC, Cmax and Cmin by 4.97-fold, 3.09-fold and 8.24-fold, respectively. A similar interaction may occur with darunavir/cobicistat.","Medicinal products that inhibit OATP1B1/3 (e.g. darunavir) increase systemic concentrations of glecaprevir. Coadministration of darunavir/ritonavir (800/100 mg once daily) and glecaprevir/pibrentasvir increased glecaprevir Cmax, AUC and Cmin by 3.09-fold, 4.97-fold and 8.24-fold, respectively. There was no change in pibrentasvir Cmax or AUC, but Cmin increased by 66%. Co-administration with darunavir is not recommended.Co-administration of Maviret with medicinal products that inhibit P-gp and BCRP (e.g. cobicistat) may slow elimination of glecaprevir and pibrentasvir and thereby increase plasma exposure of the antivirals.Coadministration of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide with glecaprevir/pibrentasvir was studied. Glecaprevir Cmax, AUC and Cmin increased by 150%, 205% and 358%, respectively. Pibrentasvir Cmax was unchanged but AUC and Cmin increased by 57% and 89%, respectively. The mechanism is P-gp, BCRP and OATP inhibition by cobicistat and OATP inhibition by elvitegravir.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Coadministration of darunavir/ritonavir (800/100 mg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 8 subjects. Glecaprevir Cmax, AUC and Cmin increased by 3.09-fold, 4.97-fold and 8.24-fold, respectively. There was no change in pibrentasvir Cmax or AUC, but Cmin increased by 66%. Darunavir Cmax and AUC increased by 30% and 29%, but there was no change in Cmin. Ritonavir Cmax and AUC increased by 103% and 87%, but there was no change in Cmin. Coadministration is not recommended.Mavyret Prescribing Information, AbbVie Inc., June 2019."
196,Glecaprevir/Pibrentasvir,Darunavir/Cobicistat/ Emtricitabine/Tenofovir alafenamide (DRV/c/FTC/TAF),Do Not Coadminister,NA,"Coadministration with Symtuza has not been studied and is not recommended as it may substantially increase glecaprevir exposure. Medicinal products that inhibit OATP1B1/3 (e.g. darunavir/cobicistat increase systemic concentrations of glecaprevir. Coadministration of darunavir/ritonavir (800/100 mg) increased glecaprevir AUC, Cmax and Cmin by 4.97-fold, 3.09-fold and 8.24-fold, respectively. A similar interaction may occur with darunavir/cobicistat. Emtricitabine and tenofovir alafenamide do not interact with this metabolic pathway.","Medicinal products that inhibit OATP1B1/3 (e.g. darunavir) increase systemic concentrations of glecaprevir. Coadministration of darunavir/ritonavir (800/100 mg once daily) and glecaprevir/pibrentasvir increased glecaprevir Cmax, AUC and Cmin by 3.09-fold, 4.97-fold and 8.24-fold, respectively. There was no change in pibrentasvir Cmax or AUC, but Cmin increased by 66%. Co-administration with darunavir is not recommended.Drug-drug interaction studies were performed with emtricitabine and tenofovir alafenamide and showed no clinically significant interactions with Maviret.Co-administration of Maviret with medicinal products that inhibit P-gp and BCRP (e.g. cobicistat) may slow elimination of glecaprevir and pibrentasvir and thereby increase plasma exposure of the antivirals.Coadministration of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide with glecaprevir/pibrentasvir was studied. Glecaprevir Cmax, AUC and Cmin increased by 150%, 205% and 358%, respectively. Pibrentasvir Cmax was unchanged but AUC and Cmin increased by 57% and 89%, respectively. The mechanism is P-gp, BCRP and OATP inhibition by cobicistat and OATP inhibition by elvitegravir.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Coadministration of darunavir/ritonavir (800/100 mg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 8 subjects. Glecaprevir Cmax, AUC and Cmin increased by 3.09-fold, 4.97-fold and 8.24-fold, respectively. There was no change in pibrentasvir Cmax or AUC, but Cmin increased by 66%. Darunavir Cmax and AUC increased by 30% and 29%, but there was no change in Cmin. Ritonavir Cmax and AUC increased by 103% and 87%, but there was no change in Cmin. Coadministration is not recommended. No dose adjustment is required when Mavyret is coadministered with emtricitabine and tenofovir alafenamide.Mavyret Prescribing Information, AbbVie Inc., June 2019."
197,Glecaprevir/Pibrentasvir,Darunavir + ritonavir,Do Not Coadminister,NA,"Coadministration with darunavir/ritonavir is not recommended as it may substantially increase glecaprevir exposure. Medicinal products that inhibit OATP1B1/3 (e.g. darunavir) increase systemic concentrations of glecaprevir. Coadministration of darunavir/ritonavir (800/100 mg) increased glecaprevir AUC, Cmax and Cmin by 4.97-fold, 3.09-fold and 8.24-fold, respectively (n=12).","Medicinal products that inhibit OATP1B1/3 (e.g. darunavir) increase systemic concentrations of glecaprevir. Coadministration of darunavir/ritonavir (800/100 mg once daily) and glecaprevir/pibrentasvir increased glecaprevir Cmax, AUC and Cmin by 3.09-fold, 4.97-fold and 8.24-fold, respectively. There was no change in pibrentasvir Cmax or AUC, but Cmin increased by 66%. Co-administration with darunavir is not recommended.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Coadministration of darunavir/ritonavir (800/100 mg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 8 subjects. Glecaprevir Cmax, AUC and Cmin increased by 3.09-fold, 4.97-fold and 8.24-fold, respectively. There was no change in pibrentasvir Cmax or AUC, but Cmin increased by 66%. Darunavir Cmax and AUC increased by 30% and 29%, but there was no change in Cmin. Ritonavir Cmax and AUC increased by 103% and 87%, but there was no change in Cmin. Coadministration is not recommended.Mavyret Prescribing Information, AbbVie Inc., June 2019."
198,Glecaprevir/Pibrentasvir,Dasatinib,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dasatinib is a substrate and an inhibitor of cytochrome CYP3A4. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of dasatinib to any clinically significant extent. Inhibition of CYP3A4 by dasatinib is unlikely to affect glecaprevir/pibrentasvir exposure due to the large therapeutic safety margins.,(See Summary)
199,Glecaprevir/Pibrentasvir,Deferiprone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Deferiprone is glucuronidated by UGT1A6 which is not affected by glecaprevir/pibrentasvir.,(See Summary)
200,Glecaprevir/Pibrentasvir,Delamanid,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Delamanid is primarily metabolised by albumin to DM-6705; metabolism of DM-6705 to other metabolites is thought to involve pathways mediated by CYP enzymes, including CYP3A4. Glecaprevir is only a weak inhibitor of CYP3A4 and is unlikely to affect this pathway to any clinically significant extent.  [Note, delamanid is not recommended in patients with moderate to severe hepatic impairment.]",(See Summary)
201,Glecaprevir/Pibrentasvir,Denosumab,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Denosumab is not eliminated via hepatic metabolism but follows the immunoglobulin clearance pathway resulting in degradation to small peptides and individual amino acids.,(See Summary)
202,Glecaprevir/Pibrentasvir,Desipramine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Desipramine is mainly metabolised by CYP2D6 which is not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
203,Glecaprevir/Pibrentasvir,Desloratadine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of desloratadine is poorly characterised and no clinically relevant interactions have been observed with other inhibitors of CYP enzymes.,(See Summary)
204,Glecaprevir/Pibrentasvir,Desmopressin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as desmopressin is not significantly metabolised.,(See Summary)
205,Glecaprevir/Pibrentasvir,Desogestrel (POP),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Desogestrel is a prodrug that requires activation to etonogestrel. Activation to etonogestrel is by CYP2C9 (and possible CYP2C19); the metabolism of etonogestrel is mediated by CYP3A4. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of desogestrel to any clinically significant extent. No dose adjustment is required when glecaprevir/pibrentasvir is co administered with progestin only contraception.,"No dose adjustment is required when Mavyret is coadministered with desogestrel as a progestrin-only contraceptive. Coadministration with ethinyl estradiol-containing products may increase the risk of ALT elevations and is not recommended.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019."
206,Glecaprevir/Pibrentasvir,Desvenlafaxine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Desvenlafaxine is a substrate of CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of desvenlafaxine to any clinically significant extent. [Note, a maximum desvenlafaxine dose of 50 mg is recommended in moderate hepatic impairment.]",(See Summary)
207,Glecaprevir/Pibrentasvir,Dexamethasone,Potential Interaction,NA,"Coadministration has not been studied and should be used with caution. Coadministration may increase dexamethasone concentrations due to inhibition of P-gp by glecaprevir/pibrentasvir, but as this is only one component of dexamethasone disposition a clinically significant effect by this route is unlikely. However, coadministration may decrease glecaprevir/pibrentasvir concentrations due to modest induction of CYP3A4 by dexamethasone and this may lead to reduced therapeutic effect. Close monitoring for dexamethasone-related side effects and for efficacy of glecaprevir/pibrentasvir is recommended.",(See Summary)
208,Glecaprevir/Pibrentasvir,Dexamfetamine,Potential Weak Interaction,NA,"Coadministration has not been studied but based on limited data for metabolism and clearance a clinically significant interaction is unlikely. Note, the role of CYP450 in the metabolism of dexamfetamine has not been fully described.",(See Summary)
209,Glecaprevir/Pibrentasvir,Dexketoprofen,No Interaction Expected,NA,"Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Dexketoprofen is mainly glucuronidated, with CYP mediated metabolism (CYP2C8/9) playing only a minor role. Glecaprevir/pibrentasvir is not expected to induce or inhibit UGTs or CYP2C8/2C9. [Note, use in patients with severe hepatic impairment (Child Pugh class C) is contraindicated in the European product label for dexketoprofen.]",(See Summary)
210,Glecaprevir/Pibrentasvir,Dextromethorphan,No Interaction Expected,NA,Coadministration of dextromethorphan (30 mg single dose) and glecaprevir/pibrentasvir (300/120 mg once daily) decreased dextromethorphan Cmax and AUC by 30% and 25% (n=12). This was not clinically significant and no dose adjustment is required.,"Drug-drug interaction studies were performed with dextromethorphan and showed no clinically significant interactions with Maviret.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.No dose adjustment is required when Mavyret is coadministered with dextromethorphan. Coadministration of dextromethorphan (30 mg single dose) and glecaprevir/pibrentasvir (300/120 mg once daily) decreased dextromethorphan Cmax and AUC by 30% and 25% (n=12).Mavyret Prescribing Information, AbbVie Inc., June 2019."
211,Glecaprevir/Pibrentasvir,Dextropropoxyphene,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dextropropoxyphene is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of dextropropoxyphene to any clinically significant extent.,(See Summary)
212,Glecaprevir/Pibrentasvir,Diamorphine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as diamorphine is metabolised mainly by deacetylation with multiple small pathway involvement.,(See Summary)
213,Glecaprevir/Pibrentasvir,Diazepam,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diazepam is metabolised by CYP3A4 and CYP2C19 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of diazepam to any clinically significant extent.,(See Summary)
214,Glecaprevir/Pibrentasvir,Diclofenac,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diclofenac is a substrate of CYP2C9, CYP3A4, UGT1A9 and UGT2B7, and is an inhibitor of the renal transporter MRP4. No effect of glecaprevir/pibrentasvir on diclofenac is expected due to the involvement of multiple enzyme pathways",(See Summary)
215,Glecaprevir/Pibrentasvir,Didanosine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Didanosine is phosphorylated to its active triphosphate form and is not a substrate of any CYP isoenzyme. It is renally excreted.,(See Summary)
216,Glecaprevir/Pibrentasvir,Dienogest,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dienogest is a substrate of CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of dienogest to any clinically significant extent.,(See Summary)
217,Glecaprevir/Pibrentasvir,Diflunisal,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diflunisal is an aldoketoreductase inhibitor but this pathway is not involved in the metabolism of glecaprevir/pibrentasvir.,(See Summary)
218,Glecaprevir/Pibrentasvir,Digoxin,Potential Interaction,NA,Coadministration with glecaprevir/pibrentasvir increased digoxin AUC by 1.48-fold and Cmax by 1.72-fold due to P-gp inhibition by glecaprevir/pibrentasvir. Use with caution. Therapeutic concentration monitoring of digoxin is recommended before initiating and during glecaprevir/pibrentasvir therapy. The US Prescribing Information for glecaprevir/pibrentasvir suggests reducing digoxin concentrations if required by decreasing the dose by approximately 50% or by modifying the dosing frequency.,"Co-administration with Maviret may increase plasma concentrations of medicinal products that are substrates of P-gp (e.g. digoxin). Coadministration of digoxin (0.5 mg single dose) and glecaprevir/pibrentasvir increased digoxin Cmax and AUC by 72% and 48% due to inhibition of P-gp. Caution and therapeutic concentration monitoring of digoxin is recommended.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Coadministration of digoxin (0.5 mg single dose) and glecaprevir/pibrentasvir (400/120 mg once daily) increased digoxin Cmax and AUC by 72% and 48% (n=12). Measure serum digoxin concentrations before initiating Mavyret. Reduce digoxin concentrations by decreasing the dose by approximately 50% or by modifying the dosing frequency and continue monitoring.Mavyret Prescribing Information, AbbVie Inc., June 2019."
219,Glecaprevir/Pibrentasvir,Dihydroartemisinin,No Interaction Expected,NA,Coadministration has not been studied. Dihydroartemisinin (the active metabolite of artesunate) induces CYP3A4 and may decrease exposure of glecaprevir/pibrentasvir but this is unlikely to be of clinical significance due to the large therapeutic safety margins.,(See Summary)
220,Glecaprevir/Pibrentasvir,Dihydrocodeine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dihydrocodeine is converted to dihydromorphine (active metabolite) by CYP2D6, to dihydrocodeine-6-glucuronide via UGT2B7 (major pathway) and to nordihydrocodeine by CYP3A4. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of dihydrocodeine to any clinically significant extent.",(See Summary)
221,Glecaprevir/Pibrentasvir,Dihydroergotamine,Potential Interaction,NA,"Coadministration has not been studied. Dihydroergotamine is metabolised by CYP3A4. Although glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4, there is the potential for serious adverse events such as ergot toxicity due to the narrow therapeutic index of dihydroergotamine.",(See Summary)
222,Glecaprevir/Pibrentasvir,Diltiazem,Potential Interaction,NA,Coadministration has not been studied. Diltiazem is a substrate of CYP3A4 and P-gp. Concentrations may increase due to inhibition of P-gp and weak inhibition of CYP3A4 by glecaprevir/pibrentasvir. Close monitoring of heart rate and blood pressure is recommended and consider dose reduction if required.,(See Summary)
223,Glecaprevir/Pibrentasvir,Diosmin,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diosmin is a naturally occurring flavonoid. Diosmin-containing products are available as dietary supplements or on prescription (in certain countries). Interaction studies suggest that diosmin may be a weak inhibitor of CYP3A4 and P-gp, but any effect on glecaprevir/pibrentasvir is unlikely to be clinically relevant.",(See Summary)
224,Glecaprevir/Pibrentasvir,Diphenhydramine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diphenhydramine is a substrate (and inhibitor) of CYP2D6 which is not expected to be affected by glecaprevir/pibrentasvir. [Note, diphenhydramine should be used with caution in patients with moderate to severe hepatic impairment.]",(See Summary)
225,Glecaprevir/Pibrentasvir,Dipyridamole,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as dipyridamole is glucuronidated and does not appear to be metabolised by cytochrome P450s.,(See Summary)
226,Glecaprevir/Pibrentasvir,Disopyramide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Disopyramide is a substrate of CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of disopyramide to any clinically significant extent.,(See Summary)
227,Glecaprevir/Pibrentasvir,Disulfiram,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Disulfiram is an inhibitor of ALDH but this pathway is not involved in the metabolism of glecaprevir/pibrentasvir.,(See Summary)
228,Glecaprevir/Pibrentasvir,Dofetilide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dofetilide is eliminated in the kidney by active secretion and is metabolized to a small extent by CYP3A4. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of dofetilide to any clinically significant extent.,(See Summary)
229,Glecaprevir/Pibrentasvir,Dolutegravir,No Interaction Expected,NA,Coadministration with dolutegravir alone has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Coadministration of dolutegravir and glecaprevir/pibrentasvir was evaluated as part of a Phase 1 study with Triumeq (abacavir/dolutegravir/lamivudine) and showed no clinically significant interaction with glecaprevir/pibrentasvir. No dose adjustment is required when glecaprevir/pibrentasvir is co administered with dolutegravir.,"Drug-drug interaction studies were performed with dolutegravir and showed no clinically significant interactions with Maviret.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.No dose adjustment is required when Mavyret is coadministered with dolutegravir.Coadministration of dolutegravir (as abacavir/dolutegravir/lamivudine, 500/50/300 mg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 12 subjects. There was no change abacavir Cmax or AUC, but Cmin increased by 31%.Mavyret Prescribing Information, AbbVie Inc., June 2019.The pharmacokinetics of glecaprevir/pibrentasvir (300/120 mg once daily) coadministered with abacavir/dolutegravir/lamivudine (600/50/300 mg once daily) was studied in 24 healthy subjects. Cmax and AUC for glecaprevir and pibrentasvir decreased by 25-28%, but there was no impact on Cmax and AUC for abacavir, dolutegravir or lamivudine. No dose adjustment is required when glecaprevir/pibrentasvir are coadministered with abacavir, dolutegravir and lamivudine.Glecaprevir and pibrentasvir interactions with combination antiretroviral regimens. Kosloski MP, Dutta S, Viani RM, et al. Conference on Retroviruses and Opportunistic Infections, Seattle, February 2017, abstract 413."
230,Glecaprevir/Pibrentasvir,Dolutegravir/rilpivirine,No Interaction Expected,NA,"Coadministration with dolutegravir/rilpivirine has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Coadministration of dolutegravir and glecaprevir/pibrentasvir was evaluated as part of a Phase 1 study with Triumeq (abacavir/dolutegravir/lamivudine) and showed no clinically significant interaction with glecaprevir/pibrentasvir. Coadministration of rilpivirine and glecaprevir/pibrentasvir increased rilpivirine Cmax, AUC and Cmin by 105%, 84% and 77%, respectively (n=12); this was deemed within safety limits. No dose adjustment is required when glecaprevir/pibrentasvir is coadministered with dolutegravir/rilpivirine.","Drug-drug interaction studies were performed with dolutegravir and rilpivirine and showed no clinically significant interactions with Maviret.Maviret Summary of Product Characteristics, AbbVie Ltd, January 2019.No dose adjustment is required when Mavyret is coadministered with dolutegravir or rilpivirine.Mavyret Prescribing Information, AbbVie Inc, August 2018.The pharmacokinetics of glecaprevir/pibrentasvir (300/120 mg once daily) coadministered with abacavir/dolutegravir/lamivudine (600/50/300 mg once daily) was studied in 24 healthy subjects. Cmax and AUC for glecaprevir and pibrentasvir decreased by 25-28%, but there was no impact on Cmax and AUC for abacavir, dolutegravir or lamivudine. No dose adjustment is required when glecaprevir/pibrentasvir are coadministered with abacavir, dolutegravir and lamivudine.Glecaprevir and pibrentasvir interactions with combination antiretroviral regimens. Kosloski MP, Dutta S, Viani RM, et al. Conference on Retroviruses and Opportunistic Infections, Seattle, February 2017, abstract 413."
231,Glecaprevir/Pibrentasvir,Domperidone,Potential Interaction,NA,"Coadministration has not been studied. Domperidone is predominantly metabolised by CYP3A4. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and may increase domperidone concentrations but to a modest extent. However, as domperidone has a narrow therapeutic index and is associated with QTc prolongation any modest increase could be clinically relevant. Use with caution and close monitoring. ",(See Summary)
232,Glecaprevir/Pibrentasvir,Donepezil,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Donepezil is metabolised by CYP3A4 and CYP2D6 (minor) but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of donepezil to any clinically significant extent.,(See Summary)
233,Glecaprevir/Pibrentasvir,Doravirine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doravirine is metabolized by CYP3A4. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 therefore is unlikely to affect the exposure of doravirine to any clinically significant extent.,(See Summary)
234,Glecaprevir/Pibrentasvir,Doravirine/Lamivudine/Tenofovir-DF,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doravirine is metabolized by CYP3A4. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 therefore is unlikely to affect the exposure of doravirine to any clinically significant extent. No clinically significant interactions were observed when tenofovir-DF (with efavirenz and emtricitabine) and glecaprevir/pibrentasvir were coadministered or when lamivudine was coadministered with glecaprevir/pibrentasvir.,(See Summary)
235,Glecaprevir/Pibrentasvir,Dorzolamide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as dorzolamide undergoes minimal metabolism and is mainly excreted unchanged by the kidney.,(See Summary)
236,Glecaprevir/Pibrentasvir,Dosulepin,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dosulepin is extensively metabolised in the liver, likely by CYP2D6 (major) and CYP3A4, but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of dosulepin to any clinically significant extent. [Note: Dosulepin should be used with caution in mild to moderate hepatic impairment and avoided in severe hepatic impairment.]",(See Summary)
237,Glecaprevir/Pibrentasvir,Doxazosin,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doxazosin is extensively metabolised by CYP3A4 and to a lesser extent CYP2D6 and CYP2C19. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of doxazosin to any clinically significant extent. [Note, the European SmPC for doxazosin does not recommend its use in severe hepatic impairment; the US Prescribing Information has a caution in hepatic impairment.]",(See Summary)
238,Glecaprevir/Pibrentasvir,Doxepin,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doxepin is primarily metabolized by CYP2C19 and CYP2D6, and to a lesser extent, by CYP1A2 and CYP2C9, none of which are expected to be affected by glecaprevir/pibrentasvir. [Note, the European and US product labels for doxepin advises caution and monitoring in patients with hepatic impairment as a dosage reduction may be required.]",(See Summary)
239,Glecaprevir/Pibrentasvir,Doxorubicin,Potential Interaction,NA,Coadministration has not been studied. Doxorubicin is metabolised by CYP enzymes and is a substrate for P-gp. Since glecaprevir/pibrentasvir inhibits P-gp and is a mild inhibitor of CYP3A4 there is the potential for increased doxorubicin exposure and a clinically significant interaction has to be considered. ,(See Summary)
240,Glecaprevir/Pibrentasvir,Doxycycline,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as doxycycline is mainly excreted in the urine and faeces as unchanged drug.,(See Summary)
241,Glecaprevir/Pibrentasvir,Doxylamine,No Interaction Expected,NA,Co-administration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Limited data available for doxylamine metabolism suggest involvement of CYP2B6 which is not affected by glecaprevir/pibrentasvir.,(See Summary)
242,Glecaprevir/Pibrentasvir,Dronedarone,Potential Interaction,NA,"Coadministration has not been studied. Dronedarone is metabolised by CYP3A4 and concentrations may increase as glecaprevir/pibrentasvir is a weak inhibitor of CYP3A4. As dronedarone has a narrow therapeutic index and unpredictable therapeutic levels, monitor patients closely for signs and symptoms of toxicity. Use with caution and consider therapeutic drug monitoring and/or ECGs during treatment. The European Summary of Product Characteristics for Maviret states that dronedarone may increase plasma exposure of glecaprevir and pibrentasvir due to inhibition of P-gp and BCRP.","Co-administration of Maviret with medicinal products that inhibit P-gp and BCRP (e.g. dronedarone) may slow elimination of glecaprevir and pibrentasvir and thereby increase plasma exposure of the antivirals.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019."
243,Glecaprevir/Pibrentasvir,Droperidol,Potential Interaction,NA,Coadministration has not been studied. Droperidol is metabolised by CYP3A4 and CYP1A2 and concentrations may increase as glecaprevir/pibrentasvir is a weak inhibitor of CYP3A4 and CYP1A2. Use with caution.,(See Summary)
244,Glecaprevir/Pibrentasvir,Drospirenone (POP),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Drospirenone is metabolised mainly without involvement of CYP enzymes with little known involvement of transporters.,(See Summary)
245,Glecaprevir/Pibrentasvir,Dulaglutide,Potential Weak Interaction,NA,"Coadministration has not been studied. Dulaglutide is degraded by general protein catabolism pathways therefore no metabolic interaction is expected. Dulaglutide delays gastric emptying but interaction studies showed no clinically significant effect on the absorption of concomitantly administered oral medicinal products. However, GLP-1 agonists such as dulaglutide also have the potential to inhibit gastric secretion and thereby impact drugs whose absorption is gastric dependent, such as glecaprevir. A reduction in glecaprevir exposure is possible with dulaglutide, however, this is unlikely to be clinically significant.",(See Summary)
246,Glecaprevir/Pibrentasvir,Duloxetine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Duloxetine is metabolized by CYP2D6 and CYP1A2 which are not expected to be affected by glecaprevir/pibrentasvir. [Note, duloxetine is contraindicated in patients with hepatic impairment as concentrations may increase due to decreased clearance of duloxetine.]",(See Summary)
247,Glecaprevir/Pibrentasvir,Dupilumab,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dupilimab is a protein and degrades to small peptides and individual amino acids. ,(See Summary)
248,Glecaprevir/Pibrentasvir,Dutasteride,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dutasteride is metabolised mainly by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of dutasteride to any clinically significant extent. [Note, the European SmPC (but not the US Prescribing Information) cautions against dutasteride use in mild to moderate hepatic impairment and contraindicates it in severe hepatic impairment.]",(See Summary)
249,Glecaprevir/Pibrentasvir,Ebastine,Potential Interaction,NA,Coadministration has not been studied. Ebastine is metabolised by CYP450 and concentrations may be increased due to mild CYP3A4 inhibition by glecaprevir. ECG monitoring should be considered as increased concentrations of ebastine can prolong the QT interval.,(See Summary)
250,Glecaprevir/Pibrentasvir,Echinacea,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Studies using a cocktail of probe drugs showed Echinacea inhibited CYP1A2 and intestinal CYP3A activity, and induced hepatic CYP3A activity. The overall effect of Echinacea on CYP3A4 is unlikely to have a clinically significant effect on glecaprevir/pibrentasvir due to the large therapeutic safety margins.",(See Summary)
251,Glecaprevir/Pibrentasvir,Ecstasy (MDMA),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. MDMA is mainly metabolized by CYP2D6 which is not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
252,Glecaprevir/Pibrentasvir,Eculizumab,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Eculizumab contains only naturally occurring amino acids and has no known active metabolites. Human antibodies are predominately catabolized by lysosomal enzymes to small peptides and amino acids. No drug interactions have been described to date.,(See Summary)
253,Glecaprevir/Pibrentasvir,Edoxaban,Potential Interaction,NA,"Co-administration has not been studied. Edoxaban is a substrate of P-gp and concentrations may increase due to inhibition of P-gp by glecaprevir/pibrentasvir. Consider a dose reduction of edoxaban if coadministered with glecaprevir/pibrentasvir, whilst reviewing clinical reasons for prescribing as dose reduction may result in suboptimal concentrations.",(See Summary)
254,Glecaprevir/Pibrentasvir,Efavirenz,Do Not Coadminister,NA,"Coadministration is not recommended as efavirenz may reduce glecaprevir/pibrentasvir concentrations and this may lead to reduced therapeutic effect. Coadministration of glecaprevir/pibrentasvir and efavirenz/emtricitabine/tenofovir-DF (600/200/300 mg once daily) was studied to determine the effect on tenofovir concentrations. The effect on glecaprevir and pibrentasvir was not directly quantified within this study, but glecaprevir and pibrentasvir exposures were significantly lower than historical controls.","Coadministration of efavirenz/emtricitabine/tenofovir-DF (600/200/300 mg once daily) and glecaprevir/pibrentasvir had no effect on tenofovir Cmax but increased AUC and Cmin by 29% and 38%. The effect of efavirenz/emtricitabine/tenofovir disoproxil fumarate on glecaprevir and pibrentasvir was not directly quantified within this study, but glecaprevir and pibrentasvir exposures were significantly lower than historical controls. Co-administration with efavirenz may lead to reduced therapeutic effect of Maviret and is not recommended. Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Efavirenz may significantly decrease plasma concentrations of glecaprevir and pibrentasvir, leading to reduced therapeutic effect of Mavyret. The use of this agent with Mavyret is not recommended. Coadministration of efavirenz/emtricitabine/tenofovir-DF (600/200/300 mg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) had no effect on tenofovir Cmax but increased AUC and Cmin by 29% and 38% (n=12).Mavyret Prescribing Information, AbbVie Inc., June 2019."
255,Glecaprevir/Pibrentasvir,Elbasvir/Grazoprevir,Do Not Coadminister,NA,Coadministration of glecaprevir/pibrentasvir with other directly acting antivirals has not been studied and therefore cannot be recommended.,(See Summary)
256,Glecaprevir/Pibrentasvir,Eletriptan,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Eletriptan is primarily metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of eletriptan to any clinically significant extent.,(See Summary)
257,Glecaprevir/Pibrentasvir,Eliglustat,Potential Interaction,NA,Coadministration has not been studied. Eliglustat is metabolised primarily by CYP2D6 and to a lesser extent by CYP3A4. Concentrations of eliglustat may increase due to mild inhibition of CYP3A4 by glecaprevir/pibrentasvir. Caution and monitoring of adverse effects associated with increased eliglustat concentrations is recommended,(See Summary)
258,Glecaprevir/Pibrentasvir,Eltrombopag,Do Not Coadminister,NA,"Coadministration is contraindicated. Concomitant use of glecaprevir/pibrentasvir with OATP1B inhibitors, such as eltrombopag, may increase the risk of ALT elevations due to a significant increase in pibrentasvir plasma concentrations caused by OATP1B1/3 inhibition.",(See Summary)
259,Glecaprevir/Pibrentasvir,Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir alafenamide (EVG/c/FTC/TAF),No Interaction Expected,NA,"Coadministration of glecaprevir/pibrentasvir and elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide increased glecaprevir Cmax, AUC and Cmin by 2.50-fold, 3.05-fold and 4.58-fold, respectively; there was no change in pibrentasvir Cmax, but AUC and Cmin increased by 57% and 89%. However these increases were deemed to be within safety limits and no dose adjustment is required.","Co-administration of Maviret with medicinal products that inhibit P-gp and BCRP (e.g. cobicistat) may slow elimination of glecaprevir and pibrentasvir and thereby increase plasma exposure of the antivirals. Medicinal products that inhibit OATP1B1/3 (elvitegravir) increase systemic concentrations of glecaprevir. Coadministration of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and glecaprevir/pibrentasvir increased glecaprevir Cmax, AUC and Cmin by 2.5-fold, 3.05-fold and 4.58-fold, respectively; there was no change in pibrentasvir Cmax, but AUC and Cmin increased by 57% and 89%. This was due to P-gp, BCRP, and OATP inhibition by cobicistat and OATP inhibition by elvitegravir. There was no change in the Cmax, AUC and Cmin of tenofovir. No dose adjustment is required.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Coadministration of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (150/150/200/10 mg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 12 subjects. Glecaprevir Cmax, AUC and Cmin increased by 2.5-fold, 3.05-fold and 4.58-fold, respectively; there was no change in pibrentasvir Cmax, but AUC and Cmin increased by 57% and 89% (data from 11 subjects). Elvitegravir Cmax, AUC and Cmin increased by 36%, 47% and 71%, respectively. There was no change tenofovir Cmax, AUC or Cmin. No dose adjustment is required when Mavyret is coadministered with elvitegravir/cobicistat, emtricitabine or tenofovir alafenamide.Mavyret Prescribing Information, AbbVie Inc., June 2019.The pharmacokinetics of glecaprevir/pibrentasvir (300/120 mg once daily) coadministered with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (150/150/200/10 mg once daily) was studied in 24 healthy subjects. Cmax and AUC for glecaprevir increased by 150-205% and for pibrentasvir increased by 24-57%. Cmax and AUC of elvitegravir and cobicistat increased by 29-47%, but there was no effect (12% or less change) on emtricitabine or tenofovir. No dose adjustment is required when glecaprevir/pibrentasvir are coadministered with elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide.Glecaprevir and pibrentasvir interactions with combination antiretroviral regimens. Kosloski MP, Dutta S, Viani RM, et al. Conference on Retroviruses and Opportunistic Infections, Seattle, February 2017, abstract 413."
260,Glecaprevir/Pibrentasvir,Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir-DF (EVG/c/FTC/TDF),No Interaction Expected,NA,"Coadministration with elvitegravir/cobicistat/emtricitabine/tenofovir-DF has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Coadministration of glecaprevir/pibrentasvir and elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide increased glecaprevir Cmax, AUC and Cmin by 2.50-fold, 3.05-fold and 4.58-fold, respectively. However these increases were deemed to be within safety limits and no dose adjustment is required.","Co-administration of Maviret with medicinal products that inhibit P-gp and BCRP (e.g. cobicistat) may slow elimination of glecaprevir and pibrentasvir and thereby increase plasma exposure of the antivirals. Medicinal products that inhibit OATP1B1/3 (elvitegravir) increase systemic concentrations of glecaprevir. Coadministration of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and glecaprevir/pibrentasvir increased glecaprevir Cmax, AUC and Cmin by 2.5-fold, 3.05-fold and 4.58-fold, respectively; there was no change in pibrentasvir Cmax, but AUC and Cmin increased by 57% and 89%. This was due to P-gp, BCRP, and OATP inhibition by cobicistat and OATP inhibition by elvitegravir. There was no change in the Cmax, AUC and Cmin of tenofovir.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.No dose adjustment is required when Mavyret is coadministered with elvitegravir/cobicistat, emtricitabine or tenofovir disoproxil fumarate.Mavyret Prescribing Information, AbbVie Inc., June 2019."
261,Glecaprevir/Pibrentasvir,Empagliflozin,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Empagliflozin is metabolised by UGTs and is a substrate of P-gp, BCRP, OAT3 and OATP1B1/1B3. Although glecaprevir/pibrentasvir is an inhibitor of P-gp and OATP, data with empagliflozin and verapamil (a P-gp inhibitor) or rifampicin (an OATP1B1 inhibitor) suggest a clinically relevant effect on empagliflozin is unlikely.",(See Summary)
262,Glecaprevir/Pibrentasvir,Emtricitabine,No Interaction Expected,NA,Studies performed with emtricitabine showed no clinically significant interactions with glecaprevir/pibrentasvir. No dose adjustment is required when glecaprevir/pibrentasvir is co administered with emtricitabine.,"Drug-drug interaction studies were performed with emtricitabine and showed no clinically significant interactions with Maviret. Coadministration of efavirenz/emtricitabine/tenofovir-DF (600/200/300 mg once daily) and glecaprevir/pibrentasvir had no effect on tenofovir Cmax, but increased AUC and Cmin by 29% and 38%. The effect of efavirenz/emtricitabine/tenofovir disoproxil fumarate on glecaprevir and pibrentasvir was not directly quantified within this study, but glecaprevir and pibrentasvir exposures were significantly lower than historical controls. Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.No dose adjustment is required when Mavyret is coadministered with emtricitabine.Mavyret Prescribing Information, AbbVie Inc., June 2019."
263,Glecaprevir/Pibrentasvir,Emtricitabine/Tenofovir alafenamide (FTC/TAF),No Interaction Expected,NA,Studies performed with emtricitabine or tenofovir alafenamide showed no clinically significant interactions with glecaprevir/pibrentasvir. No dose adjustment is required when glecaprevir/pibrentasvir is co administered with emtricitabine and tenofovir alafenamide.,"Drug-drug interaction studies were performed with emtricitabine and tenofovir alafenamide and showed no clinically significant interactions with Maviret.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.No dose adjustment is required when Mavyret is coadministered with emtricitabine and tenofovir alafenamide.Mavyret Prescribing Information, AbbVie Inc., June 2019."
264,Glecaprevir/Pibrentasvir,"Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)",No Interaction Expected,NA,"Coadministration with emtricitabine/tenofovir-DF has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. No clinically significant interactions were observed when emtricitabine and tenofovir-DF (with efavirenz) and glecaprevir/pibrentasvir were coadministered. No dose adjustment is required.","Coadministration of efavirenz/emtricitabine/tenofovir-DF (600/200/300 mg once daily) and glecaprevir/pibrentasvir had no effect on tenofovir Cmax but increased AUC and Cmin by 29% and 38%. The effect of efavirenz/emtricitabine/tenofovir disoproxil fumarate on glecaprevir and pibrentasvir was not directly quantified within this study, but glecaprevir and pibrentasvir exposures were significantly lower than historical controls. No clinically significant interactions are expected with tenofovir disoproxil fumarate. Drug-drug interaction studies were performed with emtricitabine and showed no clinically significant interactions with Maviret.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Coadministration of efavirenz/emtricitabine/tenofovir-DF (600/200/300 mg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) had no effect on tenofovir Cmax but increased AUC and Cmin by 29% and 38% (n=12). No dose adjustment is required when Mavyret is coadministered with tenofovir-DF.Mavyret Prescribing Information, AbbVie Inc., June 2019."
265,Glecaprevir/Pibrentasvir,Enalapril,Potential Interaction,NA,Coadministration has not been studied. Enalapril is a substrate of OATP1B1 and concentrations may increase due to inhibition of OATP1B1 by glecaprevir/pibrentasvir. Use enalapril at the lowest dose and closely monitor heart rate and blood pressure. A dose adjustment may be needed.,(See Summary)
266,Glecaprevir/Pibrentasvir,Enoxaparin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Enoxaparin does not undergo CYP metabolism but is desulphated and depolymerised in the liver and is then excreted predominantly renally.,(See Summary)
267,Glecaprevir/Pibrentasvir,Entecavir,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glecaprevir/pibrentasvir is metabolised by and is a weak inhibitor of CYP3A4. Entecavir is not hepatically metabolised and the potential for interactions via this route is low. Entecavir is eliminated primarily in the urine by glomerular filtration and tubular secretion by OAT1.,(See Summary)
268,Glecaprevir/Pibrentasvir,Eplerenone,Potential Interaction,NA,Coadministration has not been studied. Eplerenone is metabolised by CYP3A4 and glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4. The product label for eplerenone recommends to start eplerenone at a low dose when given with mild or moderate inhibitors of CYP3A4.,(See Summary)
269,Glecaprevir/Pibrentasvir,Epoetin alfa,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. There is no evidence that treatment with epoetin-alfa alters the metabolism of other medicinal products.,(See Summary)
270,Glecaprevir/Pibrentasvir,Epoprostenol,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Epoprostenol is rapidly hydrolysed; there does not appear to be any involvement with CYP isoenzymes or transporter proteins.",(See Summary)
271,Glecaprevir/Pibrentasvir,Eprosartan,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Eprosartan is mainly excreted in urine and bile.,(See Summary)
272,Glecaprevir/Pibrentasvir,Ergometrine (ergonovine),Potential Interaction,NA,"Coadministration has not been studied. Ergometrine is metabolised by CYP3A4 and although glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4, there is the potential for ergot toxicity due to the narrow therapeutic index of ergometrine.",(See Summary)
273,Glecaprevir/Pibrentasvir,Ergotamine,Potential Interaction,NA,"Coadministration has not been studied. Ergotamine is metabolised by CYP3A4 and although glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4, there is the potential for ergot toxicity due to the narrow therapeutic index of ergotamine.",(See Summary)
274,Glecaprevir/Pibrentasvir,Erlotinib,Potential Interaction,NA,"Coadministration has not been studied. Erlotinib is a substrate for CYP3A4 and P-gp; concentrations may increase due to the additive effect of weak inhibition of CYP3A4 and inhibition of P-gp by glecaprevir/pibrentasvir. Use with caution and with close monitoring for erlotinib mediated toxicity. A dose reduction may be required for erlotinib, particularly if toxicity is observed.",(See Summary)
275,Glecaprevir/Pibrentasvir,Ertapenem,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as ertapenem undergoes minimal metabolism and is mainly excreted unchanged by the kidney by glomerular filtration.,(See Summary)
276,Glecaprevir/Pibrentasvir,Erythromycin,Potential Interaction,NA,"Co-administration has not been studied. Concentrations of erythromycin may increase due to inhibition of P-gp by glecaprevir/pibrentasvir. No a priori dose reductions is required. However, close monitoring for effects of increased erythromycin concentrations is recommended and consider ECG monitoring if the patient at risk.",(See Summary)
277,Glecaprevir/Pibrentasvir,Escitalopram,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Escitalopram is metabolised by CYP2C19, CYP2D6 and CYP3A4. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of escitalopram to any clinically significant extent.",(See Summary)
278,Glecaprevir/Pibrentasvir,Eslicarbazepine,Do Not Coadminister,NA,Coadministration has not been studied and is not recommended. Eslicarbazepine is an inducer of CYP3A4 and may decrease concentrations of glecaprevir/pibrentasvir which may lead to reduced therapeutic effect.,"Co-administration of Maviret with medicinal products that are moderate inducers P-gp/CYP3A may decrease glecaprevir and pibrentasvir plasma concentrations (e.g. eslicarbazepine). Co-administration of moderate inducers is not recommended.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019."
279,Glecaprevir/Pibrentasvir,Esomeprazole,Potential Weak Interaction,NA,"Coadministration has not been studied but may result in decreased concentrations of glecaprevir. Coadministration with omeprazole (40 mg once daily) decreased glecaprevir AUC by ~50% and a similar effect may occur with equivalent doses of esomeprazole. For omeprazole, the European SPC for glecaprevir/pibrentasvir indicates that no dose adjustment is required and the US Prescribing Information indicates no clinically significant interaction and no dose adjustment required. However, it is important to note that currently there are no data with doses of omeprazole greater than 40 mg once daily.",(See Summary)
280,Glecaprevir/Pibrentasvir,Estazolam,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Estazolam is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of estazolam to any clinically significant extent.,(See Summary)
281,Glecaprevir/Pibrentasvir,Estradiol,Potential Weak Interaction,NA,Coadministration has not been studied. Glecaprevir/pibrentasvir is an inhibitor of OATP and in vitro studies have shown estradiol to be a high-affinity OATP substrate. The clinical significance of this is unknown and monitoring for increased side effects of estradiol may be required.,(See Summary)
282,Glecaprevir/Pibrentasvir,Estramustine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Estramustine is dephosphorylated and minimal data show it not to undergo any form of CYP metabolism.,(See Summary)
283,Glecaprevir/Pibrentasvir,Etanercept,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. [Note, there is a concern of hepatotoxic adverse events in patients with HCV receiving anti-TNF agents. Use with caution and monitor liver enzymes and HCV viral load.]",(See Summary)
284,Glecaprevir/Pibrentasvir,Etelcalcetide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro data suggest etelcalcetide is not metabolised by CYP450 nor transported by common transporter proteins.,(See Summary)
285,Glecaprevir/Pibrentasvir,Ethambutol,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ethambutol is partly metabolized by alcohol dehydrogenase (20%) and partly eliminated unchanged in the faeces (20%) and urine (50%).,(See Summary)
286,Glecaprevir/Pibrentasvir,Ethinylestradiol,Do Not Coadminister,NA,"Coadministration with ethinylestradiol is contraindicated. In interaction studies evaluating ethinylestradiol and glecaprevir/pibrentasvir in healthy female subjects, ALT elevations were observed in some subjects during coadministration. Based on increased ALT levels, coadministration of ethinylestradiol containing hormonal contraceptives or hormone replacement therapies is not recommended.","Co-administration of Maviret with ethinyloestradiol-containing products is contraindicated due to the risk of ALT elevations. Coadministration of ethinyloestradiol/norgestimate (35/250 µg once daily) and glecaprevir/pibrentasvir increased ethinyloestradiol Cmax, AUC and Cmin by 31%, 28% and 38%, respectively. There was no change in norelgestromin Cmax, but AUC and Cmin increased by 44% and 45%. Cmax, AUC and Cmin of norgestrel increased by 54%, 63% and 75%, respectively. Coadministration of ethinyloestradiol/levonorgestrel (20/100 µg once daily) and glecaprevir/pibrentasvir increased ethinyloestradiol Cmax, AUC and Cmin by 30%, 40% and 56%, respectively. Cmax, AUC and Cmin of norgestrel increased by 37%, 68% and 77%, respectively.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Coadministration of Mavyret may increase the risk of ALT elevations and is not recommended. Coadministration had no effect on glecaprevir or pibrentasvir concentrations but may increase the risk of ALT elevations and is not recommended. Coadministration of ethinyl estradiol/norgestimate (35/250 µg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 11 subjects. Ethinyl estradiol Cmax, AUC and Cmin increased by 31%, 28% and 38%, respectively. Cmax, AUC and Cmin of norgestrel increased by 54%, 63% and 75%, respectively. There was no change in norelgestromin Cmax, but AUC and Cmin increased by 44% and 45%. Coadministration of ethinyl estradiol/levonorgestrel (20/100 µg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 12 subjects. Ethinyl estradiol Cmax, AUC and Cmin increased by 30%, 40% and 56%, respectively. Cmax, AUC and Cmin of norgestrel increased by 37%, 68% and 77%, respectively.Mavyret Prescribing Information, AbbVie Inc., June 2019."
287,Glecaprevir/Pibrentasvir,Ethosuximide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ethosuximide is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of ethosuximide to any clinically significant extent.,(See Summary)
288,Glecaprevir/Pibrentasvir,Etonogestrel (implant),No Interaction Expected,NA,Coadministration with an etonogestrel-containing progestogen-only implant has not been studied. Etonogestrel is metabolised by CYP3A4 but data with other progestogens suggest that any increase in etonogestrel concentrations due to mild CYP3A4 inhibition by glecaprevir/pibrentasvir is unlikely to be clinically relevant.,(See Summary)
289,Glecaprevir/Pibrentasvir,Etonogestrel (vaginal ring),Do Not Coadminister,NA,"Coadministration of etonogestrel as a combined vaginal ring (CVR) has not been studied. Etonogestrel is coformulated in the CVR with ethinylestradiol which is released at a dose of 0.015 mg/day. Coadministration with ethinylestradiol is contraindicated. In interaction studies evaluating ethinylestradiol and glecaprevir/pibrentasvir in healthy female subjects, ALT elevations were observed in some subjects during coadministration. Based on increased ALT levels, coadministration of ethinylestradiol containing hormonal contraceptives or hormone replacement therapies is not recommended.","Co-administration of Maviret with ethinyloestradiol-containing products is contraindicated due to the risk of ALT elevations. Coadministration of ethinyloestradiol/norgestimate (35/250 µg once daily) and glecaprevir/pibrentasvir increased ethinyloestradiol Cmax, AUC and Cmin by 31%, 28% and 38%, respectively. There was no change in norelgestromin Cmax, but AUC and Cmin increased by 44% and 45%. Cmax, AUC and Cmin of norgestrel increased by 54%, 63% and 75%, respectively. Coadministration of ethinyloestradiol/levonorgestrel (20/100 µg once daily) and glecaprevir/pibrentasvir increased ethinyloestradiol Cmax, AUC and Cmin by 30%, 40% and 56%, respectively. Cmax, AUC and Cmin of norgestrel increased by 37%, 68% and 77%, respectively.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Coadministration of Mavyret may increase the risk of ALT elevations and is not recommended. Coadministration had no effect on glecaprevir or pibrentasvir concentrations but may increase the risk of ALT elevations and is not recommended. Coadministration of ethinyl estradiol/norgestimate (35/250 µg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 11 subjects. Ethinyl estradiol Cmax, AUC and Cmin increased by 31%, 28% and 38%, respectively. Cmax, AUC and Cmin of norgestrel increased by 54%, 63% and 75%, respectively. There was no change in norelgestromin Cmax, but AUC and Cmin increased by 44% and 45%. Coadministration of ethinyl estradiol/levonorgestrel (20/100 µg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 12 subjects. Ethinyl estradiol Cmax, AUC and Cmin increased by 30%, 40% and 56%, respectively. Cmax, AUC and Cmin of norgestrel increased by 37%, 68% and 77%, respectively.Mavyret Prescribing Information, AbbVie Inc., June 2019."
290,Glecaprevir/Pibrentasvir,Etoposide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance an interaction is unlikely. Etoposide is partly metabolised by CYP3A4 to reactive catechol metabolites and partly metabolised by UGT1A1. Glecaprevir/pibrentasvir causes mild CYP3A4 inhibition but this is unlikely to produce a clinically significant effect on etoposide. Monitor the standard parameters for a patient on cytotoxic medications.,(See Summary)
291,Glecaprevir/Pibrentasvir,Etoricoxib,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Etoricoxib is metabolised by multiple CYP enzymes including CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of etoricoxib to any clinically significant extent.,(See Summary)
292,Glecaprevir/Pibrentasvir,Etravirine,Do Not Coadminister,NA,Co-administration has not been studied but is not recommended. Concentration of glecaprevir/pibrentasvir may decrease due to CYP3A4 induction by etravirine which may lead to reduced therapeutic effect.,(See Summary)
293,Glecaprevir/Pibrentasvir,Eucalyptus globulus,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Eucalyptus is a mild to moderate inhibitor of CYP3A4, however, a clinically relevant effect is unlikely at doses used for supplementation.",(See Summary)
294,Glecaprevir/Pibrentasvir,Everolimus,Potential Interaction,NA,"Coadministration has not been studied. Everolimus is a substrate of CYP3A4 and P-gp; concentrations may increase due to the additive effect of weak inhibition of CYP3A4 and inhibition of P-gp. If coadministration cannot be avoided, therapeutic drug monitoring of everolimus should be performed due to its narrow therapeutic index. Inhibition of CYP3A4 by everolimus is unlikely to have a clinically significant effect on glecaprevir/pibrentasvir due to the large therapeutic safety margins.",(See Summary)
295,Glecaprevir/Pibrentasvir,Exemestane,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Exemestane is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a mild inhibitor of CYP3A4 and is unlikely to affect the exposure of exemestane to any clinically significant extent.,(See Summary)
296,Glecaprevir/Pibrentasvir,Exenatide,Potential Weak Interaction,NA,"Co-administration with exenatide has not been studied but based on metabolism and clearance a metabolic interaction is unlikely as exenatide is eliminated by glomerular filtration. However, GLP-1 agonists such as exenatide have the potential to inhibit gastric secretion and thereby impact drugs whose absorption is gastric dependent, such as glecaprevir. A reduction in glecaprevir exposure is possible with exenatide, however, this is unlikely to be clinically significant. Consider taking glecaprevir/pibrentasvir 5 hours before exenatide to minimize any impact on drug exposure for glecaprevir.",(See Summary)
297,Glecaprevir/Pibrentasvir,Ezetimibe,Potential Interaction,NA,"Coadministration has not been studied. Ezetimibe is primarily metabolized in the small intestine and liver by glucuronidation and ezetimibe glucuronide is a substrate of OATP1B1. Ezetimibe glucuronide exposures may increase due to OATP1B1 and P-gp inhibition by glecaprevir/pibrentasvir. The lowest dose should be used with monitoring for adverse effects. [Note, use of ezetimibe is not recommended in moderate to severe hepatic dysfunction.]",(See Summary)
298,Glecaprevir/Pibrentasvir,Famotidine,Potential Weak Interaction,NA,"Coadministration has not been studied but may result in decreased concentrations of glecaprevir. Coadministration with the proton pump inhibitor omeprazole (40 mg once daily) decreased glecaprevir AUC by ~50%. A reduction in glecaprevir exposure is possible with famotidine, however, this is unlikely to be clinically significant.",(See Summary)
299,Glecaprevir/Pibrentasvir,Febuxostat,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Febuxostat is extensively metabolised by multiple P450 (CYPs 1A1, CYP1A2, CYP2C8 and CYP2C9) and UGT enzymes (UGTs 1A1, 1A8, and 1A9). A clinically significant interaction is unlikely as febuxostat is metabolised by multiple pathways.",(See Summary)
300,Glecaprevir/Pibrentasvir,Felodipine,No Interaction Expected,NA,Coadministration of felodipine (2.5 mg single dose) and glecaprevir/pibrentasvir increased felodipine Cmax and AUC both by 31%. This is unlikely to be clinically significant and no dose adjustment is required.,"Clinically significant increases in exposure were not observed for sensitive substrates of CYP3A (felodipine) when administered with Maviret. Drug-drug interaction studies were performed with felodipine and showed no clinically significant interactions with Maviret.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.No dose adjustment is required when Mavyret is coadministered with felodipine. Coadministration of felodipine (2.5 mg single dose) and glecaprevir/pibrentasvir (300/120 mg once daily) increased felodipine Cmax and AUC by 31% and 31% (n=11).Mavyret Prescribing Information, AbbVie Inc., June 2019."
301,Glecaprevir/Pibrentasvir,Fenofibrate,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as fenofibrate is metabolised by multiple enzyme pathways (esterases, UGT2B7 and UGT1A1). [Note, fenofibrate is contraindicated in severe hepatic disease in the European SmPC, and the US Prescribing Information contraindicates it in active liver disease.]",(See Summary)
302,Glecaprevir/Pibrentasvir,Fentanyl,Potential Interaction,NA,"Coadministration has not been studied but fentanyl concentrations may be increased due to weak CYP3A4 inhibition by glecaprevir/pibrentasvir, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. The USPI and SmPC for prescribed fentanyl recommend avoiding concomitant use with CYP3A4 inhibitors. If concomitant use is considered necessary, use with caution, monitoring patients closely at frequent intervals. Data with glecaprevir/pibrentasvir and midazolam, another CYP3A4 substrate, show an increased AUC of 27% which was not deemed clinically significant. However, even modest increases of fentanyl levels may be significant particularly with high doses or with illicit use where any increase in plasma levels may lead to an increased risk of severe toxicities. ","The concomitant use of fentanyl (oral, transdermal or other forms of administration) with cytochrome P450 3A4 (CYP3A4) inhibitors may result in an increase in fentanyl plasma concentrations, which could increase or prolong both the therapeutic and adverse effects, and may cause serious respiratory depression. The extent of interaction with strong CYP3A4 inhibitors is expected to be greater than with weak or moderate CYP3A4 inhibitors. Cases of serious respiratory depression after coadministration of CYP3A4 inhibitors with fentanyl have been reported, including a fatal case after coadministration with a moderate CYP3A4 inhibitor. The concomitant use of CYP3A4 inhibitors and fentanyl is not recommended unless the patient is closely monitored. Effentora Summary of Product Characteristics, Teva Pharma; Victanyl Summary of Product Characteristics, Accord UK Ltd.No dose adjustment is required when Mavyret is coadministered with midazolam. Coadministration of midazolam (1 mg single dose) and glecaprevir/pibrentasvir (300/120 mg once daily) had no effect on midazolam Cmax but increased AUC by 27% (n=12).Mavyret Prescribing Information, AbbVie Inc., September 2019."
303,Glecaprevir/Pibrentasvir,Fexofenadine,Potential Weak Interaction,NA,"Coadministration has not been studied but may increase fexofenadine concentrations due to inhibition of P-gp and potentially OATP1B1 by glecaprevir/pibrentasvir. However, this is unlikely to be clinically significant due to fexofenadine’s wide therapeutic index. Monitoring for drowsiness may be considered.",(See Summary)
304,Glecaprevir/Pibrentasvir,Filgrastim,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. CYP involvement has not been displayed with filgrastim and it is mainly eliminated by neutrophil-mediated clearance, such that the serum concentration of pegfilgrastim declines rapidly with neutrophil recovery.",(See Summary)
305,Glecaprevir/Pibrentasvir,Finasteride,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Finasteride is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of finasteride to any clinically significant extent due to finasteride’s wide therapeutic index.,(See Summary)
306,Glecaprevir/Pibrentasvir,Fingolimod,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fingolimod is metabolised mainly by CYP4F2 and is unlikely to interact with substrates of CYP enzymes or the main transporter proteins.,(See Summary)
307,Glecaprevir/Pibrentasvir,Fish oils,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Although cytochrome P450 enzymes are involved in the hydroxylation of omega-3 there is no human data to indicate any clinical significance.,(See Summary)
308,Glecaprevir/Pibrentasvir,Flecainide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flecainide is metabolised by CYP2D6 which is not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
309,Glecaprevir/Pibrentasvir,Flibanserin,Potential Interaction,NA,"Coadministration has not been studied. Flibanserin is primarily metabolized by CYP3A4 and to a lesser extent by CYP2C19. Although glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4, use with caution as increased concentrations of flibanserin may increase the risk of hypotension and syncope.",(See Summary)
310,Glecaprevir/Pibrentasvir,Flucloxacillin,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flucloxacillin is mainly eliminated renally, partly by glomerular filtration and partly by active secretion via OAT1.",(See Summary)
311,Glecaprevir/Pibrentasvir,Fluconazole,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluconazole is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of fluconazole to any clinically significant extent.,(See Summary)
312,Glecaprevir/Pibrentasvir,Flucytosine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flucytosine is metabolised to 5-fluorouracil which undergoes further metabolism by dihydropyrimidine dehydrogenase.,(See Summary)
313,Glecaprevir/Pibrentasvir,Fludarabine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fludarabine phosphate is rapidly hydrolyzed (non-CYP mediated) to 2F-ara-A, the principal metabolite, which is then eliminated renally.",(See Summary)
314,Glecaprevir/Pibrentasvir,Fludrocortisone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fludrocortisone is metabolized by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of fludrocortisone to any clinically significant extent.,(See Summary)
315,Glecaprevir/Pibrentasvir,Fluindione,Potential Interaction,NA,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Fluindione is metabolised by CYP2C9 (major) and CYP1A2 (minor) which are not affected by glecaprevir/pibrentasvir. However, as liver function may change during treatment with glecaprevir/pibrentasvir, a close monitoring of INR is recommended with vitamin K antagonists.","Coadministration has not been studied. As liver function may change during treatment with Maviret, a close monitoring of International Normalised Ratio (INR) values is recommended with vitamin K antagonists.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019."
316,Glecaprevir/Pibrentasvir,Flunisolide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flunisolide is metabolized primarily by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of flunisolide to any clinically significant extent.,(See Summary)
317,Glecaprevir/Pibrentasvir,Fluoxetine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluoxetine is metabolised by CYP2D6 which is not expected to be affected by glecaprevir/pibrentasvir. Note, a lower or less frequent dose of fluoxetine should be considered in cases of hepatic insufficiency.",(See Summary)
318,Glecaprevir/Pibrentasvir,Flupentixol,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of flupentixol has been poorly described but is likely to involve CYP2D6 and potentially CYP3A4. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of flupentixol to any clinically significant extent.,(See Summary)
319,Glecaprevir/Pibrentasvir,Fluphenazine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluphenazine is metabolised by CYP2D6 which is not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
320,Glecaprevir/Pibrentasvir,Flurazepam,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flurazepam metabolism is likely by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of flurazepam to any clinically significant extent.,(See Summary)
321,Glecaprevir/Pibrentasvir,Flurbiprofen,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flurbiprofen is metabolised by CYP2C9 and UGT2B7 which are not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
322,Glecaprevir/Pibrentasvir,Fluticasone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluticasone is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of fluticasone to any clinically significant extent.,(See Summary)
323,Glecaprevir/Pibrentasvir,Fluvastatin,Potential Interaction,NA,"Coadministration has not been studied. Fluvastatin is a substrate of CYPs 2C8, 2C9 and 3A4 and OATPs 1B1/3 and BCRP. Coadministration may increase fluvastatin concentrations due to inhibition of BCRP and OATP1B1 by glecaprevir/pibrentasvir and weak inhibition of CYP3A4. Statin-associated adverse events such as myopathy should be closely monitored. The lowest necessary dose should be used when co-administered with glecaprevir/pibrentasvir. Note, use of fluvastatin in active liver disease is contraindicated.","Coadministration has not been studied but is expected to increase exposure of fluvastatin. Interactions with fluvastatin are likely and caution is recommended during the combination. A low dose of the statin is recommended at the initiation of the DAA treatment.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Coadministration may increase the concentrations of fluvastatin. Increased statin concentrations may increase the risk of myopathy, including rhabdomyolysis. Use the lowest approved dose of fluvastatin. If higher doses are needed, use the lowest necessary statin dose based on a risk/benefit assessment.Mavyret Prescribing Information, AbbVie Inc., June 2019."
324,Glecaprevir/Pibrentasvir,Fluvoxamine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluvoxamine is metabolised mainly by CYP2D6 and to a lesser extent by CYP1A2, which are not expected to be affected by glecaprevir/pibrentasvir.",(See Summary)
325,Glecaprevir/Pibrentasvir,Folic acid,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as folic acid undergoes deconjugation and reduction,(See Summary)
326,Glecaprevir/Pibrentasvir,Fondaparinux,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as fondaparinux is mainly excreted in urine.,(See Summary)
327,Glecaprevir/Pibrentasvir,Formoterol,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as formoterol is eliminated primarily by glucuronidation and O-demethylation (multiple CYP involvement).,(See Summary)
328,Glecaprevir/Pibrentasvir,Fosamprenavir,Do Not Coadminister,NA,"Coadministration has not been studied and is not recommended. Concomitant use of glecaprevir/pibrentasvir with OATP1B inhibitors, such as fosamprenavir, may increase the risk of ALT elevations due to a significant increase in glecaprevir/pibrentasvir plasma concentrations caused by OATP1B1/3 inhibition. Based on interactions studies, co-administration of glecaprevir/pibrentasvir with ritonavir-boosted HIV protease inhibitors is not recommended.",(See Summary)
329,Glecaprevir/Pibrentasvir,Foscarnet,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as foscarnet is mainly renally eliminated.,(See Summary)
330,Glecaprevir/Pibrentasvir,Fosinopril,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fosinopril is a prodrug metabolised in the liver by a non-CYP mechanism to the active metabolite.,(See Summary)
331,Glecaprevir/Pibrentasvir,Frovatriptan,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Frovatriptan is metabolised by CYP1A2 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP1A2 and is unlikely to affect the exposure of frovatriptan to any clinically significant extent.,(See Summary)
332,Glecaprevir/Pibrentasvir,Furosemide,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as furosemide is a substrate of UGTs 1A1, 1A9 and 2B7 and is excreted in urine.",(See Summary)
333,Glecaprevir/Pibrentasvir,Gabapentin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. There is no evidence of gabapentin metabolism in humans and it is eliminated unchanged solely by renal excretion with little data on transporters used.,(See Summary)
334,Glecaprevir/Pibrentasvir,Gadopentetate (gadolinium),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as gadopentetate is mainly renally eliminated.,(See Summary)
335,Glecaprevir/Pibrentasvir,Garlic,No Interaction Expected,NA,Coadministration has not been studied but a clinically significant interaction is unlikely. Garlic extract has no known effect on enzymes or transporters involved in glecaprevir/pibrentasvir disposition.,(See Summary)
336,Glecaprevir/Pibrentasvir,Gefitinib,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gefitinib is a metabolized by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect this pathway to any clinically significant extent.,(See Summary)
337,Glecaprevir/Pibrentasvir,Gemcitabine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as gemcitabine is metabolised by cytidine deaminase.,(See Summary)
338,Glecaprevir/Pibrentasvir,Gemfibrozil,Potential Interaction,NA,"Coadministration has not been studied. Gemfibrozil exposure may increase due to OATP inhibition by glecaprevir/pibrentasvir causing increased side effects including GI disturbance and muscle pain. Gemfibrozil also inhibits OATP1B1, therefore can increase glecaprevir/pibrentasvir exposures. Use lowest gemfibrozil dose possible or consider stopping for duration of glecaprevir/pibrentasvir treatment if clinical indication allows. [Note, use of gemfibrozil in hepatic impairment is contraindicated.]",(See Summary)
339,Glecaprevir/Pibrentasvir,Gentamicin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as gentamicin is mainly excreted in urine.,(See Summary)
340,Glecaprevir/Pibrentasvir,GHB (Gamma-hydroxybutyrate),Potential Interaction,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gamma-hydroxybutyrate may be metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4. However, due to the narrow therapeutic index of gamma-hydroxybutyrate, caution is advised and monitor for adverse effects.",(See Summary)
341,Glecaprevir/Pibrentasvir,Ginger (Zingiber officinale),No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Although in vitro data show gingerols moderately inhibit CYP3A4, a clinically relevant effect on DAA exposure is unlikely at standard dietary/supplement dosage.",(See Summary)
342,Glecaprevir/Pibrentasvir,Ginkgo biloba,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with standard doses (up to 240 mg) of Ginkgo biloba.,(See Summary)
343,Glecaprevir/Pibrentasvir,Ginseng,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro data show no effect of ginseng on a number of CYP isoforms including CYPs 3A4, 1A2, 2E1 and 2D6.",(See Summary)
344,Glecaprevir/Pibrentasvir,Glibenclamide (Glyburide),Potential Interaction,NA,Coadministration has not been studied. Glibenclamide is a substrate of OATP1B1 and concentrations may increase due to inhibition of OATP1B1 by glecaprevir/pibrentasvir. Close monitoring of blood glucose and adverse effects is recommended and adjust dose as required. ,(See Summary)
345,Glecaprevir/Pibrentasvir,Gliclazide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gliclazide is metabolized by CYPs 2C19 and 2C9 which are not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
346,Glecaprevir/Pibrentasvir,Glimepiride,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glimepiride is metabolised by CYP2C9 which is not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
347,Glecaprevir/Pibrentasvir,Glipizide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glipizide is mainly metabolised by CYP2C9 which is not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
348,Glecaprevir/Pibrentasvir,Glycerol phenylbutyrate,Potential Weak Interaction,NA,"Coadministration has not been studied. Glycerol phenylbutyrate is metabolised by pancreatic lipases, beta-oxidation, and glutamine conjugation, then eliminated in the urine. Glycerol phenylbutyrate has been shown to be a weak inducer of CYP3A4. This is unlikely to be clinically significant but should be considered in the event of a suboptimal response to HCV treatment. ",(See Summary)
349,Glecaprevir/Pibrentasvir,Goldenseal (Hydrastis canadensis),Potential Interaction,NA,"Coadministration has not been studied. Concentrations of both goldenseal and glecaprevir/pibrentasvir may increase due to CYP3A4 inhibition, although this effect is mild with glecaprevir. Monitor for signs and symptoms of increased glecaprevir concentrations and use with caution.",(See Summary)
350,Glecaprevir/Pibrentasvir,Goserelin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. There is minimal metabolism of goserelin and no clinically relevant accumulation with higher doses of the implant. Goserelin is renally cleared with no dose alteration required in renal or hepatic impairment.,(See Summary)
351,Glecaprevir/Pibrentasvir,Granisetron,Potential Weak Interaction,NA,"Coadministration has not been studied. Granisetron is metabolised by CYP3A4. Glecaprevir is a mild inhibitor of CYP3A4 and may cause minimal increase to granisetron concentrations but this is unlikely to be clinically significant. As granisetron may prolong the QTc interval, caution is recommended if patient has other risk factors to potentiate this.",(See Summary)
352,Glecaprevir/Pibrentasvir,Grapefruit juice,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance an interaction is unlikely. Grapefruit juice inhibits intestinal CYP3A4 but this is unlikely to have a clinically significant effect on glecaprevir/pibrentasvir due to the large therapeutic safety margins.,(See Summary)
353,Glecaprevir/Pibrentasvir,Grape seed extract,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Studies have shown that CYP3A4 inhibition by grape seed extract is mild, indicating a clinically relevant effect is unlikely.",(See Summary)
354,Glecaprevir/Pibrentasvir,Green tea (Camellia sinensis),Potential Weak Interaction,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Studies have shown variable CYP involvement with green tea metabolism but the overall effect is likely negligible. However, based on some conflicting data indicating possible CYP3A4 inhibition, consider monitoring for additional side effects of glecaprevir/pibrentasvir at high dose repeated use of green tea.",(See Summary)
355,Glecaprevir/Pibrentasvir,Griseofulvin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Griseofulvin is metabolised by CYP3A4 and also induces this enzyme. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of griseofulvin to any clinically significant extent. Induction of CYP3A4 by griseofulvin is unlikely to have a clinically significant effect on glecaprevir/pibrentasvir due to the large therapeutic safety margins.,(See Summary)
356,Glecaprevir/Pibrentasvir,Halofantrine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Halofantrine is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of halofantrine to any clinically significant extent.,(See Summary)
357,Glecaprevir/Pibrentasvir,Haloperidol,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Haloperidol is extensively metabolised by UGT2B7, carbonyl reduction and CYP2D6 (none of which are expected to be affected by glecaprevir/pibrentasvir) and by CYP3A4. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of haloperidol to any clinically significant extent.",(See Summary)
358,Glecaprevir/Pibrentasvir,Heparin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as heparin is cleared by the reticuloendothelial system and is renally excreted.,(See Summary)
359,Glecaprevir/Pibrentasvir,Heroin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Heroin is metabolised mainly by deacetylation with multiple small pathway involvement.,(See Summary)
360,Glecaprevir/Pibrentasvir,Hydralazine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydralazine is metabolised by multiple pathways including hydroxylation, conjugation and by N-acetylation.",(See Summary)
361,Glecaprevir/Pibrentasvir,Hydrochlorothiazide,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydrochlorothiazide is not metabolized and is cleared by the kidneys via OAT1, which is not affected by glecaprevir/pibrentasvir.",(See Summary)
362,Glecaprevir/Pibrentasvir,Hydrocodone,Potential Interaction,NA,"Coadministration has not been studied. Concentrations of hydrocodone may increase due to mild CYP3A4 inhibition by glecaprevir/pibrentasvir. Close monitoring is recommended. Note, use with caution in patients with hepatic impairment.",(See Summary)
363,Glecaprevir/Pibrentasvir,Hydrocortisone (topical),No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Following topical application to most areas of normal skin, only minimal amounts of the drug reach the dermis and subsequently the systemic circulation.",(See Summary)
364,Glecaprevir/Pibrentasvir,Hydromorphone,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as hydromorphone is extensively metabolised by glucuronidation. [Note, use of hydromorphone in patients with ANY degree of hepatic impairment is contraindicated in its European SmPC, but the US Prescribing Information does not recommend it for patients with severe hepatic impairment and suggests a dose reduction for patients with moderate hepatic impairment.]",(See Summary)
365,Glecaprevir/Pibrentasvir,Hydroxychloroquine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Data suggest hydroxychloroquine to be metabolised (in part) by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of hydroxychloroquine to any clinically significant extent. [Note, the European SmPC for hydroxychloroquine recommends caution in impaired hepatic function.]",(See Summary)
366,Glecaprevir/Pibrentasvir,Hydroxyzine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydroxyzine is metabolised by alcohol dehydrogenase and CYP mediated pathways. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of hydroxyzine to any clinically significant extent. [Note, as hydroxyzine elimination is impaired in patients with hepatic dysfunction, daily dose or dose frequency should be reduced in patients with impaired liver function.]",(See Summary)
367,Glecaprevir/Pibrentasvir,Hyoscine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hyoscine acts predominantly locally and undergoes minimal absorption.,(See Summary)
368,Glecaprevir/Pibrentasvir,Ibalizumab-uiyk,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. No drug interaction studies have been conducted with ibalizumab: based on ibalizumab’s mechanism of action and target-mediated drug disposition, drug-drug interactions are not expected. Glecaprevir and pibrentasvir undergo hepatic metabolism whereas ibalizumab, a monoclonal antibody binding to the CD4 receptor, is likely to be eliminated via intracellular catabolism similarly to other monoclonal antibodies.",(See Summary)
369,Glecaprevir/Pibrentasvir,Ibandronic acid,No Interaction Expected,NA,"Coadministration has not been studied but ibandronate can be administered with glecaprevir/pibrentasvir and no dose alteration is required. The portion of ibandronate that is not removed from the circulation via bone absorption is eliminated unchanged by the kidney (approximately 50% of the absorbed dose). However, administration of ibandronate should be separated from food or other medicinal products. [Note: this interaction is not specific for glecaprevir/pibrentasvir, but for any medication taken with ibandronic acid.]",(See Summary)
370,Glecaprevir/Pibrentasvir,Ibuprofen,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ibuprofen is metabolised by CYP2C8, CYP2C9 and glucuronidation which are not expected to be affected by glecaprevir/pibrentasvir.",(See Summary)
371,Glecaprevir/Pibrentasvir,Idarubicin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Idarubicin is converted to idarubicinol by aldoketoreductase.,(See Summary)
372,Glecaprevir/Pibrentasvir,Iloperidone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Iloperidone is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of iloperidone to any clinically significant extent.,(See Summary)
373,Glecaprevir/Pibrentasvir,Iloprost,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Iloprost is metabolised by beta-oxidation of the carboxyl side chain with only a minor role for CYP metabolism.,(See Summary)
374,Glecaprevir/Pibrentasvir,Imatinib,Potential Interaction,NA,Coadministration has not been studied. Imatinib is metabolised by CYP3A4 and transported by BCRP. Concentrations of imatinib may increase due to inhibition of BCRP by both pibrentasvir and glecaprevir. Close monitoring for adverse effects and blood toxicities is recommended.,(See Summary)
375,Glecaprevir/Pibrentasvir,Imipenem,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Imipenem is predominantly eliminated in the urine.,(See Summary)
376,Glecaprevir/Pibrentasvir,Imipramine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Imipramine is metabolised by CYP3A4, CYP2C19 and CYP1A2. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of imipramine to any clinically significant extent.",(See Summary)
377,Glecaprevir/Pibrentasvir,Indacaterol,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Although indacaterol is metabolised via CYP3A4 and transported by P-gp, any inhibition of these pathways is unlikely to be of clinical significance. The increased magnitude of exposure due to such interactions does not raise any concerns given the safety experience with indacaterol at doses up to twice the recommended therapeutic dose ",(See Summary)
378,Glecaprevir/Pibrentasvir,Indapamide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Indapamide is metabolised by CYP enzymes but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect indapamide exposure to any clinically significant extent.,(See Summary)
379,Glecaprevir/Pibrentasvir,Indinavir,Do Not Coadminister,NA,"Coadministration is not recommended. Concomitant use of glecaprevir/pibrentasvir with OATP1B inhibitors, such as indinavir, may increase the risk of ALT elevations due to a significant increase in pibrentasvir plasma concentrations caused by OATP1B1/3 inhibition. Based on interactions studies, coadministration of glecaprevir/pibrentasvir with ritonavir-boosted HIV protease inhibitors is not recommended.",(See Summary)
380,Glecaprevir/Pibrentasvir,Indometacin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Indometacin is predominantly acylated and then glucuronidated and there is no evidence of CYP mediated interactions.,(See Summary)
381,Glecaprevir/Pibrentasvir,Insulin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Insulin is metabolised by hydrolysis.,(See Summary)
382,Glecaprevir/Pibrentasvir,Inula racemosa,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Although alantolactone, a component of Inula racemosa, moderately inhibits CYP3A4 in vitro, a clinically relevant effect on glecaprevir/pibrentasvir exposure is unlikely.",(See Summary)
383,Glecaprevir/Pibrentasvir,Iodine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Iodides are excreted mainly in the urine with smaller amounts excreted in the faeces, sweat and saliva.",(See Summary)
384,Glecaprevir/Pibrentasvir,Ipilimumab,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ipilimumab is not metabolised by cytochrome P450 and no drug interactions were involved in studies examining multiple CYP isozymes.,(See Summary)
385,Glecaprevir/Pibrentasvir,Ipratropium bromide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ipratropium bromide is metabolised by esterases.,(See Summary)
386,Glecaprevir/Pibrentasvir,Irbesartan,Potential Interaction,NA,"Coadministration has not been studied. Irbesartan is metabolised by CYP2C9 and UGT, transported by OATP1B1, and inhibits P-gp. Inhibition of OATP1B1 and P-gp by glecaprevir/pibrentasvir may increase irbesartan levels. The clinical significance is unknown. Close monitoring of heart rate, blood pressure and for increased side effects is recommended. Inhibition of P-gp by irbesartan is unlikely to have a clinically significant effect on glecaprevir/pibrentasvir due to the large therapeutic safety margins",(See Summary)
387,Glecaprevir/Pibrentasvir,Irinotecan,Potential Interaction,NA,"Coadministration has not been studied. Irinotecan is a substrate of CYP3A4, P-gp, BCRP and UGT1B1. Concentrations may increase due to the additive effect of weak inhibition of CYP3A4, inhibition of P-gp and inhibition of BCRP by glecaprevir/pibrentasvir. Use with caution and monitor closely for increased cytotoxic side effects. A decrease in irinotecan dose may be needed. ",(See Summary)
388,Glecaprevir/Pibrentasvir,Iron supplements,No Interaction Expected,NA,Coadministration has not been studied but a clinically significant interaction is unlikely.,(See Summary)
389,Glecaprevir/Pibrentasvir,Isavuconazole,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Inhibition of CYP3A4 (moderate) and P-gp (weak) by isavuconazole is unlikely to have a clinically significant effect on glecaprevir/pibrentasvir due to the large therapeutic safety margins. Isavuconazole is a CYP3A4/5 substrate but glecaprevir and pibrentasvir are only weak inhibitors of CYP3A4 and likely to have only a minor impact on isavuconazole exposure. No dose adjustment is required for isavuconazole when coadministered with mild CYP3A4 inhibitors.,(See Summary)
390,Glecaprevir/Pibrentasvir,Isoflurane,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Isoflurane is mainly metabolised by CYP2E1 which is not affected by glecaprevir/pibrentasvir.,(See Summary)
391,Glecaprevir/Pibrentasvir,Isoniazid,Potential Weak Interaction,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Isoniazid is metabolised by N-acetyl transferase and CYP2E1 which are not expected to be affected by glecaprevir/pibrentasvir. [Note, use of isoniazid should be carefully monitored with patients with current chronic liver disease. Severe and sometimes fatal hepatitis associated with isoniazid therapy may occur and may develop even after many months of treatment.]",(See Summary)
392,Glecaprevir/Pibrentasvir,Isosorbide mononitrate,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Isosorbide mononitrate is completely absorbed and is not subject to first pass metabolism by the liver. It is excreted mainly in the urine.,(See Summary)
393,Glecaprevir/Pibrentasvir,Isotretinoin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Isotretinoin is metabolized mainly by CYP2C8 and CYP3A4 with participation from CYP2B6 and CYP2C9 and no single isoform appears to have a predominant role. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of isotretinoin to any clinically significant extent.,(See Summary)
394,Glecaprevir/Pibrentasvir,Ispaghula husk,No Interaction Expected,NA,"Coadministration has not been studied. The mode of action of ispaghula husk is physical and does not depend on absorption into the systemic circulation. However, ispaghula husk may delay or reduce gastrointestinal absorption of other drugs and it is advisable to separate administration if possible. [Note: this interaction is not specific for glecaprevir/pibrentasvir, but for any medication taken with ispaghula husk.]",(See Summary)
395,Glecaprevir/Pibrentasvir,Isradipine,Potential Interaction,NA,"Coadministration has not been studied. Concentrations of isradipine may increase due to mild inhibition of CYP3A4 and inhibition of P-gp by glecaprevir/pibrentasvir. Close monitoring of heart rate and blood pressure, and for side effects such as oedema, postural hypotension and headache is recommended.",(See Summary)
396,Glecaprevir/Pibrentasvir,Itraconazole,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Itraconazole is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of itraconazole to any clinically significant extent. Inhibition of CYP3A4 by itraconazole is unlikely to have a clinically significant effect on glecaprevir/pibrentasvir due to the large therapeutic safety margins. The European Summary of Product Characteristics for Maviret states that itraconazole may increase glecaprevir and pibrentasvir plasma exposure due to inhibition of P-gp and BCRP.,"Co-administration of Maviret with medicinal products that inhibit P-gp and BCRP (e.g. itraconazole) may slow elimination of glecaprevir and pibrentasvir and thereby increase plasma exposure of the antivirals.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019."
397,Glecaprevir/Pibrentasvir,Ivabradine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ivabradine is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of ivabradine to any clinically significant extent.,(See Summary)
398,Glecaprevir/Pibrentasvir,Ivermectin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ivermectin is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of ivermectin to any clinically significant extent.,(See Summary)
399,Glecaprevir/Pibrentasvir,Ixazomib,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Ixazomib is metabolised by multiple CYP and non-CYP enzymes. Coadministration of ixazomib with clarithromycin (a strong CYP3A4 inhibitor) did not result in a clinically meaningful change in exposure of ixazomib (Cmax decreased by 4%; AUC increased by 11%). Ixazomib is not expected to cause transporter-mediated drug-drug interactions.",(See Summary)
400,Glecaprevir/Pibrentasvir,Kava kava (Piper methysticum),No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Kava kava appears to inhibit CYP3A4 in vitro only, therefore, a clinically relevant effect is not expected. However, monitor patient as variations in potency amongst preparations is large.",(See Summary)
401,Glecaprevir/Pibrentasvir,Ketamine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ketamine is metabolised mainly by CYP3A4 with CYP2B6 and CYP2C9 having a minor contribution. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of ketamine to any clinically significant extent. However, if used outside of anaesthesia ensure that the patient is aware of signs of toxicity such as respiratory depression and hallucinations.",(See Summary)
402,Glecaprevir/Pibrentasvir,Ketoconazole,Potential Interaction,NA,Coadministration has not been studied. Ketoconazole is a substrate and inhibitor of CYP3A4 and P-gp. Concomitant use of systemic ketoconazole and glecaprevir/pibrentasvir may increase glecaprevir/pibrentasvir exposure and may increase the overall risk of hepatotoxicity. Inhibition of P-gp and BCRP by glecaprevir/pibrentasvir may increase ketoconazole concentrations. Monitor LFTs and use with caution.,"Co-administration of Maviret with medicinal products that inhibit P-gp and BCRP (e.g. ketoconazole) may slow elimination of glecaprevir and pibrentasvir and thereby increase plasma exposure of the antivirals.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019."
403,Glecaprevir/Pibrentasvir,Ketoprofen,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ketoprofen is metabolized by UGTs which are not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
404,Glecaprevir/Pibrentasvir,Labetalol,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of labetalol is thought to be by UGT1A1 and UGT2B7 which are not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
405,Glecaprevir/Pibrentasvir,Lacidipine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lacidipine is metabolised by CYP enzymes including CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of lacidipine to any clinically significant extent. [Note, caution is advised in patients with hepatic impairment.]",(See Summary)
406,Glecaprevir/Pibrentasvir,Lacosamide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lacosamide is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of lacosamide to any clinically significant extent.,(See Summary)
407,Glecaprevir/Pibrentasvir,Lactulose,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metabolism of lactulose to lactic acid occurs via gastro-intestinal microbial flora only.,(See Summary)
408,Glecaprevir/Pibrentasvir,Lamivudine (HBV),No Interaction Expected,NA,"Coadministration with lamivudine alone has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Interaction studies performed with lamivudine (as Triumeq, abacavir/dolutegravir/lamivudine) showed no clinically significant interactions with glecaprevir/pibrentasvir. Lamivudine may be coadministered with glecaprevir/pibrentasvir without dose adjustment.","Drug-drug interaction studies were performed with lamivudine and showed no clinically significant interactions with Maviret.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.No dose adjustment is required when Mavyret is coadministered with lamivudine.Mavyret Prescribing Information, AbbVie Inc., June 2019.The pharmacokinetics of glecaprevir/pibrentasvir (300/120 mg once daily) coadministered with abacavir/dolutegravir/lamivudine (600/50/300 mg once daily) was studied in 24 healthy subjects. Cmax and AUC for glecaprevir and pibrentasvir decreased by 25-28%, but there was no impact on Cmax and AUC for abacavir, dolutegravir or lamivudine. No dose adjustment is required when glecaprevir/pibrentasvir are coadministered with abacavir, dolutegravir and lamivudine.Glecaprevir and pibrentasvir interactions with combination antiretroviral regimens. Kosloski MP, Dutta S, Viani RM, et al. Conference on Retroviruses and Opportunistic Infections, Seattle, February 2017, abstract 413."
409,Glecaprevir/Pibrentasvir,Lamivudine (HIV),No Interaction Expected,NA,"Coadministration with lamivudine alone has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Interaction studies performed with lamivudine (as Triumeq, abacavir/dolutegravir/lamivudine) showed no clinically significant interactions with glecaprevir/pibrentasvir. Lamivudine may be coadministered with glecaprevir/pibrentasvir without dose adjustment.","Drug-drug interaction studies were performed with lamivudine and showed no clinically significant interactions with Maviret.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.No dose adjustment is required when Mavyret is coadministered with lamivudine.Mavyret Prescribing Information, AbbVie Inc., June 2019.The pharmacokinetics of glecaprevir/pibrentasvir (300/120 mg once daily) coadministered with abacavir/dolutegravir/lamivudine (600/50/300 mg once daily) was studied in 24 healthy subjects. Cmax and AUC for glecaprevir and pibrentasvir decreased by 25-28%, but there was no impact on Cmax and AUC for abacavir, dolutegravir or lamivudine. No dose adjustment is required when glecaprevir/pibrentasvir are coadministered with abacavir, dolutegravir and lamivudine.Glecaprevir and pibrentasvir interactions with combination antiretroviral regimens. Kosloski MP, Dutta S, Viani RM, et al. Conference on Retroviruses and Opportunistic Infections, Seattle, February 2017, abstract 413."
410,Glecaprevir/Pibrentasvir,Lamotrigine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lamotrigine is metabolised by UGT1A4 which is not expected to be affected by glecaprevir/pibrentasvir.,"Drug-drug interaction studies were performed with lamotrigine and showed no clinically significant interactions with Maviret.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.No dose adjustment is required when Mavyret is coadministered with lamotrigine.Mavyret Prescribing Information, AbbVie Inc., June 2019."
411,Glecaprevir/Pibrentasvir,Lanreotide,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The limited data available indicate the somatostatin analogues, such as lanreotide, may increase concentrations of CYP450 substrates but this is unlikely to have a clinically significant effect on glecaprevir/pibrentasvir due to the large therapeutic safety margins.",(See Summary)
412,Glecaprevir/Pibrentasvir,Lansoprazole,Potential Weak Interaction,NA,"Coadministration has not been studied but may result in decreased concentrations of glecaprevir. Coadministration with omeprazole (40 mg once daily) decreased glecaprevir AUC by ~50% and a similar effect may occur with equivalent doses of lansoprazole. For omeprazole, the European SPC for glecaprevir/pibrentasvir indicates that no dose adjustment is required and the US Prescribing Information indicates no clinically significant interaction and no dose adjustment required. However, it is important to note that currently there are no data with doses of omeprazole greater than 40 mg once daily.",(See Summary)
413,Glecaprevir/Pibrentasvir,Lapatinib,Potential Interaction,NA,"Coadministration has not been studied. Concentrations of lapatinib may increase due to mild inhibition of CYP3A4, inhibition of P-gp, and inhibition of BCRP by glecaprevir/pibrentasvir. Use with caution and consider a dose decrease of lapatinib.",(See Summary)
414,Glecaprevir/Pibrentasvir,Ledipasvir/Sofosbuvir,Do Not Coadminister,NA,Coadministration of glecaprevir/pibrentasvir with other directly acting antivirals has not been studied and therefore cannot be recommended.,(See Summary)
415,Glecaprevir/Pibrentasvir,Lenalidomide,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lenalidomide undergoes limited metabolism and is not metabolised by cytochrome P450 enzymes. It does not induce CYPs, or inhibit CYPs, UGT1A1, P-gp and OATP1B1. Lenalidomide is not a substrate of OATP1B1 or BCRP therefore no effect is expected due to inhibition of OATP1B1 or BCRP by glecaprevir/pibrentasvir. Although lenalidomide is a substrate of P-gp, no effect due to inhibition of P-gp by glecaprevir/pibrentasvir is expected as no clinically relevant effect on lenalidomide was observed with quinidine (a strong P-gp inhibitor) or temsirolimus (a moderate P-gp inhibitor). ",(See Summary)
416,Glecaprevir/Pibrentasvir,Lercanidipine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lercanidipine is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of lercanidipine to any clinically significant extent.,(See Summary)
417,Glecaprevir/Pibrentasvir,Letrozole,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Letrozole is metabolised CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of letrozole to any clinically significant extent.,(See Summary)
418,Glecaprevir/Pibrentasvir,Levetiracetam,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levetiracetam is not extensively metabolised in humans and production of the primary metabolite is not mediated by liver cytochrome P450 isoenzymes.,(See Summary)
419,Glecaprevir/Pibrentasvir,Levocetirizine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Less than 14% of cetirizine is metabolised (CYP3A4 and multiple identified enzymes). Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of levocetirizine to any clinically significant extent.,(See Summary)
420,Glecaprevir/Pibrentasvir,Levofloxacin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as levofloxacin is mainly excreted in urine.,(See Summary)
421,Glecaprevir/Pibrentasvir,Levomepromazine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levomepromazine is metabolised by CYP2D6 which is not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
422,Glecaprevir/Pibrentasvir,Levonorgestrel (COC),Do Not Coadminister,NA,"In interaction studies evaluating ethinylestradiol and glecaprevir/pibrentasvir in healthy female subjects, ALT elevations were observed in some subjects during coadministration. Based on increased ALT levels, coadministration of ethinylestradiol containing hormonal contraceptives or hormone replacement therapies is not recommended. Coadministration of ethinylestradiol/levonorgestrel (20/100 µg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) increased ethinylestradiol Cmax, AUC and Cmin by 30%, 40% and 56%, respectively; Cmax, AUC and Cmin of norgestrel increased by 37%, 68% and 77%, respectively (n=12).","Co-administration of Maviret with ethinyloestradiol-containing products is contraindicated due to the risk of ALT elevations. Coadministration of ethinyloestradiol/norgestimate (35/250 µg once daily) and glecaprevir/pibrentasvir increased ethinyloestradiol Cmax, AUC and Cmin by 31%, 28% and 38%, respectively. There was no change in norelgestromin Cmax, but AUC and Cmin increased by 44% and 45%. Cmax, AUC and Cmin of norgestrel increased by 54%, 63% and 75%, respectively. Coadministration of ethinyloestradiol/levonorgestrel (20/100 µg once daily) and glecaprevir/pibrentasvir increased ethinyloestradiol Cmax, AUC and Cmin by 30%, 40% and 56%, respectively. Cmax, AUC and Cmin of norgestrel increased by 37%, 68% and 77%, respectively.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Coadministration of Mavyret may increase the risk of ALT elevations and is not recommended. Coadministration had no effect on glecaprevir or pibrentasvir concentrations but may increase the risk of ALT elevations and is not recommended. Coadministration of ethinyl estradiol/norgestimate (35/250 µg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 11 subjects. Ethinyl estradiol Cmax, AUC and Cmin increased by 31%, 28% and 38%, respectively. Cmax, AUC and Cmin of norgestrel increased by 54%, 63% and 75%, respectively. There was no change in norelgestromin Cmax, but AUC and Cmin increased by 44% and 45%. Coadministration of ethinyl estradiol/levonorgestrel (20/100 µg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 12 subjects. Ethinyl estradiol Cmax, AUC and Cmin increased by 30%, 40% and 56%, respectively. Cmax, AUC and Cmin of norgestrel increased by 37%, 68% and 77%, respectively.Mavyret Prescribing Information, AbbVie Inc., June 2019."
423,Glecaprevir/Pibrentasvir,Levonorgestrel (Emergency Contraception),No Interaction Expected,NA,Coadministration with levonorgestrel for emergency contraception has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Coadministration of glecaprevir/pibrentasvir with levonorgestrel/ethinylestradiol (as an oral contraceptive) increased norgestrel exposure by 68%. This observed increased in exposure is not expected to affect efficacy for emergency contraception and no dose adjustment is required.,"Coadministration of ethinyloestradiol/levonorgestrel (20/100 µg once daily) and glecaprevir/pibrentasvir increased ethinyloestradiol Cmax, AUC and Cmin by 30%, 40% and 56%, respectively. Cmax, AUC and Cmin of norgestrel increased by 37%, 68% and 77%, respectively.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Coadministration of ethinyl estradiol/levonorgestrel (20/100 µg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 12 subjects. Ethinyl estradiol Cmax, AUC and Cmin increased by 30%, 40% and 56%, respectively. Cmax, AUC and Cmin of norgestrel increased by 37%, 68% and 77%, respectively.Mavyret Prescribing Information, AbbVie Inc., June 2019."
424,Glecaprevir/Pibrentasvir,Levonorgestrel (HRT),Potential Weak Interaction,NA,"Coadministration with levonorgestrel as hormone replacement therapy (HRT) has not been studied. Levonorgestrel for HRT is coformulated with estradiol in a transdermal patch. Transdermally applied estrogens and progestogens are less susceptible than oral hormones to drug interactions by enzyme inducers/inhibitors due to avoidance of first-pass metabolism in the liver. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Estradiol is metabolized by CYPs 3A4 and 1A2, and is glucuronidated. Coadministration of glecaprevir/pibrentasvir with levonorgestrel/ethinylestradiol (as an oral contraceptive) increased norgestrel exposure by 68%. This observed increased in exposure is not expected to affect efficacy. However, glecaprevir/pibrentasvir is an inhibitor of OATP and in vitro studies have shown estradiol to be a high-affinity OATP substrate. The clinical significance of this is unknown and monitoring for increased side effects of estradiol may be required.","Coadministration of ethinyloestradiol/levonorgestrel (20/100 µg once daily) and glecaprevir/pibrentasvir increased ethinyloestradiol Cmax, AUC and Cmin by 30%, 40% and 56%, respectively. Cmax, AUC and Cmin of norgestrel increased by 37%, 68% and 77%, respectively.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Coadministration of ethinyl estradiol/levonorgestrel (20/100 µg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 12 subjects. Ethinyl estradiol Cmax, AUC and Cmin increased by 30%, 40% and 56%, respectively. Cmax, AUC and Cmin of norgestrel increased by 37%, 68% and 77%, respectively.Mavyret Prescribing Information, AbbVie Inc., June 2019."
425,Glecaprevir/Pibrentasvir,Levonorgestrel (implant),No Interaction Expected,NA,Coadministration with a levonorgestrel progestogen-only implant has not been studied but a clinically significant interaction is unlikely. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Coadministration of glecaprevir/pibrentasvir with levonorgestrel/ethinylestradiol (as an oral contraceptive) increased norgestrel exposure by 68%. This observed increased in exposure is not expected to affect efficacy.,"Coadministration of ethinyloestradiol/levonorgestrel (20/100 µg once daily) and glecaprevir/pibrentasvir increased ethinyloestradiol Cmax, AUC and Cmin by 30%, 40% and 56%, respectively. Cmax, AUC and Cmin of norgestrel increased by 37%, 68% and 77%, respectively. No dose adjustment is required with levonorgestrel, as a contraceptive progestogen. Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Coadministration of ethinyl estradiol/levonorgestrel (20/100 µg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 12 subjects. Ethinyl estradiol Cmax, AUC and Cmin increased by 30%, 40% and 56%, respectively. Cmax, AUC and Cmin of norgestrel increased by 37%, 68% and 77%, respectively.Mavyret Prescribing Information, AbbVie Inc., June 2019."
426,Glecaprevir/Pibrentasvir,Levonorgestrel (IUD),No Interaction Expected,NA,Coadministration with a levonorgestrel intra-uterine device (IUD) has not been studied but there is little potential for an interaction given the local mechanism of action of levonorgestrel.,(See Summary)
427,Glecaprevir/Pibrentasvir,Levonorgestrel (POP),Potential Weak Interaction,NA,Coadministration with a levonorgestrel progestogen-only pill (POP) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Levonorgestrel is metabolized by CYP3A4 and is glucuronidated to a minor extent. Coadministration of glecaprevir/pibrentasvir with levonorgestrel/ethinylestradiol (as an oral contraceptive) increased norgestrel exposure by 68%. This observed increased in exposure is not expected to affect efficacy.,"Coadministration of ethinyloestradiol/levonorgestrel (20/100 µg once daily) and glecaprevir/pibrentasvir increased ethinyloestradiol Cmax, AUC and Cmin by 30%, 40% and 56%, respectively. Cmax, AUC and Cmin of norgestrel increased by 37%, 68% and 77%, respectively.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Coadministration of ethinyl estradiol/levonorgestrel (20/100 µg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 12 subjects. Ethinyl estradiol Cmax, AUC and Cmin increased by 30%, 40% and 56%, respectively. Cmax, AUC and Cmin of norgestrel increased by 37%, 68% and 77%, respectively.Mavyret Prescribing Information, AbbVie Inc., June 2019."
428,Glecaprevir/Pibrentasvir,Levothyroxine,No Interaction Expected,NA,Coadministration has not been studied and thyroid metabolism is complicated. The major pathway is sequential deiodination (but there are few published data on the enzymes involved) and conjugation with glucuronides and sulphates also occurs. A few individual case reports indicate some potential CYP involvement but this is unlikely to be clinically significant. Data suggest that endogenous T3 and T4 may be transported by OATP1B1 but no data that they cause inhibition. In the absence of further data consider monitoring thyroid levels.,(See Summary)
429,Glecaprevir/Pibrentasvir,Lidocaine (Lignocaine),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lidocaine is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of lidocaine to any clinically significant extent.,(See Summary)
430,Glecaprevir/Pibrentasvir,Linaclotide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Linaclotide is metabolised locally within the gastrointestinal tract and extensive studies have shown no CYP or transporter interactions occur.,(See Summary)
431,Glecaprevir/Pibrentasvir,Linagliptin,No Interaction Expected,NA,"Coadministration has not been studied. Linagliptin is a P-gp substrate and a mild to moderate inhibitor of CYP3A4 and P-gp. Glecaprevir/pibrentasvir is an inhibitor of P-gp, however, a clinically relevant interaction is not expected due to the large safety window of linagliptin. Inhibition of P-gp by linagliptin is unlikely to have a clinically significant effect on glecaprevir/pibrentasvir due to the large therapeutic safety margins.",(See Summary)
432,Glecaprevir/Pibrentasvir,Linezolid,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Linezolid is not metabolised by CYP450 and is not known to affect any of the key metabolic enzymes.,(See Summary)
433,Glecaprevir/Pibrentasvir,Liraglutide,Potential Weak Interaction,NA,"Coadministration has not been studied. Liraglutide is degraded by endogenous endopeptidases therefore no metabolic interaction is expected. However, GLP-1 agonists such as liraglutide have the potential to inhibit gastric secretion and thereby impact drugs whose absorption is gastric dependent, such as glecaprevir. A reduction in glecaprevir exposure is possible with liraglutide, however, this is unlikely to be clinically significant. Consider taking glecaprevir/pibrentasvir 5 hours before liraglutide to minimize any impact on drug exposure for glecaprevir.",(See Summary)
434,Glecaprevir/Pibrentasvir,Lisinopril,No Interaction Expected,NA,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril does not undergo metabolism and is excreted entirely unchanged into the urine. [Note, lisinopril exposure is increased in cirrhotic patients due to decreased clearance.]",(See Summary)
435,Glecaprevir/Pibrentasvir,Lithium ,No Interaction Expected,NA,"Coadministration has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely as lithium is mainly excreted in urine.",(See Summary)
436,Glecaprevir/Pibrentasvir,Lixisenatide,No Interaction Expected,NA,"Coadministration has not been studied. Lixisenatide is a peptide and is not metabolised by cytochrome P450. However, delayed gastric emptying due to lixisenatide may reduce absorption of orally administered medicinal products. Glecaprevir/pibrentasvir should be taken at least 1 hour before or 4 hours after lixisenatide injection. [Note: this interaction is not specific for glecaprevir/pibrentasvir, but for any medication taken with lixisenatide.]",(See Summary)
437,Glecaprevir/Pibrentasvir,Lofexidine,Potential Weak Interaction,NA,"Coadministration has not been studied but based on limited data for metabolism and clearance a clinically significant interaction is unlikely. However, since the metabolism of lofexidine has not been fully described and CYP2D6 may be involved, in the absence of further data, monitoring for side effects is suggested.",(See Summary)
438,Glecaprevir/Pibrentasvir,Loperamide,Potential Weak Interaction,NA,"Coadministration has not been studied but may increase loperamide concentrations due to inhibition of P-gp by glecaprevir/pibrentasvir. The clinical relevance of this is unknown and monitoring may be required. Use with caution in patients with hepatic impairment as no pharmacokinetic data are available and in such patients reduced first pass metabolism may result in a relative overdose leading to CNS toxicity. [Note, use with caution in patients with hepatic impairment as no pharmacokinetic data are not available and in such patients reduced first pass metabolism may result in a relative overdose leading to CNS toxicity. The US Food and Drug Administration has issued a safety alert over the use of high doses of loperamide from abuse and misuse with case reports of cardiac events including QT interval prolongation. Cardiac events are unlikely to occur when loperamide is dosed as an antidiarrheal even if coadministered with glecaprevir/pibrentasvir. However caution is advised when loperamide is used at high doses for reducing stoma output, particularly as patients may be at increased risk of cardiac events due to electrolytes disturbances.]",(See Summary)
439,Glecaprevir/Pibrentasvir,Lopinavir,Do Not Coadminister,NA,"Coadministration is not recommended. Concomitant use of glecaprevir/pibrentasvir with OATP1B inhibitors, such as lopinavir, may increase the risk of ALT elevations due to a significant increase in glecaprevir/pibrentasvir plasma concentrations caused by OATP1B1/3 inhibition. Coadministration of lopinavir/ritonavir and glecaprevir/pibrentasvir increased glecaprevir Cmax, AUC and Cmin by 2.55-fold, 4.38-fold and 18.6-fold; pibrentasvir Cmax, AUC and Cmin increased by 1.40-fold, 2.46-fold and 5.24-fold, respectively.","Medicinal products that inhibit OATP1B1/3 (e.g. lopinavir) increase systemic concentrations of glecaprevir. Coadministration of lopinavir/ritonavir (400/100 mg twice daily) and glecaprevir/pibrentasvir increased glecaprevir Cmax, AUC and Cmin by 2.55-fold, 4.38-fold and 18.6-fold; pibrentasvir Cmax, AUC and Cmin increased by 1.40-fold, 2.46-fold and 5.24-fold. Coadministration is not recommended.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Coadministration is not recommended. Coadministration of lopinavir/ritonavir (400/100 mg twice daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 9 subjects. Glecaprevir Cmax, AUC and Cmin increased by 2.55-fold, 4.38-fold and 18.6-fold; pibrentasvir Cmax, AUC and Cmin increased by 1.40-fold, 2.46-fold and 5.24-fold. Mavyret Prescribing Information, AbbVie Inc., June 2019."
440,Glecaprevir/Pibrentasvir,Loratadine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Loratadine is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of loratadine to any clinically significant extent.,(See Summary)
441,Glecaprevir/Pibrentasvir,Lorazepam,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lorazepam is metabolized by multiple UGTs which are not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
442,Glecaprevir/Pibrentasvir,Lormetazepam,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lormetazepam is metabolized by UGTs which are not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
443,Glecaprevir/Pibrentasvir,Losartan,No Interaction Expected,NA,"Coadministration of losartan and glecaprevir/pibrentasvir increased losartan Cmax and AUC by 151% and 56%. Cmax of the losartan active carboxylic metabolite was increased by 118% , but there was no change in AUC (14% increase). These effects were not deemed clinically significant and no dose adjustment is required when glecaprevir/pibrentasvir is coadministered with losartan.","Coadministration of losartan (50 mg single dose) and glecaprevir/pibrentasvir increased the Cmax and AUC of losartan by 2.51-fold and 1.56-fold; Cmax and AUC of losartan carboxylic acid increased by 2.18-fold and 1.14-fold. No dose adjustment is required.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.No dose adjustment is required when Mavyret is coadministered with losartan. Coadministration of losartan (50 mg single dose) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 12 subjects. Cmax and AUC of losartan increased by 2.51-fold and 1.56-fold; Cmax of losartan acid increased by 2.18-fold but there was no change in AUC.Mavyret Prescribing Information, AbbVie Inc., June 2019.Coadministration of glecaprevir/pibrentasvir (300/120 mg once daily) and losartan (50 mg single dose) was studied in 12 healthy subjects. Losartan Cmax and AUC increased by 151% and 56%; Cmax of the losartan active carboxylic metabolite increased by 118%, but AUC was similar (14% or less difference). Exposures of glecaprevir and pibrentasvir were similar (23% or less difference). No dose adjustment is required when glecaprevir/pibrentasvir are coadministered with losartan.Drug-drug interactions between direct acting antivirals ABT-493 and ABT-530 with angiotensin II receptor blockers (losartan or valsartan). Kosloski MP, Dutta S, Jiang Q, et al. Hepatol, 2016, 64 (1, Suppl); 420A (AASLD The Liver Meeting, Abstract 854)."
444,Glecaprevir/Pibrentasvir,Lovastatin,Do Not Coadminister,NA,"Coadministration is not recommended. Coadministration of lovastatin and glecaprevir/pibrentasvir had no effect on lovastatin Cmax and increased AUC by 70%; the Cmax and AUC of lovastatin acid increased by 5.73-fold and 4.10-fold. High lovastatin exposures could increase the risk of myopathy/rhabdomyolysis. If coadministered, lovastatin should not exceed a dose of 20 mg/day and patients should be monitored.","Co-administration with Maviret may increase plasma concentrations of medicinal products that are substrates of OATP1B1/3 (e.g. lovastatin). Coadministration of lovastatin (10 mg once daily) and glecaprevir/pibrentasvir had no effect lovastatin Cmax but increased AUC by 70%; Cmax and AUC of lovastatin acid increased by 5.73-fold and 4.10-fold. This was due to inhibition of OATP1B1/3, P-gp and BCRP. Co-administration is not recommended. If used, lovastatin should not exceed a dose of 20 mg/day and patients should be monitored.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Coadministration of lovastatin (10 mg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 12 subjects. There was no effect lovastatin Cmax but AUC increased by 70%. Cmax and AUC of lovastatin acid increased by 5.73-fold and 4.10-fold. Increased statin concentrations may increase the risk of myopathy, including rhabdomyolysis. Coadministration with this statin is not recommended.Mavyret Prescribing Information, AbbVie Inc., June 2019."
445,Glecaprevir/Pibrentasvir,LSD (Lysergic acid diethylamide),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lysergic acid diethylamide (LSD) is metabolized to hyroxy-LSD and N-desmethyl-LSD partly by CYP (unknown isoenzyme). Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of LSD to any clinically significant extent.,(See Summary)
446,Glecaprevir/Pibrentasvir,Lubiprostone,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metabolism of lubiprostone rapidly occurs within the stomach and jejunum, most likely in the absence of any systemic absorption. In vitro studies show that no CYP mediated interactions occur.",(See Summary)
447,Glecaprevir/Pibrentasvir,Lumacaftor/Ivacaftor,Do Not Coadminister,NA,Co-administration has not been studied but would not be recommended. Lumacaftor is a potent inducer of CYP3A4 and coadministration may result in decreased concentrations of glecaprevir/pibrentasvir and loss of therapeutic effect.,"Co-administration of Maviret with medicinal products that are moderate inducers P-gp/CYP3A may decrease glecaprevir and pibrentasvir plasma concentrations (e.g. lumacaftor). Co-administration of moderate inducers is not recommended.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019."
448,Glecaprevir/Pibrentasvir,Lumefantrine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lumefantrine is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of lumefantrine to any clinically significant extent.,(See Summary)
449,Glecaprevir/Pibrentasvir,Lymecycline,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely. Lymecycline is not metabolised and is excreted unchanged by renal and biliary routes.,(See Summary)
450,Glecaprevir/Pibrentasvir,Macitentan,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Macitentan is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of macitentan to any clinically significant extent.,(See Summary)
451,Glecaprevir/Pibrentasvir,Macrogol,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Macrogol is not absorbed from the gastro-intestinal tract and is excreted in urine.,(See Summary)
452,Glecaprevir/Pibrentasvir,Magnesium,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Magnesium is eliminated in the kidney, mainly by glomerular filtration.",(See Summary)
453,Glecaprevir/Pibrentasvir,Maprotiline,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Maprotiline is metabolised mainly by CYP2D6 which is not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
454,Glecaprevir/Pibrentasvir,Maraviroc,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Any increase in maraviroc concentrations due to inhibition of P-gp by glecaprevir/pibrentasvir is unlikely to be clinically relevant in patients with normal renal function.,(See Summary)
455,Glecaprevir/Pibrentasvir,Mebeverine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mebevirine is metabolised by hydrolysis.,(See Summary)
456,Glecaprevir/Pibrentasvir,Medroxyprogesterone (depot injection),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Medroxyprogesterone is metabolized by CYP3A4. Glecaprevir is a weak inhibitor of CYP3A4 but is unlikely to affect this pathway to any clinically significant extent.,(See Summary)
457,Glecaprevir/Pibrentasvir,Medroxyprogesterone (oral),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Medroxyprogesterone is metabolized by CYP3A4. Glecaprevir is a weak inhibitor of CYP3A4 but is unlikely to affect this pathway to any clinically significant extent.,(See Summary)
458,Glecaprevir/Pibrentasvir,Mefenamic acid,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mefenamic acid is metabolized by CYP2C9 and glucuronidated by UGTs 2B7 and 1A9, none of which are expected to be affected by glecaprevir/pibrentasvir.",(See Summary)
459,Glecaprevir/Pibrentasvir,Mefloquine,Potential Interaction,NA,"Coadministration has not been studied. Mefloquine is a substrate of CYP3A4 and P-gp; concentrations may increase due to the additive effect of weak inhibition of CYP3A4 and inhibition of P-gp by glecaprevir/pibrentasvir but the clinical significance is unknown. Monitor closely for psychiatric and other associated side effects of mefloquine. [Note, the use of mefloquine in patients with severe impairment of liver function is contraindicated in the European SmPC for mefloquine, but not in the US Prescribing Information.]",(See Summary)
460,Glecaprevir/Pibrentasvir,Melatonin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Melatonin is metabolised by CYP1A2 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP1A2 and is unlikely to affect the exposure of melatonin to any clinically significant extent.,(See Summary)
461,Glecaprevir/Pibrentasvir,Meloxicam,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Meloxicam is a substrate of CYP2C9 (major) and CYP3A4 (minor). Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of meloxicam to any clinically significant extent.,(See Summary)
462,Glecaprevir/Pibrentasvir,Memantine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Memantine does not appear to undergo CYP metabolism and is renally excreted.,(See Summary)
463,Glecaprevir/Pibrentasvir,Mephedrone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mephedrone is metabolized mainly by CYP2D6 which is not affected by glecaprevir/pibrentasvir.,(See Summary)
464,Glecaprevir/Pibrentasvir,Mercaptopurine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mercaptopurine is converted into active thioguanine nucleotides by xanthine oxidase and undergoes methylation by thiopurine methyltransferase to form S- methylated nucleotides, which are also cytotoxic.",(See Summary)
465,Glecaprevir/Pibrentasvir,Meropenem,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Meropenem is mainly excreted in urine.,(See Summary)
466,Glecaprevir/Pibrentasvir,Mesalazine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as mesalazine largely acts locally in the gut and is acetylated there.,(See Summary)
467,Glecaprevir/Pibrentasvir,Metamizole (Dipyrone),Potential Interaction,NA,"Coadministration has not been studied and should be used with caution. Coadministration is expected to decrease concentrations of glecaprevir/pibrentasvir due to induction of CYP3A4 by metamizole, but the clinical significance of this is unknown.",(See Summary)
468,Glecaprevir/Pibrentasvir,Metformin,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metformin is mainly excreted renally and is transported by OCT2 which is not expected to be affected by glecaprevir/pibrentasvir. [Note, metformin is contraindicated with hepatic insufficiency, acute alcohol intoxication, and alcoholism.]",(See Summary)
469,Glecaprevir/Pibrentasvir,Methadone,No Interaction Expected,NA,Interaction studies were performed with methadone and showed no clinically significant interactions with glecaprevir/pibrentasvir. No dose adjustment is required when glecaprevir/pibrentasvir is co administered with methadone.,"Drug-drug interaction studies were performed with methadone and showed no clinically significant interactions with Maviret.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.No dose adjustment is required when Mavyret is coadministered with methadone.Mavyret Prescribing Information, AbbVie Inc., June 2019.Coadministration of glecaprevir/pibrentasvir (300/120 mg once daily) and methadone was studied in 12 subjects on individualized regimens of methadone. Dose normalized Cmax, AUC and C24 for R- and S-methadone were unaffected by coadministration with glecaprevir/pibrentasvir (5% or less change). Exposures of glecaprevir and pibrentasvir were similar to the observed values in previous studies. Pharmacodynamics of the methadone regimen were not significantly impacted. No dose adjustments are required for coadministration of glecaprevir/pibrentasvir with methadone. Absence of significant drug-drug interactions between next generation direct acting antivirals ABT-493 and ABT530 and methadone or buprenorphine/naloxone in subjects on opioid maintenance therapy. Kosloski MP, Dutta S, Zhao W, et al. Hepatol, 2015, 62 (1, Suppl); 569A (AASLD The Liver Meeting, Abstract 723)."
470,Glecaprevir/Pibrentasvir,Methamphetamine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methamphetamine is metabolized mainly by CYP2D6 which is not expected to be affected by glecaprevir/pibrentasvir. ,(See Summary)
471,Glecaprevir/Pibrentasvir,Methenamine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methenamine is mainly excreted unchanged in the urine,(See Summary)
472,Glecaprevir/Pibrentasvir,Methotrexate,Potential Interaction,NA,Coadministration has not been studied. Methotrexate is a substrate of BCRP and concentrations could increase due to inhibition of BCRP by glecaprevir/pibrentasvir. Patients should be closely monitored for methotrexate associated toxicities.,(See Summary)
473,Glecaprevir/Pibrentasvir,Methylcellulose,No Interaction Expected,NA,"Coadministration has not been studied. Methylcellulose is not absorbed and a pharmacokinetic interaction is unlikely. However, bulk laxatives such as oral methylcellulose lower the transit time through the gut and could affect the absorption of other drugs. It is advisable to separate administration if possible. [Note: this interaction is not specific for glecaprevir/pibrentasvir, but for any medication taken with methylcellulose.]",(See Summary)
474,Glecaprevir/Pibrentasvir,Methyldopa,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as methyldopa is mainly renally cleared. [Note, methyldopa is contraindicated in active hepatitis and active cirrhosis in both the European and US product labels.]",(See Summary)
475,Glecaprevir/Pibrentasvir,Methylergonovine,Potential Interaction,NA,"Coadministration has not been studied. Methylergonovine is metabolised by CYP3A4 and although glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4, there is the potential for ergot toxicity due to the narrow therapeutic index of methylergonovine.",(See Summary)
476,Glecaprevir/Pibrentasvir,Methylphenidate,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as methylphenidate is metabolised by de-esterification.,(See Summary)
477,Glecaprevir/Pibrentasvir,Methylprednisolone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methylprednisolone is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of methylprednisolone to any clinically significant extent.,(See Summary)
478,Glecaprevir/Pibrentasvir,Metoclopramide,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoclopramide is metabolised by CYP2D6 which is not expected to be affected by glecaprevir/pibrentasvir. [Note, a reduced dosage is recommended in patients with hepatic insufficiency.]",(See Summary)
479,Glecaprevir/Pibrentasvir,Metolazone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metolazone is mainly excreted in urine and there are few published data on transporter interactions.,(See Summary)
480,Glecaprevir/Pibrentasvir,Metoprolol,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoprolol is largely metabolised by CYP2D6 which is not expected to be affected by glecaprevir/pibrentasvir. [Note, in patients with severe hepatic dysfunction a reduction in dosage may be necessary.]",(See Summary)
481,Glecaprevir/Pibrentasvir,Metronidazole,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of metronidazole is not well described.,(See Summary)
482,Glecaprevir/Pibrentasvir,Mexiletine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mexiletine is metabolised by CYP2D6 and CYP1A2 which are not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
483,Glecaprevir/Pibrentasvir,Mianserin,Potential Weak Interaction,NA,"Coadministration has not been studied. Mianserin is metabolized by CYPs 2D6 and 1A2, and to a lesser extent by CYP3A4. Grazoprevir is a weak CYP3A4 inhibitor. The clinical significance of any potential interaction is unknown.",(See Summary)
484,Glecaprevir/Pibrentasvir,Miconazole,No Interaction Expected,NA,Coadministration has not been studied. A clinically significant interaction is unlikely after topical administration due to the limited systemic availability. Inhibition of CYP3A4 and CYP2C9 by miconazole when administered systemically is unlikely to have a clinically significant effect on glecaprevir/pibrentasvir due to the large therapeutic safety margins.,(See Summary)
485,Glecaprevir/Pibrentasvir,Midazolam (oral),No Interaction Expected,NA,Coadministration of glecaprevir/pibrentasvir and midazolam (1 mg single dose) increased midazolam AUC by 27%. This was not deemed clinically significant and no dose adjustment is required when glecaprevir/pibrentasvir is coadministered with midazolam.,"Clinically significant increases in exposure were not observed for sensitive substrates of CYP3A (midazolam) when administered with Maviret. Drug-drug interaction studies were performed with midazolam and showed no clinically significant interactions with Maviret.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.No dose adjustment is required when Mavyret is coadministered with midazolam. Coadministration of midazolam (1 mg single dose) and glecaprevir/pibrentasvir (300/120 mg once daily) had no effect on midazolam Cmax, but increased AUC by 27% (n=12).Mavyret Prescribing Information, AbbVie Inc., June 2019."
486,Glecaprevir/Pibrentasvir,Midazolam (parenteral),No Interaction Expected,NA,Coadministration of glecaprevir/pibrentasvir and midazolam (1 mg single dose) increased midazolam AUC by 27%. This was not deemed clinically significant and no dose adjustment is required when glecaprevir/pibrentasvir is co administered with midazolam.,"Clinically significant increases in exposure were not observed for sensitive substrates of CYP3A (midazolam) when administered with Maviret. Drug-drug interaction studies were performed with midazolam and showed no clinically significant interactions with Maviret.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.No dose adjustment is required when Mavyret is coadministered with midazolam. Coadministration of midazolam (1 mg single dose) and glecaprevir/pibrentasvir (300/120 mg once daily) had no effect on midazolam Cmax, but increased AUC by 27% (n=12).Mavyret Prescribing Information, AbbVie Inc., June 2019."
487,Glecaprevir/Pibrentasvir,Mifepristone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mifepristone is metabolized by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of mifepristone to any clinically significant extent.,(See Summary)
488,Glecaprevir/Pibrentasvir,Milk thistle (Silymarin),No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Drug interaction studies suggest that milk thistle has limited clinical impact on substrates of CYP3A, UGT, P-gp and OATP.",(See Summary)
489,Glecaprevir/Pibrentasvir,Milnacipran,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as milnacipran undergoes minimal CYP450 related metabolism. [Note, no dosage adjustment is necessary for patients with hepatic impairment, but caution should be exercised in patients with severe hepatic impairment. Milnacipran should ordinarily not be prescribed to patients with substantial alcohol use or evidence of chronic liver disease.]",(See Summary)
490,Glecaprevir/Pibrentasvir,Minoxidil,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Minoxidil is mainly metabolised by UGTs which are not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
491,Glecaprevir/Pibrentasvir,Mirabegron,Potential Interaction,NA,"Coadministration has not been studied. Mirabegron is metabolized by multiple pathways including hydrolysis, glucuronidation and oxidation by CYP2D6 and CYP3A4. It is also a substrate of P-gp. Coadministration may increase mirabegron concentrations, however, only a modest increase in mirabegron exposure was observed with ketoconazole (a strong inhibitor of CYP3A4/P-gp). No dose adjustment is recommended when mirabegron is combined with strong inhibitors of CYP3A4 and/or P-gp in patients with normal hepatic or renal function. However, a dose decrease of mirabegron to 25 mg once daily is recommended for patients who have mildly impaired hepatic or renal function and who are taking a strong inhibitor of CYP3A4 or P-gp, such as glecaprevir/pibrentasvir (strong P-gp inhibitor). It is not recommended in patients with severe renal impairment (GFR 15-29 mL/min/1.73m2) or in patients with moderate hepatic impairment (Child-Pugh Class B) concomitantly receiving strong CYP3A/P-gp inhibitors.",(See Summary)
492,Glecaprevir/Pibrentasvir,Mirtazapine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mirtazapine is metabolised by CYP2D6 and CYP1A2 which are not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
493,Glecaprevir/Pibrentasvir,Misoprostol,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Misoprostol is predominantly metabolised via fatty acid oxidising systems and has no effect on the CYP450 enzyme system.,(See Summary)
494,Glecaprevir/Pibrentasvir,Mitoxantrone,Potential Interaction,NA,Coadministration has not been studied. Mitoxantrone is metabolized to inactive carboxylic acid derivatives possibly by CYP450. It is a substrate of BCRP. In vitro inhibition of CYP450 was shown to increase mitoxantrone cytotoxicity. Concentrations of mitoxantrone may increase due to inhibition of CYP450 and BCRP by glecaprevir/pibrentasvir. Close monitoring for increased side effects and toxicities is recommended.,(See Summary)
495,Glecaprevir/Pibrentasvir,Moclobemide,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Moclobemide is metabolised by multiple pathways, including CYP2C19 and CYP2D6, but these are not expected to be affected by glecaprevir/pibrentasvir.",(See Summary)
496,Glecaprevir/Pibrentasvir,Modafinil,Potential Interaction,NA,Co-administration has not been studied. Modafinil is a mild-moderate inducer of CYP3A4 and may decrease concentrations of glecaprevir/pibrentasvir may decrease. Use with caution as the clinical significance of this is unknown.,(See Summary)
497,Glecaprevir/Pibrentasvir,Mometasone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mometasone is metabolised by CYP3A4 but very low concentrations are achieved in plasma after inhaled dosing. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of mometasone to any clinically significant extent.,(See Summary)
498,Glecaprevir/Pibrentasvir,Montelukast,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance an interaction is unlikely. Montelukast is metabolised by CYP2C8 which is not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
499,Glecaprevir/Pibrentasvir,Morphine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Morphine predominantly undergoes glucuronidation largely by UGT2B7 and UGT1A3 with a minor contribution from CYP2D6 and CYP3A4, none of which is expected to be affected by glecaprevir/pibrentasvir.",(See Summary)
500,Glecaprevir/Pibrentasvir,Moxifloxacin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Moxifloxacin predominantly undergoes glucuronidation by UGT1A1 which is not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
501,Glecaprevir/Pibrentasvir,Moxonidine,No Interaction Expected,NA,Coadministration has not been studied but a clinically significant interaction is unlikely as moxonidine is only minimally metabolized and undergoes renal excretion.,(See Summary)
502,Glecaprevir/Pibrentasvir,Mycophenolate,No Interaction Expected,NA,"Coadministration has not been studied but a clinically significant interaction is unlikely. Mycophenolate is completely metabolized to an active metabolite, MPA, which is presystemically metabolized by glucuronyl transferase to form inactive phenolic glucuronide (MPAG) metabolites which are renally excreted. ",(See Summary)
503,Glecaprevir/Pibrentasvir,Naftidrofuryl,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Naftidrofuryl is metabolised by the liver but this has not been well described; the metabolites are renally excreted,(See Summary)
504,Glecaprevir/Pibrentasvir,Nalmefene,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro studies have shown that nalmefene is metabolised by UGTs 2B7, 1A3 and 1A8 which are not affected by glecaprevir/pibrentasvir.",(See Summary)
505,Glecaprevir/Pibrentasvir,Naloxegol,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Naloxegol is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of naloxegol to any clinically significant extent.,(See Summary)
506,Glecaprevir/Pibrentasvir,Naloxone,No Interaction Expected,NA,Coadministration of buprenorphine/naloxone and glecaprevir/pibrentasvir increased exposure of buprenorphine and its metabolite norbuprenorphine up to 30% but had no effect on naloxone. Exposures of glecaprevir and pibrentasvir were similar to the observed values in previous studies. No dose adjustment is required when glecaprevir/pibrentasvir is coadministered with naloxone.,"Drug-drug interaction studies were performed with naloxone and showed no clinically significant interactions with Maviret.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.No dose adjustment is required when Mavyret is coadministered with naloxone.Mavyret Prescribing Information, AbbVie Inc., June 2019.Coadministration of glecaprevir/pibrentasvir (300/120 mg once daily) and buprenorphine/naloxone was studied in 12 subjects on individualized regimens of buprenorphine/naloxone. Dose normalized Cmax, AUC and C24 were slightly increased for buprenorphine (8%, 17% and 24%) and norbuprenorphine (25%, 30% and 21%). Naloxone dose-normalised Cmax and AUC were minimally affected (12% change or less). Exposures of glecaprevir and pibrentasvir were similar to the observed values in previous studies. Pharmacodynamics of the buprenorphine/naloxone regimen were not significantly impacted. No dose adjustments are required for coadministration of glecaprevir/pibrentasvir with buprenorphine/naloxone.Absence of significant drug-drug interactions between next generation direct acting antivirals ABT-493 and ABT530 and methadone or buprenorphine/naloxone in subjects on opioid maintenance therapy. Kosloski MP, Dutta S, Zhao W, et al. Hepatol, 2015, 62 (1, Suppl); 569A (AASLD The Liver Meeting, Abstract 723)."
507,Glecaprevir/Pibrentasvir,Naltrexone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro studies have shown that naltrexone is metabolised by UGTs which are not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
508,Glecaprevir/Pibrentasvir,Naproxen,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Naproxen is metabolised by CYP1A2, CYP2C9 and UGT2B7 and these enzymes are not expected to be affected by glecaprevir/pibrentasvir.",(See Summary)
509,Glecaprevir/Pibrentasvir,Naratriptan,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Naratriptan is metabolised by a wide range of CYP enzymes and is mainly excreted in urine. Significant metabolic drug interactions with naratriptan are not anticipated.,(See Summary)
510,Glecaprevir/Pibrentasvir,Nateglinide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nateglinide is metabolised by CYP2C9 with minor involvement of CYP3A4. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of nateglinide to any clinically significant extent.,(See Summary)
511,Glecaprevir/Pibrentasvir,Nebivolol,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nebivolol is metabolised by CYP2D6 followed by glucuronidation and these enzymes are not expected to be affected by glecaprevir/pibrentasvir. [Note, the European SmPC contraindicates the use of nebivolol in patients with hepatic insufficiency and the US Prescribing Information recommends an initial dose of 2.5 mg once daily in patients with moderate hepatic impairment.]",(See Summary)
512,Glecaprevir/Pibrentasvir,Nefazodone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nefazodone is metabolized by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of nefazodone to any clinically significant extent.,(See Summary)
513,Glecaprevir/Pibrentasvir,Neostigmine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Neostigmine metabolism has not been well described but limited data suggest metabolism occurs via hydrolysis by cholinesterase with up to 50% of a dose being excreted unchanged in urine.,(See Summary)
514,Glecaprevir/Pibrentasvir,Nevirapine,Do Not Coadminister,NA,Coadministration has not been studied and is not recommended. Coadministration may decrease glecaprevir/pibrentasvir concentrations due to induction of CYP3A4 by nevirapine which may lead to reduced therapeutic effect.,(See Summary)
515,Glecaprevir/Pibrentasvir,Nicardipine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nicardipine is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of nicardipine to any clinically significant extent.,(See Summary)
516,Glecaprevir/Pibrentasvir,Nicorandil,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nicorandil metabolism is mainly by denitrition of the molecule into the nicotinamide pathway.,(See Summary)
517,Glecaprevir/Pibrentasvir,Nifedipine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nifedipine is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of nifedipine to any clinically significant extent.,(See Summary)
518,Glecaprevir/Pibrentasvir,Nilotinib,Potential Interaction,NA,"Coadministration has not been studied. Nilotinib is metabolised by CYP3A4 and transported by BCRP. Glicaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect this pathway to any clinically significant extent. However, concentrations of nilotinib may increase as both pibrentasvir and glecaprevir inhibit BCRP.",(See Summary)
519,Glecaprevir/Pibrentasvir,Niraparib,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Niraparib undergoes minimal oxidative metabolism and, due to high permeability and bioavailability, does not have clinically relevant interactions with P-gp and BCRP transporters.",(See Summary)
520,Glecaprevir/Pibrentasvir,Nisoldipine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nisoldipine is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of nisoldipine to any clinically significant extent.,(See Summary)
521,Glecaprevir/Pibrentasvir,Nitrendipine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nitrendipine is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the nitrendipine to any clinically significant extent.,(See Summary)
522,Glecaprevir/Pibrentasvir,Nitrofurantoin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Approximately 50-70% of a nitrofurantoin dose is metabolised (unknown mechanism) and 30% is excreted in urine.,(See Summary)
523,Glecaprevir/Pibrentasvir,Nitrous oxide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Most inhaled nitrous oxide is rapidly eliminated unchanged through the lungs.,(See Summary)
524,Glecaprevir/Pibrentasvir,Nivolumab,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Like other protein therapeutics, nivolumab is expected to be degraded into small peptides and amino acids via catabolic pathways and is not anticipated to alter drug-metabolising enzymes.",(See Summary)
525,Glecaprevir/Pibrentasvir,Norfloxacin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Norfloxacin is metabolized by CYP1A2 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP1A2 and is unlikely to affect the exposure of norfloxacin to any clinically significant extent.,(See Summary)
526,Glecaprevir/Pibrentasvir,Nortriptyline,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nortriptyline is metabolised mainly by CYP2D6 which is not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
527,Glecaprevir/Pibrentasvir,Nusinersan,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nusinersan is metabolized slowly and predominantly via exonuclease (3'- and 5'-) mediated hydrolysis and is not a substrate, inhibitor or inducer of CYP450 enzymes. The likelihood of interaction with transporters is low.",(See Summary)
528,Glecaprevir/Pibrentasvir,Nystatin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Systemic absorption of nystatin from oral or topical dosing is minimal and nystatin is mainly excreted in the faeces.,(See Summary)
529,Glecaprevir/Pibrentasvir,Obeticholic acid,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glecaprevir and pibrentasvir are metabolized by CYP3A4 and are substrates of P-gp and/or BCRP. Glecaprevir is also a substrate of OATP1B1/3. Obeticholic acid does not interact with these pathways. Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. Note: the Mavyret prescribing information contraindicates its use in patients with severe hepatic impairment.,(See Summary)
530,Glecaprevir/Pibrentasvir,Obinutuzumab,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Like other protein therapeutics, obinutuzumab is expected to be degraded into small peptides and amino acids via catabolic pathways and is not anticipated to alter drug-metabolising enzymes.",(See Summary)
531,Glecaprevir/Pibrentasvir,Ocrelizumab,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Ocrelizumab is cleared principally by catabolism into peptides and amino acids and is not expected to interact with drugs metabolised via CYP450 or transported by common transporters.",(See Summary)
532,Glecaprevir/Pibrentasvir,Ofatumumab,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Like other protein therapeutics, ofatumumab is expected to be degraded into small peptides and amino acids via catabolic pathways and is not anticipated to alter drug-metabolising enzymes.",(See Summary)
533,Glecaprevir/Pibrentasvir,Ofloxacin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ofloxacin is eliminated unchanged renally by glomerular filtration and active tubular secretion by both cationic and anionic transport systems. These transporters are not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
534,Glecaprevir/Pibrentasvir,Olanzapine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Olanzapine is metabolised by CYP1A2 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP1A2 and is unlikely to affect the exposure of olanzapine to any clinically significant extent.,(See Summary)
535,Glecaprevir/Pibrentasvir,Olaratumab,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Like other protein therapeutics, olaratumab is expected to be degraded into small peptides and amino acids via catabolic pathways and is not anticipated to alter drug-metabolising enzymes.",(See Summary)
536,Glecaprevir/Pibrentasvir,Olmesartan,Potential Interaction,NA,Coadministration has not been studied. Olmesartan is a substrate (but not an inhibitor) of OATP1B1. Glecaprevir/pibrentasvir inhibits OATP1B1 and OATP1B3 and may increase exposure of olmesartan. Close monitoring of heart rate and blood pressure and other side effects is recommended. [Note the European SmPC for olmesartan recommends an initial 10 mg dose of olmesartan (with a maximum 20 mg daily dose) in moderate hepatic impairment. It does not recommend olmersartan in severe hepatic impairment. No dosage restrictions are given in the US Prescribing Information.],(See Summary)
537,Glecaprevir/Pibrentasvir,Omalizumab,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cytochrome P450 enzymes, efflux pumps and protein-binding mechanisms are not involved in the metabolism and clearance of omalizumab.",(See Summary)
538,Glecaprevir/Pibrentasvir,Ombitasvir/Paritaprevir/r,Do Not Coadminister,NA,Glecaprevir/pibrentasvir is a complete regiment and there is no data on combination with other NS5A containing regimens.,(See Summary)
539,Glecaprevir/Pibrentasvir,Ombitasvir/Paritaprevir/r + Dasabuvir,Do Not Coadminister,NA,Glecaprevir/pibrentasvir is a complete regiment and there is no data on combination with other NS5A containing regimens.,(See Summary)
540,Glecaprevir/Pibrentasvir,Omeprazole,Potential Weak Interaction,NA,"Coadministration of glecaprevir/pibrentasvir and omeprazole (20 mg once daily) decreased glecaprevir Cmax and AUC by 22% and 29%. Coadministration of glecaprevir/pibrentasvir and omeprazole (40 mg once daily taken 1 hour before breakfast) decreased glecaprevir Cmax and AUC by 64% and 51%. When omeprazole was administered in the evening without food, glecaprevir Cmax and AUC decreased by 46% and 49%. Despite the decrease in glecaprevir exposure with omeprazole there is no change in pibrentasvir exposure and, therefore, virological suppression is expected to be maintained. The European SPC for glecaprevir/pibrentasvir indicates that no dose adjustment is required and the US Prescribing Information indicates no clinically significant interaction and no dose adjustment required. However, it is important to note that currently there are no data with doses of omeprazole greater than 40 mg once daily.","Coadministration of omeprazole (20 mg once daily) and glecaprevir/pibrentasvir decreased glecaprevir Cmax and AUC by 22% and 29% due to an increase in gastric pH value. There was no effect on pibrentasvir Cmax or AUC. Coadministration of omeprazole (40 mg once daily) 1 hour before breakfast decreased glecaprevir Cmax and AUC by 64% and 51%; pibrentasvir Cmax and AUC were unaltered. Coadministration of omeprazole (40 mg once daily) in the evening without food decreased glecaprevir Cmax and AUC by 46% and 49%; pibrentasvir Cmax and AUC were unaltered. No dose adjustment is required.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.No dose adjustment is required when Mavyret is coadministered with omeprazole. No clinically significant interaction was observed. Coadministration of omeprazole (20 mg once daily) and glecaprevir/pibrentasvir (300/120 mg single dose) decreased glecaprevir Cmax and AUC by 22% and 29% (n=9). Coadministration of omeprazole (20 mg single dose) and glecaprevir/pibrentasvir (300/120 mg once daily) decreased omeprazole Cmax and AUC by 43% and 21% (n=12). Coadministration of omeprazole (40 mg once daily) 1 hour before glecaprevir/pibrentasvir (300/120 mg single dose) decreased glecaprevir Cmax and AUC by 64% and 51%; pibrentasvir Cmax and AUC were unaltered (n=12). Mavyret Prescribing Information, AbbVie Inc., June 2019."
541,Glecaprevir/Pibrentasvir,Ondansetron,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ondansetron is metabolised by multiple CYP enzymes including CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of ondansetron to any clinically significant extent. [Note, in subjects with moderate or severe hepatic impairment ondansetron clearance is significantly reduced and half-life significantly increased; in such patients the ondansetron total daily dose should not exceed 8 mg and parenteral or oral administration is recommended.]",(See Summary)
542,Glecaprevir/Pibrentasvir,Orlistat,Potential Weak Interaction,NA,"Coadministration has not been studied. Orlistat is minimally absorbed after oral doses with about 97% of a dose excreted in the faeces, 83% of which is unchanged orlistat. A clinically significant pharmacokinetic interaction is unlikely, however, because of its effect on fat absorption in the GI tract, it cannot be ruled out that absorption of glecaprevir/pibrentasvir could be reduced. [Note: this interaction is not specific for glecaprevir/pibrentasvir, but for any medication taken with orlistat.]",(See Summary)
543,Glecaprevir/Pibrentasvir,Orphenadrine,No Interaction Expected,NA,"Coadministration has not been studied but based on very limited data on the metabolism and clearance of orphenadrine, a clinically significant interaction is unlikely. Orphenadrine is an inhibitor CYP2B6, but this enzyme is not involved in the metabolism of glecaprevir/pibrentasvir.",(See Summary)
544,Glecaprevir/Pibrentasvir,Oseltamivir,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oseltamivir is converted to oseltamivir carboxylate by esterases which are unlikely to be affected by glecaprevir/pibrentasvir.,(See Summary)
545,Glecaprevir/Pibrentasvir,Oxaliplatin,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxaliplatin undergoes non enzymatic biotransformation and is eliminated renally by OCT2, MATE2-K and, to a lesser extent, MATE-1. Significant inhibition of these transporters by glecaprevir/pibrentasvir is not expected.",(See Summary)
546,Glecaprevir/Pibrentasvir,Oxamniquine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Limited data suggest that oxamniquine is likely to be a substrate of CYP2D6 which is not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
547,Glecaprevir/Pibrentasvir,Oxazepam,No Interaction Expected,NA,Coadministration has not been studied but based on the metabolism and clearance a clinically significant interaction is unlikely. Oxazepam is mainly metabolised by UGTs which are not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
548,Glecaprevir/Pibrentasvir,Oxcarbazepine,Do Not Coadminister,NA,Coadministration has not been studied and is not recommended. Induction of CYP3A4 and/or P-gp by oxcarbazepine may significantly decrease plasma concentrations of glecaprevir and pibrentasvir resulting in loss of efficacy and potential virological failure.,"Co-administration of Maviret with medicinal products that are moderate inducers P-gp/CYP3A may decrease glecaprevir and pibrentasvir plasma concentrations (e.g. oxcarbazepine). Co-administration of moderate inducers is not recommended.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019."
549,Glecaprevir/Pibrentasvir,Oxprenolol,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oxprenolol is largely metabolised by UGTs which are not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
550,Glecaprevir/Pibrentasvir,Oxycodone,Potential Interaction,NA,"Coadministration has not been studied. Oxycodone is metabolised by CYP3A4 and CYP2D6. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4, however since oxycodone has a narrow therapeutic window, increased levels could increase or prolong adverse drug effects and may cause respiratory depression. Monitor patients receiving oxycodone and any CYP3A4 inhibitor. [Note, use of oxycodone in patients with moderate to severe hepatic failure is contraindicated in its European SmPC but not in its US Prescribing Information.]",(See Summary)
551,Glecaprevir/Pibrentasvir,Paclitaxel,Potential Interaction,NA,Coadministration has not been studied. Paclitaxel is primarily metabolized by CYP2C8 and to a lesser extent by CYP3A4. Glecaprevir is a weak inhibitor of CYP3A4 and could potentially increase paclitaxel exposure. Monitor paclitaxel induced toxicity.,(See Summary)
552,Glecaprevir/Pibrentasvir,Paliperidone,Potential Interaction,NA,"Coadministration has not been studied. Paliperidone is primarily eliminated renally, with minimal metabolism occurring by CYP2D6 and CYP3A4. Paliperidone is a substrate of P-gp and concentrations may increase due to P-gp inhibition by glecaprevir/pibrentasvir. The clinical significance of this is unknown. No a priori dose change should be required, but in the absence of further data, monitor for additional side effects.",(See Summary)
553,Glecaprevir/Pibrentasvir,Pamidronate,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pamidronate is not hepatically metabolised and is almost exclusively renally excreted.,(See Summary)
554,Glecaprevir/Pibrentasvir,Panitumumab,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Like other protein therapeutics, panitumumab is expected to be degraded into small peptides and amino acids via catabolic pathways and is not anticipated to alter drug-metabolising enzymes.",(See Summary)
555,Glecaprevir/Pibrentasvir,Pantoprazole,Potential Weak Interaction,NA,"Coadministration has not been studied but may result in decreased concentrations of glecaprevir. Coadministration with omeprazole (40 mg once daily) decreased glecaprevir AUC by ~50% and a similar effect may occur with equivalent doses of pantoprazole. For omeprazole, the European SPC for glecaprevir/pibrentasvir indicates that no dose adjustment is required and the US Prescribing Information indicates no clinically significant interaction and no dose adjustment required. However, it is important to note that currently there are no data with doses of omeprazole greater than 40 mg once daily.",(See Summary)
556,Glecaprevir/Pibrentasvir,Paracetamol (Acetaminophen),No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paracetamol is metabolised by multiple pathways (UGT1A1, GSH conjugation, CYP2E1, CYP1A2), none of which are expected to be affected by glecaprevir/pibrentasvir",(See Summary)
557,Glecaprevir/Pibrentasvir,Paroxetine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paroxetine is metabolised mainly by CYP2D6 which is not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
558,Glecaprevir/Pibrentasvir,Peginterferon alfa-2a,Potential Interaction,NA,Coadministration is not recommended for hepatitis C treatment as glecaprevir/pibrentasvir is a complete interferon free regimen. Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Glecaprevir/pibrentasvir are metabolised by CYP3A4 and are substrates of P-gp and/or BCRP. Glecaprevir is also a substrate of OATP1B1/3. These pathways are not affected by peginterferon alfa-2a.,(See Summary)
559,Glecaprevir/Pibrentasvir,Peginterferon alfa-2b,Potential Interaction,NA,Coadministration is not recommended for hepatitis C treatment as glecaprevir/pibrentasvir is a complete interferon free regimen. Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Glecaprevir/pibrentasvir are metabolised by CYP3A4 and are substrates of P-gp and/or BCRP. Glecaprevir is also a substrate of OATP1B1/3. These pathways are not affected by peginterferon alfa-2b.,(See Summary)
560,Glecaprevir/Pibrentasvir,Pembrolizumab,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glecaprevir/pibrentasvir is metabolised by and is a weak inhibitor of CYP3A4. Pembrolizumab is primarily metabolised through catabolic pathways and drug-drug interactions are not expected.,(See Summary)
561,Glecaprevir/Pibrentasvir,Penicillamine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as multiple mechanisms are thought to be involved in the metabolism of penicillamine.,(See Summary)
562,Glecaprevir/Pibrentasvir,Penicillin V,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as penicillin V is mainly excreted in urine.,(See Summary)
563,Glecaprevir/Pibrentasvir,Pentamidine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pentamidine is metabolised by CYP1A2 and CYP2D6 which are not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
564,Glecaprevir/Pibrentasvir,Pentoxifylline,No Interaction Expected,NA,Coadministration has not been studied but based on limited data for metabolism and clearance a clinically significant interaction is unlikely. The metabolism of pentoxifylline is not well characterised.,(See Summary)
565,Glecaprevir/Pibrentasvir,Perampanel,No Interaction Expected,NA,"Coadministration has not been studied. Perampanel is metabolised by CYP3A4, but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of perampanel to any clinically significant extent.",(See Summary)
566,Glecaprevir/Pibrentasvir,Perazine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Perazine is metabolised by CYP3A4 and CYP2C9 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of perazine to any clinically significant extent.,(See Summary)
567,Glecaprevir/Pibrentasvir,Periciazine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of periciazine has not been well characterised but is likely to involve CYP2D6 which is not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
568,Glecaprevir/Pibrentasvir,Perindopril,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Perindopril is a prodrug metabolised in the liver to the active perindoprilat and multiple inactive metabolites. It is metabolised by hydrolysis, glucuronidation and cyclization. These enzymes are not expected to be affected by glecaprevir/pibrentasvir.",(See Summary)
569,Glecaprevir/Pibrentasvir,Perphenazine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Perphenazine is predominantly metabolised by CYP2D6 which is not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
570,Glecaprevir/Pibrentasvir,Pethidine (Meperidine),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pethidine is metabolised mainly by CYP2B6 which is not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
571,Glecaprevir/Pibrentasvir,Phencyclidine (PCP),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Phencyclidine is metabolised mainly by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of phencyclidine to any clinically significant extent.,(See Summary)
572,Glecaprevir/Pibrentasvir,Phenobarbital,Do Not Coadminister,NA,Coadministration has not been studied and is contraindicated. Induction of P-gp by phenobarbital may significantly decrease plasma concentrations of glecaprevir/pibrentasvir resulting in loss of efficacy and potential virological failure.,"Concomitant use with strong P-gp and CYP3A inducers (e.g. phenobarbital) is contraindicated. Medicinal products that are strong P-gp and CYP3A inducers (e.g. phenobarbital) could significantly decrease glecaprevir or pibrentasvir plasma concentrations and may lead to reduced therapeutic effect of Maviret or loss of virologic response. Co-administration of such medicinal products with Maviret is contraindicated. Coadministration has not been studied but is expected to decrease exposure of glecaprevir and pibrentasvir. Co administration may lead to reduced therapeutic effect of Maviret and is contraindicated.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019."
573,Glecaprevir/Pibrentasvir,Phenprocoumon,Potential Interaction,NA,"Coadministration has not been studied. Phenprocoumon is metabolized by CYP2C9 and CYP3A4. Glecaprevir/pibrentasvir is a weak inhibitor of CYP3A4 but could increase phenprocoumon exposure, although to a small extent. Monitor INR closely.","Coadministration has not been studied. As liver function may change during treatment with Maviret, a close monitoring of International Normalised Ratio (INR) values is recommended with vitamin K antagonists.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019."
574,Glecaprevir/Pibrentasvir,Phenylephrine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as phenylephrine is metabolised by MAO.,(See Summary)
575,Glecaprevir/Pibrentasvir,Phenytoin,Do Not Coadminister,NA,Coadministration has not been studied and is contraindicated. Induction of P-gp by phenytoin may significantly decrease plasma concentrations of glecaprevir/pibrentasvir resulting in loss of efficacy and potential virological failure.,"Concomitant use with strong P-gp and CYP3A inducers (e.g. phenytoin) is contraindicated. Medicinal products that are strong P-gp and CYP3A inducers (e.g. phenytoin) could significantly decrease glecaprevir or pibrentasvir plasma concentrations and may lead to reduced therapeutic effect of Maviret or loss of virologic response. Co-administration of such medicinal products with Maviret is contraindicated. Coadministration has not been studied but is expected to decrease exposure of glecaprevir and pibrentasvir. Coadministration may lead to reduced therapeutic effect of Maviret and is contraindicated.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Phenytoin may significantly decrease plasma concentrations of glecaprevir and pibrentasvir, leading to the reduced therapeutic effect of MAVYRET. The use of phenytoin with MAVYRET is not recommended.Mavyret Prescribing Information, AbbVie Inc., June 2019."
576,Glecaprevir/Pibrentasvir,Pilocarpine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pilocarpine is metabolised by CYP2A6 which is not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
577,Glecaprevir/Pibrentasvir,Pimozide,Do Not Coadminister,NA,Coadministration has not been studied and is not recommended. Pimozide is metabolised mainly by CYP3A4 and glecaprevir/pibrentasvir is a weak inhibitor of CYP3A4. The European and US product labels for pimozide recommend avoiding coadministration with any CYP3A4 inhibitor.,(See Summary)
578,Glecaprevir/Pibrentasvir,Pindolol,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pindolol is only partially metabolised and is renally excreted both unchanged and as metabolites. No CYP involvement has been described to date.,(See Summary)
579,Glecaprevir/Pibrentasvir,Pioglitazone,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pioglitazone is metabolised by CYP2C8 and CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of pioglitazone to any clinically significant extent. [Note, pioglitazone is contraindicated in hepatic impairment in the European SmPC, but caution is advised in the US Prescribing Information.]",(See Summary)
580,Glecaprevir/Pibrentasvir,Piperacillin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Piperacillin is only minimally metabolised and is excreted largely unchanged in the urine,(See Summary)
581,Glecaprevir/Pibrentasvir,Pipotiazine,No Interaction Expected,NA,Coadministration has not been studied but based on limited data on the metabolism and clearance of pipotiazine an interaction appears unlikely.,(See Summary)
582,Glecaprevir/Pibrentasvir,Piracetam,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as piracetam is excreted largely unchanged in the urine.,(See Summary)
583,Glecaprevir/Pibrentasvir,Pirfenidone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pirfenidone is mainly metabolised by CYP1A2 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP1A2 and is unlikely to affect the exposure of pirfenidone to any clinically significant extent.,(See Summary)
584,Glecaprevir/Pibrentasvir,Piroxicam,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Piroxicam is a substrate of CYP2C9 and is also metabolised by hydrolysis; these pathways are not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
585,Glecaprevir/Pibrentasvir,Pitavastatin,Potential Interaction,NA,"Coadministration has not been studied but a reduced dose of pitavastatin is recommended. Pitavastatin is a substrate of OATP1B1 and concentrations may increase due to OATP1B1/3 inhibition by glecaprevir/pibrentasvir. [Note, use of pitavastatin in active liver disease is contraindicated in its US Prescribing Information.]","Coadministration has not been studied but is expected to increase exposure of pitavastatin. Interactions with pitavastatin are likely and caution is recommended during the combination. A low dose of the statin is recommended at the initiation of the DAA treatment.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Coadministration may increase the concentrations of pitavastatin. Increased statin concentrations may increase the risk of myopathy, including rhabdomyolysis. Use the lowest approved dose of pitavastatin. If higher doses are needed, use the lowest necessary statin dose based on a risk/benefit assessment.Mavyret Prescribing Information, AbbVie Inc., June 2019."
586,Glecaprevir/Pibrentasvir,Pivmecillinam,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pivmecillinam is hydrolysed to mecillinam which is excreted primarily in the urine with some biliary excretion.,(See Summary)
587,Glecaprevir/Pibrentasvir,Pizotifen,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pizotifen is glucuronidated by UGT2B10 which is not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
588,Glecaprevir/Pibrentasvir,Posaconazole,Potential Interaction,NA,"Coadministration has not been studied. Posaconazole is eliminated mainly unchanged in the faeces and only a minimal amount undergoes biotransformation (mainly glucuronidation by UGT1A4). However, posaconazole concentrations may increase due to P-gp inhibition by glecaprevir/pibrentasvir. Use with caution and monitor for side effects. Although posaconazole is a strong inhibitor of CYP3A4 and could potentially increase glecaprevir/pibrentasvir exposure, this is unlikely to be clinically significant. ",(See Summary)
589,Glecaprevir/Pibrentasvir,Potassium,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.,(See Summary)
590,Glecaprevir/Pibrentasvir,Pramipexole,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as pramipexole is not hepatically metabolised and is mainly excreted in urine.,(See Summary)
591,Glecaprevir/Pibrentasvir,Prasugrel,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prasugrel is metabolized by primarily by CYP3A4 and CYP2B6, and to a lesser extent by CYP2C9 and CYP2C19. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of prasugrel to any clinically significant extent.",(See Summary)
592,Glecaprevir/Pibrentasvir,Pravastatin,Potential Interaction,NA,Coadministration of glecaprevir/pibrentasvir and a single dose of pravastatin increased pravastatin Cmax and AUC by 2.23-fold and 2.3-fold due to OATP1B1 inhibition by glecaprevir/pibrentasvir. The European SPC recommends that the pravastatin dose should not exceed 20 mg per day and the US Prescribing Information recommends that the pravastatin dose should be reduced by 50%.,"Co-administration with Maviret may increase plasma concentrations of medicinal products that are substrates of OATP1B1/3 (e.g. pravastatin). Coadministration of pravastatin (10 mg once daily) and glecaprevir/pibrentasvir increased pravastatin Cmax and AUC by 2.23-fold and 2.30-fold due to inhibition of OATP1B1/3. Caution is recommended. Pravastatin dose should not exceed 20 mg per day.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Coadministration of pravastatin (10 mg once daily) and glecaprevir/pibrentasvir (400/120 mg once daily) increased pravastatin Cmax and AUC by 2.23-fold and 2.30-fold (n=12). Increased statin concentrations may increase the risk of myopathy, including rhabdomyolysis. Reduce pravastatin dose by 50% when coadministered with Mavyret.Mavyret Prescribing Information, AbbVie Inc., June 2019."
593,Glecaprevir/Pibrentasvir,Praziquantel,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Praziquantel is metabolised predominantly by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of praziquantel to any clinically significant extent.,(See Summary)
594,Glecaprevir/Pibrentasvir,Prazosin,Potential Interaction,NA,Co-administration has not been studied. Prazosin is a substrate of BCRP and concentrations may increase due to inhibition of BCRP by glecaprevir/pibrentasvir.,(See Summary)
595,Glecaprevir/Pibrentasvir,Prednicarbate,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prednicarbate is metabolised to prednisolone-17-ethylcarbonate and then further metabolised to prednisolone. Following topical application, neither prednicarbate nor its metabolites are detected in the systemic circulation.",(See Summary)
596,Glecaprevir/Pibrentasvir,Prednisone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prednisone is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of prednisone to any clinically significant extent.,(See Summary)
597,Glecaprevir/Pibrentasvir,Pregabalin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as pregabalin is mainly excreted in urine.,(See Summary)
598,Glecaprevir/Pibrentasvir,Primaquine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Primaquine is metabolised mainly by a non-CYP mediated mechanism with a small fraction of the drug metabolised by multiple CYPs.,(See Summary)
599,Glecaprevir/Pibrentasvir,Primidone,Do Not Coadminister,NA,Coadministration has not been studied and is contraindicated. Induction of P-gp by primidone may significantly decrease plasma concentrations of glecaprevir/pibrentasvir resulting in loss of efficacy and potential virological failure.,"Concomitant use with strong P-gp and CYP3A inducers (e.g. primidone) is contraindicated. Medicinal products that are strong P-gp and CYP3A inducers (e.g. primidone) could significantly decrease glecaprevir or pibrentasvir plasma concentrations and may lead to reduced therapeutic effect of Maviret or loss of virologic response. Co-administration of such medicinal products with Maviret is contraindicated. Coadministration has not been studied but is expected to decrease exposure of glecaprevir and pibrentasvir. Co administration may lead to reduced therapeutic effect of Maviret and is contraindicated.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019."
600,Glecaprevir/Pibrentasvir,Prochlorperazine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prochlorperazine is metabolised by CYP2D6 and CYP2C19 which are not expected to be affected by glecaprevir/pibrentasvir. Note, prochlorperazine should be avoided in patients with hepatic or renal dysfunction.",(See Summary)
601,Glecaprevir/Pibrentasvir,Proguanil,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Proguanil is metabolised by CYP2C19 which is not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
602,Glecaprevir/Pibrentasvir,Promethazine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as promethazine undergoes renal elimination.,(See Summary)
603,Glecaprevir/Pibrentasvir,Propafenone,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Propafenone is metabolised by CYP2D6, CYP3A4 and CYP1A2 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of propafenone to any clinically significant extent.",(See Summary)
604,Glecaprevir/Pibrentasvir,Propofol,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Propofol is metabolised by UGTs 1A9 and 1A8, and to a limited extent by CYP2B6; these enzymes are not expected to be affected by glecaprevir/pibrentasvir.",(See Summary)
605,Glecaprevir/Pibrentasvir,Propranolol,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Propranolol is mainly metabolised by CYP2D6 which is not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
606,Glecaprevir/Pibrentasvir,Protamine sulphate,No Interaction Expected,NA,"Coadministration has not been studied, but based on very limited data concerning the metabolism, elimination and toxicity profiles of protamine an interaction would appear unlikely. Protamine complexed with heparin is thought to be metabolised by fibrinolysin and no CYP metabolism has been described.",(See Summary)
607,Glecaprevir/Pibrentasvir,Prucalopride,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prucalopride undergoes mainly renal elimination and is a weak substrate for P-gp. Any increase in concentrations due to inhibition of P-gp by glecaprevir/pibrentasvir is unlikely to be clinically relevant.,(See Summary)
608,Glecaprevir/Pibrentasvir,Pseudoephedrine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pseudoephedrine is minimally metabolised by MAOs and ~70% is excreted unchanged in the urine.,(See Summary)
609,Glecaprevir/Pibrentasvir,Pyrantel,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Only a very small proportion of pyrantel is absorbed from the gastrointestinal tract thus there is limited potential for interactions. Pyrantel is metabolised by CYP2D6 which is not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
610,Glecaprevir/Pibrentasvir,Pyrazinamide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pyrazinamide is metabolised by xanthine oxidase which is not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
611,Glecaprevir/Pibrentasvir,Pyridostigmine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pyridostigmine is predominantly eliminated unchanged via renal tubular secretion.,(See Summary)
612,Glecaprevir/Pibrentasvir,Pyrimethamine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Data on the exact pathways of metabolism of pyrimethamine are limited but few interactions have been described with this drug.,(See Summary)
613,Glecaprevir/Pibrentasvir,Quazepam,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Quazepam is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of quazepam to any clinically significant extent.,(See Summary)
614,Glecaprevir/Pibrentasvir,Quetiapine,Potential Interaction,NA,"Coadministration with quetiapine does not preclude the use of glecaprevir/pibrentasvir. Quetiapine is metabolised by CYP3A4 and in vitro is a substrate of P-gp. Concentrations of quetiapine may increase as glecaprevir/pibrentasvir is a weak inhibitor of CYP3A4 and P-gp (27% increase in AUC with probe 3A4 substrate midazolam; 45% increase in AUC of tacrolimus).Whilst unlikely to be clinically significant in most patients (a recent study having looked at the efficacy and safety of G/P in patients with chronic HCV and psychiatric disorders) , caution is advised when using higher doses of quetiapine (e.g. over 400mg/day), or with liver impairment, the elderly, patients with cardiac conduction abnormalities or other drugs known to prolong QT interval. Concomitant administration of cytochrome P450 3A4 inhibitors, such as HIV-protease inhibitors, azole-antifungal agents, erythromycin, clarithromycin and nefazodone, is contraindicated in the European label for quetiapine.","The combination of Maviret with tacrolimus should be used with caution. Increase of tacrolimus exposure is expected. Therefore, therapeutic drug monitoring of tacrolimus is recommended and a dose adjustment of tacrolimus made accordingly. Tacrolimus (CYP3A4 and P-gp substrate) has AUC increase of 45% (24-70%). Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Single dose midazolam in combination with glecaprevir/pibrentasvir had AUC increase of 27% (11%-45%).Mavyret Prescribing Information, AbbVie Inc., June 2019.Concomitant administration of cytochrome P450 3A4 inhibitors, such as HIV-protease inhibitors, azole-antifungal agents, erythromycin, clarithromycin and nefazodone, is contraindicated.Alaquet Summary of Product Characteristics, Mylan, May 2017.Glecaprevir/pibrentasvir is well tolerated and demonstrates high adherence rates in patients with chronic HCV infection and psychiatric disorders.Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis. Back D, Belperio P, Bondin M, et al. J Viral Hepat, 2019, 26: 951-960."
615,Glecaprevir/Pibrentasvir,Quinapril,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as quinapril is metabolised by esterases and is mainly excreted in urine.,(See Summary)
616,Glecaprevir/Pibrentasvir,Quinidine,Potential Interaction,NA,Coadministration has not been studied. Concentrations of quinidine may increase due to inhibition of P-gp by glecaprevir/pibrentasvir. There is risk of torsades de pointes associated with use of this drug. Caution is warranted as quinidine has a narrow therapeutic index and close monitoring is recommended. Use the lowest possible dose.,(See Summary)
617,Glecaprevir/Pibrentasvir,Quinine,Potential Interaction,NA,Coadministration has not been studied. Concentrations of quinine may increase due to inhibition of P-gp by glecaprevir/pibrentasvir. Close monitoring for increased side effects is recommended.,(See Summary)
618,Glecaprevir/Pibrentasvir,Rabeprazole,Potential Weak Interaction,NA,"Coadministration has not been studied but may result in decreased concentrations of glecaprevir. Coadministration with omeprazole (40 mg once daily) decreased glecaprevir AUC by ~50% and a similar effect may occur with equivalent doses of rabeprazole. For omeprazole, the European SPC for glecaprevir/pibrentasvir indicates that no dose adjustment is required and the US Prescribing Information indicates no clinically significant interaction and no dose adjustment required. However, it is important to note that currently there are no data with doses of omeprazole greater than 40 mg once daily.",(See Summary)
619,Glecaprevir/Pibrentasvir,Raloxifene,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Raloxifene is metabolised by UGTs, but glecaprevir and pibrentasvir are weak inhibitors of UGT1A1 in vivo but not of other UGTs.",(See Summary)
620,Glecaprevir/Pibrentasvir,Raltegravir,No Interaction Expected,NA,"Coadministration with glecaprevir/pibrentasvir increased raltegravir Cmax, AUC and Cmin by 34%, 47% and 164%, due to inhibition of UGT1A1. However this increase was within safety bounds and is not deemed clinically significant. No dose adjustment is required when glecaprevir/pibrentasvir is coadministered with raltegravir.","Clinically significant increases in exposure were not observed for sensitive substrates of UGT1A1 (raltegravir) when administered with Maviret. Coadministration of raltegravir (400 mg twice daily) and glecaprevir/pibrentasvir increased raltegravir Cmax, AUC and Cmin by 34%, 47% and 164%, respectively, due to inhibition of UGT1A1. No dose adjustment is required.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.No dose adjustment is required when Mavyret is coadministered with raltegravir. Coadministration of raltegravir (400 mg twice daily) and glecaprevir/pibrentasvir (300/120 mg once daily) increased raltegravir Cmax, AUC and Cmin by 34%, 47% and 164%, respectively (n=12). Mavyret Prescribing Information, AbbVie Inc., June 2019."
621,Glecaprevir/Pibrentasvir,Ramipril,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ramipril is metabolised by esterases and glucuronidation and these pathways are not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
622,Glecaprevir/Pibrentasvir,Ranitidine,Potential Weak Interaction,NA,"Coadministration has not been studied but may result in decreased concentrations of glecaprevir. Coadministration with the proton pump inhibitor omeprazole (40 mg once daily) decreased glecaprevir AUC by ~50%. A reduction in glecaprevir exposure is possible with ranitidine, however, this is unlikely to be clinically significant.",(See Summary)
623,Glecaprevir/Pibrentasvir,Ranolazine,Potential Interaction,NA,Coadministration has not been studied. Concentrations of ranolazine may increase due to P-gp inhibition by glecaprevir/pibrentasvir. A dose decrease should be considered. ,(See Summary)
624,Glecaprevir/Pibrentasvir,Rasagiline,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rasagiline is metabolised by CYP1A2 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP1A2 and is unlikely to affect the exposure of rasagiline to any clinically significant extent.,(See Summary)
625,Glecaprevir/Pibrentasvir,Repaglinide,Potential Interaction,NA,Coadministration has not been studied. Concentrations of repaglinide may increase due to inhibition of OATP1B1 by glecaprevir/pibrentasvir. Monitor blood glucose closely and titrate to effect.,(See Summary)
626,Glecaprevir/Pibrentasvir,Retigabine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. There is no evidence for hepatic oxidative metabolism of retigabine or its metabolites by cytochrome P450 enzymes.,(See Summary)
627,Glecaprevir/Pibrentasvir,Retinol (Vitamin A),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Retinol does not undergo CYP metabolism and is metabolised by UGTs which are not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
628,Glecaprevir/Pibrentasvir,Ribavirin,No Interaction Expected,NA,"Ribavirin had no effect on exposures of glecaprevir or pibrentasvir in studies evaluating the efficacy, safety and pharmacokinetics of glecaprevir and pibrentasvir. However, glecaprevir/pibrentasvir is a complete directly acting antiviral combination and there is usually no requirement for adding ribavirin. Glecaprevir/pibrentasvir is metabolised by and is a weak inhibitor of CYP3A4. Ribavirin is partly metabolised (non-CYP-mediated) and partly excreted in the urine. Ribavirin does not induce or inhibit CYP enzymes.","Two open-label, multi-centre studies evaluated the efficacy, safety and pharmacokinetics of following coadministration of glecaprevir and pibrentasvir with and without ribavirin in GT1-, GT2- and GT3-infected subjects. Ribavirin had no effect on exposures of glecaprevir or pibrentasvir.Pharmacokinetics of coadministration of pan-genotypic, direct acting antiviral agents ABT-493 and ABT-530, with or without ribavirin for 12 weeks in HCV infected subjects without cirrhosis. Lin CW, Liu W, Asatryan A, et al. Hepatol, 2015, 62 (1, Suppl); 567A (AASLD The Liver Meeting, Abstract 719)."
629,Glecaprevir/Pibrentasvir,Riboflavin (Vitamin B2),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as riboflavin does not undergo CYP metabolism and is primarily eliminated in urine.,(See Summary)
630,Glecaprevir/Pibrentasvir,Rifabutin,Do Not Coadminister,NA,Coadministration has not been studied and is not recommended. Induction of P-gp by rifabutin may significantly decrease plasma concentrations of glecaprevir/pibrentasvir leading to a reduced therapeutic effect.,(See Summary)
631,Glecaprevir/Pibrentasvir,Rifampicin,Do Not Coadminister,NA,"Coadministration is contraindicated. Concentrations of glecaprevir/pibrentasvir may be significantly decreased due to strong CYP3A induction after multiple doses of rifampicin. This may lead to loss of virologic response to glecaprevir/pibrentasvir. Coadministration of rifampicin (600 mg once daily) and glecaprevir/pibrentasvir decreased glecaprevir Cmax and AUC by 86% and 88%; pibrentasvir Cmax and AUC decreased by 83% and 87%. Note, following coadministration with a single dose of rifampicin, concentrations of glecaprevir were substantially increased by 8.55-fold, due to inhibition of OATP1B1/3.","Concomitant use with strong P-gp and CYP3A inducers (e.g., rifampicin) is contraindicated. Medicinal products that are strong P-gp and CYP3A inducers (e.g., rifampicin) could significantly decrease glecaprevir or pibrentasvir plasma concentrations and may lead to reduced therapeutic effect of Maviret or loss of virologic response. Co-administration of such medicinal products with Maviret is contraindicated. Coadministration of rifampicin (600 mg single dose) and glecaprevir/pibrentasvir increased glecaprevir Cmax and AUC by 6.52-fold and 8.55-fold, but had no effect on pibrentasvir; this was due to inhibition of OATP1B1/3. Coadministration of rifampicin (600 mg once daily) decreased glecaprevir Cmax and AUC by 86% and 88%; pibrentasvir Cmax and AUC decreased by 83% and 87% (effect of rifampicin on glecaprevir and pibrentasvir 24 hours after final rifampicin dose). This was due to induction of P-gp/BCRP/CYP3A. Co-administration is contraindicated.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Mavyret is contraindicated with rifampin. Coadministration of rifampin (600 mg first dose) and glecaprevir/pibrentasvir (300/120 mg single dose) increased glecaprevir Cmax and AUC by 6.52-fold and 8.55-fold, but had no effect on pibrentasvir. Coadministration of rifampin (600 mg once daily) and glecaprevir/pibrentasvir (300/120 mg single dose) decreased glecaprevir Cmax and AUC by 86% and 88%; pibrentasvir Cmax and AUC decreased by 83% and 87% (effect of rifampin on glecaprevir and pibrentasvir 24 hours after final rifampin dose). Coadministration is contraindicated because of potential loss of therapeutic effect.Mavyret Prescribing Information, AbbVie Inc., June 2019."
632,Glecaprevir/Pibrentasvir,Rifapentine,Do Not Coadminister,NA,Coadministration has not been studied and is not recommended. Coadministration may decrease glecaprevir/pibrentasvir concentrations due to induction of CYP3A4 and P-gp by rifapentine; this may lead to reduced therapeutic effect.,(See Summary)
633,Glecaprevir/Pibrentasvir,Rifaximin,Potential Interaction,NA,"Coadministration has not been studied. Rifaximin is a substrate of P-gp and concentrations may increase due to inhibition of P-gp by glecaprevir/pibrentasvir. The effect on pibrentasvir and glecaprevir is unclear as rifaximin is an inducer of CYP3A4 and an inhibitor of P-gp. Use with caution. Close monitoring for an appropriate and expected response to rifamixin and glecaprevir/pibrentasvir is recommended. [Note, caution should be exercised when rifamixin is administered to patients with severe hepatic impairment as whilst a clinically significant induction is unlikely at normal doses, the effect of higher concentrations of rifaximin in patients with hepatic impairment is unknown.]",(See Summary)
634,Glecaprevir/Pibrentasvir,Rilmenidine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as rilmenidine is not metabolised to any great extent.,(See Summary)
635,Glecaprevir/Pibrentasvir,Rilpivirine,No Interaction Expected,NA,"Coadministration of rilpivirine and glecaprevir/pibrentasvir increased rilpivirine Cmax, AUC and Cmin by 105%, 84% and 77%, respectively (n=12). This was deemed within safety limits and no dose adjustment is required when glecaprevir/pibrentasvir is coadministered with rilpivirine.","Drug-drug interaction studies were performed with rilpivirine and showed no clinically significant interactions with Maviret.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.No dose adjustment is required when Mavyret is coadministered with rilpivirine. Coadministration of rilpivirine (25 mg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) increased rilpivirine Cmax, AUC and Cmin by 105%, 84% and 77%, respectively (n=12). Mavyret Prescribing Information, AbbVie Inc., June 2019."
636,Glecaprevir/Pibrentasvir,Rilpivirine/ Emtricitabine/Tenofovir alafenamide (RPV/FTC/TAF),No Interaction Expected,NA,"Coadministration with rilpivirine/emtricitabine/tenofovir alafenamide has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Coadministration of rilpivirine and glecaprevir/pibrentasvir increased rilpivirine Cmax, AUC and Cmin by 105%, 84% and 77%, respectively (n=12). This was deemed within safety limits. Studies performed with emtricitabine or tenofovir alafenamide showed no clinically significant interactions with glecaprevir/pibrentasvir. No dose adjustment is required when glecaprevir/pibrentasvir is coadministered with rilpivirine/emtricitabine/tenofovir alafenamide.","Drug-drug interaction studies were performed with rilpivirine, emtricitabine and tenofovir alafenamide and showed no clinically significant interactions with Maviret.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.No dose adjustment is required when Mavyret is coadministered with rilpivirine, emtricitabine or tenofovir alafenamide.Mavyret Prescribing Information, AbbVie Inc., June 2019."
637,Glecaprevir/Pibrentasvir,Rimantadine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rimantadine undergoes complex liver metabolism being both hydroxylated and glucuronidated. These pathways are not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
638,Glecaprevir/Pibrentasvir,Riociguat,No Interaction Expected,NA,"Co-administration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Riociguat is metabolized by CYP1A1, CYP3A4, CYP2C8, CYP2J2 and is also eliminated unchanged in the bile and renally. Riociguat is a substrate of P-gp and BCRP. Glecaprevir and pibrentasvir are P-gp/BCRP inhibitors but only weak inhibitors of CYP3A and UGT1A1 and are unlikely to affect riociguat exposure to any clinically significant extent. A clinically significant effect on glecaprevir/pibrentasvir exposure is unlikely.",(See Summary)
639,Glecaprevir/Pibrentasvir,Risedronate,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. There is no evidence of systemic metabolism of risedronate; 60% of the dose is distributed to bone and the remainder is excreted in urine. However the absorption of risedronate may be affected by food, drinks (other than plain water) or other medicinal products. Risedronate should be taken at least 2 hours before and at least 2 hours after any food, medicinal product or drink. [Note: this interaction is not specific for glecaprevir/pibrentasvir, but for any medication taken with risedronate.]",(See Summary)
640,Glecaprevir/Pibrentasvir,Risperidone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Risperidone undergoes metabolism by CYP2D6 and CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of risperidone to any clinically significant extent.,(See Summary)
641,Glecaprevir/Pibrentasvir,Ritonavir,Do Not Coadminister,NA,"Coadministration is not recommended. Concomitant use of glecaprevir/pibrentasvir with OATP1B inhibitors, such as ritonavir, may increase glecaprevir/pibrentasvir plasma concentrations.","Co-administration of Maviret with medicinal products that inhibit P-gp and BCRP (e.g., ritonavir) may slow the elimination of glecaprevir and pibrentasvir and thereby increase plasma exposure of the antivirals. Coadministration of atazanavir/ritonavir (300/100 mg once daily) and glecaprevir/pibrentasvir increased glecaprevir Cmax, AUC and Cmin by at least 4.06-fold, 6.53-fold and 14.3-fold, respectively. Pibrentasvir Cmax, AUC and Cmin increased by at least 29%, 64% and 129%, respectively. Coadministration of darunavir/ritonavir (800/100 mg once daily) and glecaprevir/pibrentasvir increased glecaprevir Cmax, AUC and Cmin by 3.09-fold, 4.97-fold and 8.24-fold, respectively. There was no change in pibrentasvir Cmax or AUC, but Cmin increased by 66%. Coadministration of lopinavir/ritonavir (400/100 mg twice daily) and glecaprevir/pibrentasvir increased glecaprevir Cmax, AUC and Cmin by 2.55-fold, 4.38-fold and 18.6-fold; pibrentasvir Cmax, AUC and Cmin increased by 1.40-fold, 2.46-fold and 5.24-fold. Coadministration is not recommended.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Coadministration of atazanavir/ritonavir (300/100 mg once daily) and glecaprevir/pibrentasvir increased glecaprevir Cmax, AUC and Cmin by at least 4.06-fold, 6.53-fold and 14.3-fold, respectively. Pibrentasvir Cmax, AUC and Cmin increased by at least 29%, 64% and 129%, respectively. Coadministration of darunavir/ritonavir (800/100 mg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 8 subjects. Glecaprevir Cmax, AUC and Cmin increased by 3.09-fold, 4.97-fold and 8.24-fold, respectively. There was no change in pibrentasvir Cmax or AUC, but Cmin increased by 66%. Darunavir Cmax and AUC increased by 30% and 29%, but there was no change in Cmin. Ritonavir Cmax and AUC increased by 103% and 87%, but there was no change in Cmin. Coadministration is not recommended.Coadministration of lopinavir/ritonavir (400/100 mg twice daily) and glecaprevir/pibrentasvir increased glecaprevir Cmax, AUC and Cmin by 2.55-fold, 4.38-fold and 18.6-fold; pibrentasvir Cmax, AUC and Cmin increased by 1.40-fold, 2.46-fold and 5.24-fold. Coadministration is not recommended.Mavyret Prescribing Information, AbbVie Inc., June 2019."
642,Glecaprevir/Pibrentasvir,Rituximab,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rituximab is removed by opsonization via the reticularendothelial system.,(See Summary)
643,Glecaprevir/Pibrentasvir,Rivaroxaban,Potential Interaction,NA,"Coadministration has not been studied. Rivaroxaban is a substrate of CYP3A4, P-gp and BCRP. Coadministration may increase rivaroxaban concentrations due to the additive effect of weak inhibition of CYP3A4, inhibition of P-gp and inhibition of BCRP by glecaprevir/pibrentasvir. This may lead to an increased risk of bleeding and close monitoring is recommended.",(See Summary)
644,Glecaprevir/Pibrentasvir,Rizatriptan,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as rizatriptan is metabolised by MAO.,(See Summary)
645,Glecaprevir/Pibrentasvir,Ropinirole,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ropinirole is metabolised by CYP1A2 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP1A2 and is unlikely to affect the exposure of ropinirole to any clinically significant extent.,(See Summary)
646,Glecaprevir/Pibrentasvir,Rosiglitazone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rosiglitazone is metabolized by CYP2C8 which is not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
647,Glecaprevir/Pibrentasvir,Rosuvastatin,Potential Interaction,NA,"Coadministration of glecaprevir/pibrentasvir and rosuvastatin (5 mg) increased rosuvastatin Cmax and AUC by 5.62-fold and 2.15-fold. Use with caution. The European SPC recommends that the rosuvastatin dose should not exceed 5 mg/day, whereas the US Prescribing Information recommends that rosuvastatin should not exceed 10 mg/day. Note, rosuvastatin is contraindicated in patients with active liver disease and should be used with caution in patients who consume excessive quantities of alcohol and/or have a history of liver disease.","Co-administration with Maviret may increase plasma concentrations of medicinal products that are substrates of OATP1B1/3 (e.g. rosuvastatin). Coadministration of rosuvastatin (5 mg once daily) and glecaprevir/pibrentasvir increased rosuvastatin Cmax and AUC by 5.62-fold and 2.15-fold due to inhibition of OATP1B1/3 and BCRP. Caution is recommended. Rosuvastatin dose should not exceed 5 mg per day.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Coadministration of rosuvastatin (5 mg once daily) and glecaprevir/pibrentasvir (400/120 mg once daily) increased rosuvastatin Cmax and AUC by 5.62-fold and 2.15-fold (n=11). Increased statin concentrations may increase the risk of myopathy, including rhabdomyolysis. Rosuvastatin may be administered with Mavyret at a dose that does not exceed 10 mg.Mavyret Prescribing Information, AbbVie Inc., June 2019."
648,Glecaprevir/Pibrentasvir,Rufinamide,Potential Interaction,NA,Coadministration has not been studied and should be used with caution. Coadministration may decrease glecaprevir/pibrentasvir concentrations due to weak induction of CYP3A4 and P-gp by rufinamide; this may lead to reduced therapeutic effect.,(See Summary)
649,Glecaprevir/Pibrentasvir,Salbutamol,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as salbutamol is metabolised by sulfotransferases.,(See Summary)
650,Glecaprevir/Pibrentasvir,Salmeterol,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Salmeterol is metabolised predominantly by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of salmeterol to any clinically significant extent.,(See Summary)
651,Glecaprevir/Pibrentasvir,Saquinavir,Do Not Coadminister,NA,"Coadministration is contraindicated. Concomitant use of glecaprevir/pibrentasvir with OATP1B inhibitors, such as saquinavir, may increase the risk of ALT elevations due to a significant increase in pibrentasvir plasma concentrations caused by OATP1B1/3 inhibition. Based on interactions studies, coadministration of glecaprevir/pibrentasvir with ritonavir-boosted HIV protease inhibitors is not recommended.",(See Summary)
652,Glecaprevir/Pibrentasvir,Saxagliptin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Saxagliptin is metabolised predominantly by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of saxagliptin to any clinically significant extent.,(See Summary)
653,Glecaprevir/Pibrentasvir,Selexipag,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Selexipag is hydrolysed to its active metabolite by carboxylesterase 1 (CES1). Both selexipag and its active metabolite undergo oxidative metabolism by CYP2C8 and CYP3A4. The active metabolite is also glucuronidated by UGT1A3 and UGT2B7. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to significantly impact the exposure of the active metabolite as CYP3A4 is a minor pathway in the elimination of the active metabolite. Clinically relevant effects of drug transporter inhibitors (e.g. P-gp and OATP) are unlikely.,(See Summary)
654,Glecaprevir/Pibrentasvir,Senna,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.,(See Summary)
655,Glecaprevir/Pibrentasvir,Serenoa repens,No Interaction Expected,NA,Coadministration has not been studied. Serenoa repens has been shown to be a potent inhibitor of CYP3A4 but this is unlikely to have a clinically significant effect on glecaprevir/pibrentasvir due to the large therapeutic safety margins.,(See Summary)
656,Glecaprevir/Pibrentasvir,Sertraline,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sertraline is metabolised by CYP2B6 (major) and CYPs 3A4, CYP2C9/19 and CYP2D6. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of sertraline to any clinically significant extent. [Note, use with caution in patients with hepatic impairment when a lower or less frequent dose may be required. Sertraline should not be used in patients with severe hepatic impairment.]",(See Summary)
657,Glecaprevir/Pibrentasvir,Sevelamer,Potential Weak Interaction,NA,"Coadministration has not been studied. Sevelamer is not absorbed from the GI tract and may potentially affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer. [Note: this interaction is not specific for glecaprevir/pibrentasvir, but for any medication taken with sevelamer.]",(See Summary)
658,Glecaprevir/Pibrentasvir,Sildenafil (erectile dysfunction),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sildenafil is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of sildenafil to any clinically significant extent.,(See Summary)
659,Glecaprevir/Pibrentasvir,Sildenafil (pulmonary arterial hypertension),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sildenafil is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of sildenafil to any clinically significant extent.,(See Summary)
660,Glecaprevir/Pibrentasvir,Silodosin,Potential Interaction,NA,Coadministration has not been studied. Silodosin is a substrate of CYP3A4 and P-gp. Concentrations of silodosin may increase as glecaprevir/pibrentasvir is a mild CYP3A4 inhibitor and a moderate to strong P-gp inhibitor. Caution is requires as coadministration with strong P-gp inhibitors is not recommended. Monitor for additional side effects due to increased silodosin concentrations.,(See Summary)
661,Glecaprevir/Pibrentasvir,Simeprevir,Do Not Coadminister,NA,Glecaprevir/pibrentasvir is a NS3A-containing directly acting antiviral regimen. There are no data to support the coadministration with other HCV protease inhibitors.,(See Summary)
662,Glecaprevir/Pibrentasvir,Simeticone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as simeticone is not absorbed from the gastro-intestinal tract.,(See Summary)
663,Glecaprevir/Pibrentasvir,Simvastatin,Do Not Coadminister,NA,Coadministration is contraindicated due to the increased risk of myopathy/rhabdomyolysis. Coadministration of glecaprevir/pibrentasvir and simvastatin (5 mg once daily) increased simvastatin Cmax and AUC by 99% and 132%; Cmax and AUC of simvastatin acid increased by 10.2-fold and 4.48-fold.,"Concomitant use with simvastatin is contraindicated. Co-administration with Maviret may increase plasma concentrations of medicinal products that are substrates of OATP1B1/3 (e.g. simvastatin). Coadministration of simvastatin (5 mg once daily) and glecaprevir/pibrentasvir increased simvastatin Cmax and AUC by 1.99-fold and 2.32-fold; Cmax and AUC of simvastatin acid increased by 10.7-fold and 4.48-fold. This was due to inhibition of OATP1B1/3, P-gp and BCRP. Co-administration with simvastatin is contraindicated./div>Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Coadministration of simvastatin (5 mg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 12 subjects. Simvastatin Cmax and AUC increased by 1.99-fold and 2.32-fold; Cmax and AUC of simvastatin acid increased by 10.7-fold and 4.48-fold. Increased statin concentrations may increase the risk of myopathy, including rhabdomyolysis. Coadministration with this statin is not recommended.Mavyret Prescribing Information, AbbVie Inc., June 2019."
664,Glecaprevir/Pibrentasvir,Sirolimus,Potential Interaction,NA,"Coadministration has not been studied. Sirolimus is a substrate of CYP3A4 and P-gp; concentrations may increase due to the additive effect of weak inhibition of CYP3A4 and inhibition of P-gp by glecaprevir/pibrentasvir. If coadministration cannot be avoided, therapeutic drug monitoring of sirolimus should be performed.",(See Summary)
665,Glecaprevir/Pibrentasvir,Sitagliptin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sitagliptin is mainly eliminated unchanged and only metabolised to a small extent (~20%) by CYP3A4. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of sitagliptin to any clinically significant extent.,(See Summary)
666,Glecaprevir/Pibrentasvir,Sodium stibogluconate,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as elimination of sodium stibogluconate is predominantly by renal glomerular filtration.,(See Summary)
667,Glecaprevir/Pibrentasvir,Sofosbuvir,No Interaction Expected,NA,"Coadministration of sofosbuvir (400 mg single dose) and glecaprevir/pibrentasvir increased sofosbuvir Cmax and AUC by 66% and 125%; there was no change in the Cmax and AUC of GS-33107 (the active metabolite of sofosbuvir) but Cmin increased by 85%. Cmax, AUC and Cmin of glecaprevir and pibrentasvir were unaltered. No dose adjustment is required.","Coadministration of sofosbuvir (400 mg single dose) and glecaprevir/pibrentasvir increased the Cmax and AUC of sofosbuvir by 66% and 125%; there was no change in the Cmax and AUC of GS-33107 (the active metabolite of sofosbuvir) but Cmin increased by 85%. This was due to P-gp/BCRP inhibition. Cmax, AUC and Cmin of glecaprevir and pibrentasvir were unaltered. No dose adjustment is required.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.No dose adjustment is required when Mavyret is coadministered with sofosbuvir. Coadministration of sofosbuvir (400 mg once daily) and glecaprevir/pibrentasvir (400/120 mg once daily) was studied in 8 subjects. Cmax and AUC of sofosbuvir increased by 66% and 125%; there was no change in the Cmax and AUC of GS-33107 (the active metabolite of sofosbuvir) but Cmin increased by 85%.Mavyret Prescribing Information, AbbVie Inc., June 2019."
668,Glecaprevir/Pibrentasvir,Sofosbuvir/Velpatasvir,Do Not Coadminister,NA,Coadministration of glecaprevir/pibrentasvir with other directly acting antivirals has not been studied and therefore cannot be recommended.,(See Summary)
669,Glecaprevir/Pibrentasvir,Sofosbuvir/Velpatasvir/Voxilaprevir,Do Not Coadminister,NA,Sofosbuvir/velpatasvir/voxilaprevir is a complete regimen. There are no data to support coadministration with glecaprevir/pibrentasvir.,(See Summary)
670,Glecaprevir/Pibrentasvir,Solifenacin,Potential Weak Interaction,NA,"Coadministration has not been studied. Solifenacin is metabolized by CYP3A4 and concentrations may increase due to mild inhibition of CYP3A4 by glecaprevir/pibrentasvir. Although a clinically significant interaction is unlikely, be aware of increased side effects.",(See Summary)
671,Glecaprevir/Pibrentasvir,Sorafenib,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sorafenib is metabolised by CYP3A4 and glucuronidation. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of sorafenib to any clinically significant extent.,(See Summary)
672,Glecaprevir/Pibrentasvir,Sotalol,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as sotalol is mainly excreted in urine.,(See Summary)
673,Glecaprevir/Pibrentasvir,Spectinomycin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as spectinomycin is predominantly eliminated unchanged via the kidneys.,(See Summary)
674,Glecaprevir/Pibrentasvir,Spironolactone,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Spironolactone is extensively metabolised and can induce certain enzymes but this is not known to include P-gp, BCRP or OATP1B1.",(See Summary)
675,Glecaprevir/Pibrentasvir,Stavudine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as stavudine is predominantly eliminated unchanged via the kidneys.,(See Summary)
676,Glecaprevir/Pibrentasvir,St John's wort,Do Not Coadminister,NA,"Coadministration has not been studied and is not recommended. Coadministration may decrease concentrations of glecaprevir/pibrentasvir which may lead to reduced therapeutic effect of glecaprevir/pibrentasvir. However, the constituent of St John’s Wort responsible for induction of enzymes and transporters, hyperforin, can be highly variable between extracts. A recent study suggests a low risk of a clinically relevant pharmacokinetic interaction with low-hyperforin formulations (< 1 mg/day) of St John’s Wort. Coadministration may be considered with St John’s Wort formulations that clearly state the hyperforin content and which have a total daily hyperforin dose of < 1 mg.","Concomitant use with strong P-gp and CYP3A inducers (e.g., St. John’s wort (Hypericum perforatum)) is contraindicated. Medicinal products that are strong P-gp and CYP3A inducers (e.g., St. John’s wort (Hypericum perforatum)) could significantly decrease glecaprevir or pibrentasvir plasma concentrations and may lead to reduced therapeutic effect of Maviret or loss of virologic response. Coadministration of such medicinal products with Maviret is contraindicated. Coadministration with St John’s wort has not been studied but is expected to decrease exposure of glecaprevir and pibrentasvir. Coadministration may lead to reduced therapeutic effect of Maviret and is contraindicated.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.St. John’s wort may significantly decrease plasma concentrations of glecaprevir and pibrentasvir, leading to the reduced therapeutic effect of Mavyret. The use of this agent with Mavyret is not recommended.Mavyret Prescribing Information, AbbVie Inc., June 2019.Coadministration of the low hyperforin (≤ 0.2% ) St John’s Wort extract Ze 117 and a probe substrate cocktail containing caffeine, bupropion, flurbiprofen, omeprazole, dextromethorphan, midazolam and fexofenadine was studied in 20 subjects. No induction of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP3A4 or P-gp was seen. The authors suggest that low hyperforin preparations of St John’s Wort containing a daily dose of < 1 mg may help mitigate risk of a herb-drug interaction when administered with other medications./div>No clinically relevant interactions of St John’s Wort extract Ze 117 low in hyperforin with cytochrome P450 enzymes and P-glycoprotein. Zahner C, Kruttschnitt E, Uricher J et al. Clin Pharm Ther, 2019, 106, 432-440."
677,Glecaprevir/Pibrentasvir,Streptokinase,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Streptokinase does not undergo CYP metabolism in the liver and is eliminated renally.,(See Summary)
678,Glecaprevir/Pibrentasvir,Streptomycin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as streptomcyin is predominantly eliminated unchanged by the kidneys.,(See Summary)
679,Glecaprevir/Pibrentasvir,Strontium ranelate,Potential Weak Interaction,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as strontium is predominantly eliminated unchanged via the kidneys. However, food and milk can affect strontium absorption and administration should be separated by at least 2 hours. [Note: this interaction is not specific for glecaprevir/pibrentasvir, but for any medication taken with strontium ranelate.]",(See Summary)
680,Glecaprevir/Pibrentasvir,Sulfadiazine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sulfadiazine is partly metabolised by CYP2C9 which is not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
681,Glecaprevir/Pibrentasvir,Sulfadoxine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sulfadoxine is partly metabolised by CYP2C9 which is not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
682,Glecaprevir/Pibrentasvir,Sulfasalazine,Potential Interaction,NA,Coadministration has not been studied. Sulfasalazine is a substrate of BCRP and concentrations may increase due to inhibition of BCRP by glecaprevir/pibrentasvir. Monitor patients closely. ,(See Summary)
683,Glecaprevir/Pibrentasvir,Sulpiride,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as sulpiride is mainly excreted in the urine and faeces as unchanged drug.,(See Summary)
684,Glecaprevir/Pibrentasvir,Sultiame,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Limited data suggest that sultiame is a substrate and inhibitor of CYP3A4. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of sultiame to any clinically significant extent. Inhibition of CYP3A4 by sultiame is unlikely to have a clinically significant effect on glecaprevir/pibrentasvir due to the large therapeutic safety margins.,(See Summary)
685,Glecaprevir/Pibrentasvir,Sumatriptan,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as sumatriptan is metabolised by MAO.,(See Summary)
686,Glecaprevir/Pibrentasvir,Sunitinib,Potential Interaction,NA,"Coadministration has not been studied. Sunitinib is metabolised by CYP3A4 and transported by BCRP. Glecaprevir/pibrentasvir is a weak inhibitor of CYP3A4. Currently the clinical significance of this interaction is unknown and it is suggested to monitor for side effects. In vivo data suggest sunitinib is a substrate and/or inhibitor of P-gp and BCRP but this is unlikely to have a clinically significant effect on glecaprevir/pibrentasvir due to the large therapeutic safety margins. However, glecaprevir/pibrentasvir is a BCRP inhibitor. The clinical significance of this interaction is unclear; however, it may lead to an increased risk of sunitinib-associated adverse events. Use with caution; dose adjustment of sunitinib may be required.",(See Summary)
687,Glecaprevir/Pibrentasvir,Tacrolimus,Potential Interaction,NA,"Coadministration of glecaprevir/pibrentasvir with systemic tacrolimus (1 mg single dose) increased tacrolimus Cmax and AUC by 1.5-fold and 1.45-fold. There was no change in the Cmax, AUC and Cmin of glecaprevir or pibrentasvir. As tacrolimus is a narrow therapeutic index drug, use with caution. Therapeutic blood monitoring should be performed.","Coadministration of tacrolimus (1 mg single dose) and glecaprevir/pibrentasvir increased tacrolimus Cmax and AUC by 50% and 45% due to CYP3A4 and P-gp inhibition. There was no change in the Cmax, AUC and Cmin of glecaprevir or pibrentasvir. The combination of Maviret with tacrolimus should be used with caution. Increase of tacrolimus exposure is expected. Therefore, a therapeutic drug monitoring of tacrolimus is recommended and a dose adjustment of tacrolimus made accordingly.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.No dose adjustment is required when Mavyret is coadministered with tacrolimus. Coadministration of tacrolimus (1 mg single dose) and glecaprevir/pibrentasvir (300/120 mg once daily) increased tacrolimus Cmax and AUC by 50% and 45% (n=10). Mavyret Prescribing Information, AbbVie Inc., June 2019.Coadministration of glecaprevir/pibrentasvir (300/120 mg once daily) and tacrolimus (1 mg single dose) was studied in 12 healthy subjects. Tacrolimus Cmax, AUC and C23 slightly increased (50%, 53% and 45%), but there was minimal effect on glecaprevir (11% or less change) or pibrentasvir (2% or less change). No dose adjustment is required for glecaprevir/pibrentasvir with tacrolimus. However, dose reduction of tacrolimus may be required based on therapeutic monitoring.Drug-drug interactions between next generation direct acting antivirals ABT-493 and ABT-530 with cyclosporine or tacrolimus in healthy subjects. Kosloski MP, Dutta S, Zhao W, et al. Hepatol, 2015, 62 (1, Suppl); 561A (AASLD The Liver Meeting, Abstract 710)."
688,Glecaprevir/Pibrentasvir,Tadalafil (erectile dysfunction),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tadalafil is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of tadalafil to any clinically significant extent.,(See Summary)
689,Glecaprevir/Pibrentasvir,Tadalafil (pulmonary arterial hypertension),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tadalafil is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of tadalafil to any clinically significant extent.,(See Summary)
690,Glecaprevir/Pibrentasvir,Tamoxifen,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tamoxifen is mainly metabolized by CYPs 2D6, 3A4 and 3A5, but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of tamoxifen to any clinically significant extent.",(See Summary)
691,Glecaprevir/Pibrentasvir,Tamsulosin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tamsulosin is metabolised by CYP3A4 and CYP2D6 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of tamsulosin to any clinically significant extent.,(See Summary)
692,Glecaprevir/Pibrentasvir,Tapentadol,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tapentadol undergoes complex metabolic pathways including glucuronidation followed by some minimal metabolism by CYPs 2C9, 2C19 and 2D6. A clinically significant effect is not expected.",(See Summary)
693,Glecaprevir/Pibrentasvir,Tazobactam,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tazobactam is only minimally metabolised and is eliminated primarily by renal excretion.,(See Summary)
694,Glecaprevir/Pibrentasvir,Telbivudine,No Interaction Expected,NA,Studies performed with emtricitabine or telbivudine showed no clinically significant interactions with glecaprevir/pibrentasvir. No dose adjustment is required when glecaprevir/pibrentasvir is co administered with telbivudine.,(See Summary)
695,Glecaprevir/Pibrentasvir,Telithromycin,Potential Interaction,NA,"Coadministration has not been studied. Concentrations of glecaprevir/pibrentasvir and/or telithromycin could increase due to inhibition of P-gp. Although no a priori dose modification is recommended, there are concerns regarding the hepatotoxicity of telithromycin.",(See Summary)
696,Glecaprevir/Pibrentasvir,Telmisartan,Potential Interaction,NA,"Coadministration has not been studied. Telmisartan is substrate but not inhibitor of OATP1B1. Glecaprevir/pibrentasvir are OATP inhibitors (OATP1B1 and OATP1B3) and could increase telmisartan concentrations. The clinical significance of this is unknown. Close monitoring of heart rate and blood pressure, and for side effects is recommended.",(See Summary)
697,Glecaprevir/Pibrentasvir,Temazepam,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Temazepam is metabolised by glucuronidation and sulfation and these pathways are not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
698,Glecaprevir/Pibrentasvir,Temocillin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as temocillin is excreted unchanged in the urine.,(See Summary)
699,Glecaprevir/Pibrentasvir,Temsirolimus,Potential Interaction,NA,"Coadministration has not been studied. Temsirolimus is a substrate and inhibitor of CYP3A4 and P-gp. Coadministration of CYP3A4 and/or P-gp inhibitors should be used with caution. If concomitant use is required, a dose reduction and therapeutic drug monitoring is recommended.",(See Summary)
700,Glecaprevir/Pibrentasvir,Tenofovir alafenamide,No Interaction Expected,NA,Studies performed with emtricitabine or tenofovir alafenamide showed no clinically significant interactions with glecaprevir/pibrentasvir. No dose adjustment is required when glecaprevir/pibrentasvir is coadministered with tenofovir alafenamide.,"Drug-drug interaction studies were performed with tenofovir alafenamide and showed no clinically significant interactions with Maviret.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.No dose adjustment is required when Mavyret is coadministered with tenofovir alafenamide.Mavyret Prescribing Information, AbbVie Inc., June 2019."
701,Glecaprevir/Pibrentasvir,Tenofovir-DF (HBV),No Interaction Expected,NA,Coadministration with tenofovir-DF alone has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. No clinically significant interactions were observed when tenofovir-DF (with efavirenz and emtricitabine) and glecaprevir/pibrentasvir were coadministered. No dose adjustment is required.,"Coadministration of efavirenz/emtricitabine/tenofovir-DF (600/200/300 mg once daily) and glecaprevir/pibrentasvir had no effect on tenofovir Cmax, but increased AUC and Cmin by 29% and 38%. The effect of efavirenz/emtricitabine/tenofovir disoproxil fumarate on glecaprevir and pibrentasvir was not directly quantified within this study, but glecaprevir and pibrentasvir exposures were significantly lower than historical controls. No clinically significant interactions are expected with tenofovir disoproxil fumarate.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Coadministration of efavirenz/emtricitabine/tenofovir-DF (600/200/300 mg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) had no effect on tenofovir Cmax, but increased AUC and Cmin by 29% and 38% (n=12). No dose adjustment is required when Mavyret is coadministered with tenofovir-DF.Mavyret Prescribing Information, AbbVie Inc., June 2019."
702,Glecaprevir/Pibrentasvir,Tenofovir-DF (HIV),No Interaction Expected,NA,Coadministration with tenofovir-DF alone has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. No clinically significant interactions were observed when tenofovir-DF (with efavirenz and emtricitabine) and glecaprevir/pibrentasvir were coadministered. No dose adjustment is required.,"Coadministration of efavirenz/emtricitabine/tenofovir-DF (600/200/300 mg once daily) and glecaprevir/pibrentasvir had no effect on tenofovir Cmax, but increased AUC and Cmin by 29% and 38%. The effect of efavirenz/emtricitabine/tenofovir disoproxil fumarate on glecaprevir and pibrentasvir was not directly quantified within this study, but glecaprevir and pibrentasvir exposures were significantly lower than historical controls. No clinically significant interactions are expected with tenofovir disoproxil fumarate.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Coadministration of efavirenz/emtricitabine/tenofovir-DF (600/200/300 mg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) had no effect on tenofovir Cmax, but increased AUC and Cmin by 29% and 38% (n=12). No dose adjustment is required when Mavyret is coadministered with tenofovir-DF.Mavyret Prescribing Information, AbbVie Inc., June 2019."
703,Glecaprevir/Pibrentasvir,Terbinafine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Terbinafine is metabolized by at least seven CYPs and the potential for interaction with other drugs is predicted to be low. [Note, terbinafine in patients with chronic or active liver disease has not been studied in prospective clinical trials and therefore cannot be recommended for such patients.]",(See Summary)
704,Glecaprevir/Pibrentasvir,Terfenadine,Potential Interaction,NA,"Coadministration has not been studied. Terfenadine undergoes extensive metabolism mainly by CYP3A4, Terfenadine concentrations may increase due to mild CYP3A4 inhibition by glecaprevir/pibrentasvir which may result in serious or life-threatening effects (such as cardiac arrhythmias, breathing difficulties) or excessive sleepiness.",(See Summary)
705,Glecaprevir/Pibrentasvir,Tetracyclines,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as tetracyclines are predominantly eliminated unchanged by the kidneys,(See Summary)
706,Glecaprevir/Pibrentasvir,Thalidomide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as thalidomide is cleared by non-enzymatic pathways of hydrolysis.,(See Summary)
707,Glecaprevir/Pibrentasvir,Theophylline,Potential Interaction,NA,Coadministration has not been studied. Theophylline is metabolised by CYP1A2 and CYP3A4 and concentrations may increase due the combined effect of mild CYP1A2 and CYP3A4 inhibition by glecaprevir/pibrentasvir. Caution is advised as theophylline has a narrow therapeutic index.,(See Summary)
708,Glecaprevir/Pibrentasvir,Thiamine (Vitamin B1),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as thiamine is predominantly eliminated unchanged by the kidneys.,(See Summary)
709,Glecaprevir/Pibrentasvir,Thiopental,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The isoenzymes involved in thiopental metabolism have not been identified but data from animal studies suggest that enzyme inducers or inhibitors do not modify the duration of surgical anaesthesia or sleep time.,(See Summary)
710,Glecaprevir/Pibrentasvir,Thioridazine,Potential Interaction,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Thioridazine is metabolised by CYP3A4 and glecaprevir/pibrentasvir is a weak inhibitor of CYP3A4. Caution is recommended as thioridazine has a narrow therapeutic index and has been discontinued in many countries due to toxicities. ,(See Summary)
711,Glecaprevir/Pibrentasvir,Tiagabine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tiagabine is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of tiagabine to any clinically significant extent.,(See Summary)
712,Glecaprevir/Pibrentasvir,Tianeptine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as tianeptine is predominantly metabolised by beta-oxidation and N-demethylation.,(See Summary)
713,Glecaprevir/Pibrentasvir,Tiapride,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as tiapride is excreted largely unchanged in the urine. There is little evidence of any renal transporter mediated interaction with glecaprevir/pibrentasvir.,(See Summary)
714,Glecaprevir/Pibrentasvir,Ticagrelor,Potential Interaction,NA,Coadministration has not been studied. Ticagrelor is a substrate of CYP3A4 and P-gp; concentrations may increase due to the additive effect of weak inhibition of CYP3A4 and inhibition of P-gp by glecaprevir/pibrentasvir. The clinical significance of this is unknown and close monitoring is recommended due to the narrow therapeutic index of ticagrelor.,(See Summary)
715,Glecaprevir/Pibrentasvir,Ticarcillin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Ticarcillin is eliminated by the kidney and excreted largely unchanged in the urine.,(See Summary)
716,Glecaprevir/Pibrentasvir,Ticlopidine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ticlopidine is a prodrug that is converted to its active metabolites by CYPs 2C19, 3A4 and 2B6. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of ticlopidine to any clinically significant extent.",(See Summary)
717,Glecaprevir/Pibrentasvir,Timolol,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Timolol is predominantly metabolised by CYP2D6 which is not expected to be affected by glecaprevir/pibrentasvir. [Note, the European SmPC and the US Prescribing Information mention that timolol should be used at a reduced dose in hepatic impairment.]",(See Summary)
718,Glecaprevir/Pibrentasvir,Tinzaparin,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tinzaparin is partially metabolized by desulphation and depolymerization, and then renally excreted.",(See Summary)
719,Glecaprevir/Pibrentasvir,Tiotropium,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tiotropium is metabolized by multiple pathways (including CYP2D6 and CYP3A4) and ~74% is excreted unchanged in the urine. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of tiotropium to any clinically significant extent.,(See Summary)
720,Glecaprevir/Pibrentasvir,Tipranavir,Do Not Coadminister,NA,"Coadministration is contraindicated. Concomitant use of glecaprevir/pibrentasvir with OATP1B inhibitors, such as tipranavir, may increase the risk of ALT elevations due to a significant increase in pibrentasvir plasma concentrations caused by OATP1B1/3 inhibition. Based on interactions studies, coadministration of glecaprevir/pibrentasvir with ritonavir-boosted HIV protease inhibitors is not recommended.",(See Summary)
721,Glecaprevir/Pibrentasvir,Tizanidine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tizanidine is metabolised by CYP1A2 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP1A2 and is unlikely to affect the exposure of tizanidine to any clinically significant extent.,(See Summary)
722,Glecaprevir/Pibrentasvir,Tolbutamide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tolbutamide is metabolised by CYP2C9 and to a lesser extent by CYP2C8 and CYP2C19; these pathways are not expected to be affected by glecaprevir/pibrentasvir.,"Drug-drug interaction studies were performed with tolbutamide and showed no clinically significant interactions with Maviret.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.No dose adjustment is required when Mavyret is coadministered with tolbutamide.Mavyret Prescribing Information, AbbVie Inc., June 2019."
723,Glecaprevir/Pibrentasvir,Tolterodine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tolterodine is metabolised by CYP2D6 or by CYP3A4 in individuals who are poor metabolisers of CYP2D6 substrates. CYP2D6 is not expected to be affected by glecaprevir/pibrentasvir and glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of tolterodine to any clinically significant extent.,(See Summary)
724,Glecaprevir/Pibrentasvir,Topiramate,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Topiramate is mainly eliminated by renal elimination in unchanged form (up to 60% of the dose) and partly by oxidation.,(See Summary)
725,Glecaprevir/Pibrentasvir,Torasemide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Torasemide is metabolized by CYP2C8 and CYP2C9 which are not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
726,Glecaprevir/Pibrentasvir,Tramadol,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tramadol is metabolised by CYP3A4 and CYP2D6 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of tramadol to any clinically significant extent.,(See Summary)
727,Glecaprevir/Pibrentasvir,Trandolapril,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trandolapril is metabolised by esterases to trandolaprilat and then by glucuronidation. Note, dose modification may be required in patients with hepatic impairment.",(See Summary)
728,Glecaprevir/Pibrentasvir,Tranexamic Acid,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as tranexamic acid is mainly cleared by glomerular filtration.,(See Summary)
729,Glecaprevir/Pibrentasvir,Trazodone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trazodone is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of trazodone to any clinically significant extent.,(See Summary)
730,Glecaprevir/Pibrentasvir,Treprostinil,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Treprostinil is mainly metabolized by CYP2C8 and to a lesser extent by CYP2C9, neither of which are affected by glecaprevir/pibrentasvir.",(See Summary)
731,Glecaprevir/Pibrentasvir,Triamcinolone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Triamcinolone is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of triamcinolone to any clinically significant extent.,(See Summary)
732,Glecaprevir/Pibrentasvir,Triazolam,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Triazolam is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of triazolam to any clinically significant extent.,(See Summary)
733,Glecaprevir/Pibrentasvir,Trifluoperazine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. There are limited data on the metabolism of trifluoperazine, though animal studies have shown little affinity for CYP enzymes.",(See Summary)
734,Glecaprevir/Pibrentasvir,Trimebutine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trimebutine does not appear to be metabolised by CYP enzymes and there are no data on involvement of transporters.,(See Summary)
735,Glecaprevir/Pibrentasvir,Trimethoprim/ Sulfamethoxazole,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trimethoprim is mainly excreted in urine (40-60%) with some evidence that it may be a substrate and inhibitor of CYP2C8. Sulphamethoxazole is mainly excreted in urine.,(See Summary)
736,Glecaprevir/Pibrentasvir,Trimipramine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trimipramine is metabolised by CYP2D6 which is not expected to be affected by glecaprevir/pibrentasvir. [Note, the European SmPC for trimipramine contraindicates the use of trimipramine in severe liver disease; the US Prescribing Information recommends caution in impaired liver function.]",(See Summary)
737,Glecaprevir/Pibrentasvir,Troleandomycin,Do Not Coadminister,NA,"Coadministration is not recommended. Concomitant use of glecaprevir/pibrentasvir with OATP1B inhibitors, such as troleandomycin, may increase the risk of ALT elevations due to a significant increase in pibrentasvir plasma concentrations caused by OATP1B1/3 inhibition.",(See Summary)
738,Glecaprevir/Pibrentasvir,Turmeric (curcumin),No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro data show turmeric may inhibit CYP3A4/P-gp, however, subsequent in vivo data indicate short term use is unlikely to result in clinically relevant interactions.",(See Summary)
739,Glecaprevir/Pibrentasvir,Ursodeoxycholic acid,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glecaprevir and pibrentasvir are metabolized by CYP3A4 and are substrates of P-gp and/or BCRP. Ursodeoxycholic acid is conjugated with glycine or taurine in the liver and secreted into bile. In vitro studies suggest ursodeoxycholic acid is a CYP3A inducer; however, this does not appear to be clinically relevant. [Note: the Mavyret prescribing information contraindicates its use in patients with severe hepatic impairment.]",(See Summary)
740,Glecaprevir/Pibrentasvir,Valaciclovir,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and elimination a clinically significant interaction is unlikely. Valaciclovir is eliminated renally (as aciclovir) by glomerular filtration. It is a substrate for OAT3 which is not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
741,Glecaprevir/Pibrentasvir,Valerian,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as valerian has no significant effect on CYP enzymes.,(See Summary)
742,Glecaprevir/Pibrentasvir,Valproate,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Valproate is mainly metabolised by glucuronidation with CYP mediated metabolism being relatively minor; these pathways are not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
743,Glecaprevir/Pibrentasvir,Valsartan,No Interaction Expected,NA,Coadministration of glecaprevir/pibrentasvir and valsartan increased valsartan Cmax and AUC by 36% and 31% and had no effect on glecaprevir or pibrentasvir. No dose adjustment is required when glecaprevir/pibrentasvir is coadministered with valsartan.,"Coadministration of valsartan (80 mg single dose) and glecaprevir/pibrentasvir increased valsartan Cmax and AUC by 36% and 31% due to inhibition of OATP1B1/3. No dose adjustment is required.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.No dose adjustment is required when Mavyret is coadministered with valsartan. Coadministration of valsartan (80 mg single dose) and glecaprevir/pibrentasvir (300/120 mg once daily) increased valsartan Cmax and AUC by 36% and 31% (n=12).Mavyret Prescribing Information, AbbVie Inc., June 2019.Coadministration of glecaprevir/pibrentasvir (300/120 mg once daily) and valsartan (80 mg single dose) was studied in 12 healthy subjects. Valsartan Cmax and AUC slightly increased by 36% and 31% and exposures of glecaprevir and pibrentasvir were similar (23% or less difference). No dose adjustment is required when glecaprevir/pibrentasvir are coadministered with valsartan.Drug-drug interactions between direct acting antivirals ABT-493 and ABT-530 with angiotensin II receptor blockers (losartan or valsartan). Kosloski MP, Dutta S, Jiang Q, et al. Hepatol, 2016, 64 (1, Suppl); 420A (AASLD The Liver Meeting, Abstract 854)."
744,Glecaprevir/Pibrentasvir,Vancomycin,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as vancomycin is mainly excreted in urine.,(See Summary)
745,Glecaprevir/Pibrentasvir,Vardenafil,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vardenafil is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of vardenafil to any clinically significant extent.,(See Summary)
746,Glecaprevir/Pibrentasvir,Varenicline,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as varenicline is predominantly eliminated unchanged by the kidneys.,(See Summary)
747,Glecaprevir/Pibrentasvir,Venlafaxine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Venlafaxine is metabolised by CYP3A4 and CYP2D6 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of venlafaxine to any clinically significant extent.,(See Summary)
748,Glecaprevir/Pibrentasvir,Verapamil,Potential Interaction,NA,"Coadministration has not been studied. Verapamil is metabolised by multiple CYPs including CYP3A4 and is a substrate and inhibitor of P-gp. Concentrations of verapamil may increase as glecaprevir/pibrentasvir is a weak inhibitor of CYP3A4 and an inhibitor of P-gp. Inhibition of CYP3A4 and P-gp by verapamil may also increase glecaprevir/pibrentasvir concentrations but this is unlikely to be clinically significant. Patients should be monitored for adverse effects such as hypotension, bradyarrythymias and lactic acidosis.",(See Summary)
749,Glecaprevir/Pibrentasvir,Vernakalant,No Interaction Expected,NA,Coadministration with has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vernakalant is metabolised by CYP2D6 and UGTs which are not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
750,Glecaprevir/Pibrentasvir,Vigabatrin,No Interaction Expected,NA,Coadministration has not been studied but a clinically significant interaction is unlikely as vigabatrin is not metabolised and is cleared mainly by glomerular filtration.,(See Summary)
751,Glecaprevir/Pibrentasvir,Vildagliptin,Potential Weak Interaction,NA,Coadministration with has not been studied. Vildagliptan is metabolised by hydrolysis and is a substrate of P-gp. Concentrations of vildagliptin may increase due to inhibition of P-gp by glecaprevir/pibrentasvir. The clinical significance is unknown and monitoring of blood glucose and for other adverse effects may be required.,(See Summary)
752,Glecaprevir/Pibrentasvir,Vinblastine,Do Not Coadminister,NA,Coadministration has not been studied and is not recommended. Vinblastine is a substrate of P-gp and concentrations may increase due to inhibition of P-gp by glecaprevir/pibrentasvir. This may lead to severe adverse effects.,(See Summary)
753,Glecaprevir/Pibrentasvir,Vincristine,Do Not Coadminister,NA,Coadministration has not been studied and is not recommended. Vincristine is a substrate of P-gp and concentrations may increase due to inhibition of P-gp by glecaprevir/pibrentasvir. This may lead to severe adverse effects.,(See Summary)
754,Glecaprevir/Pibrentasvir,Vinorelbine,Potential Interaction,NA,"Coadministration has not been studied. Vinorelbine is a substrate of P-gp and concentrations may increase due to inhibition of P-gp by glecaprevir/pibrentasvir. Use with caution and monitor closely for toxicity as increased concentrations may increase the risk and severity of autonomic and peripheral neuropathy, and of myelosuppression.",(See Summary)
755,Glecaprevir/Pibrentasvir,Vitamin E,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as vitamin E is minimally metabolised by the liver.,(See Summary)
756,Glecaprevir/Pibrentasvir,Voriconazole,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Voriconazole is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of voriconazole to any clinically significant extent.,(See Summary)
757,Glecaprevir/Pibrentasvir,Vortioxetine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vortioexetine is primarily metabolised by CYP2D6, with minor involvement from CYP3A4. CYP2D6 is not expected to be affected by glecaprevir/pibrentasvir. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of vortioxetine to any clinically significant extent.",(See Summary)
758,Glecaprevir/Pibrentasvir,Warfarin,Potential Interaction,NA,"Coadministration has not been studied. Warfarin is a substrate of CYP2C9 and CYP1A2. Glecaprevir/pibrentasvir is a mild inhibitor of CYP1A and is unlikely to affect the exposure of warfarin to any clinically significant extent. However, close monitoring of INR is recommended as this may change as a result of improved liver function.","Coadministration has not been studied. As liver function may change during treatment with Maviret, a close monitoring of International Normalised Ratio (INR) values is recommended with vitamin K antagonists.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Fluctuations in INR values may occur in patients receiving warfarin concomitant with HCV treatment, including treatment with MAVYRET. If MAVYRET is coadministered with warfarin, close monitoring of INR values is recommended during treatment and post-treatment follow-up.Mavyret Prescribing Information, AbbVie Inc., June 2019."
759,Glecaprevir/Pibrentasvir,Xipamide,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Approximately 90% of xipamide is excreted in the urine, mainly as unchanged drug (~50%) and glucuronides (30%).",(See Summary)
760,Glecaprevir/Pibrentasvir,Zaleplon,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zaleplon is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of zaleplon to any clinically significant extent.,(See Summary)
761,Glecaprevir/Pibrentasvir,Zanamivir,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zanamivir is not extensively metabolised and only a small amount of the orally inhaled drug is systematically absorbed. Absorbed zanamivir is excreted unchanged in the urine whereas unabsorbed zanamivir is excreted in the faeces.,(See Summary)
762,Glecaprevir/Pibrentasvir,Zidovudine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zidovudine is metabolised by UGTs 2B7 and 1A9 which are not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
763,Glecaprevir/Pibrentasvir,Ziprasidone,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ziprasidone is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of ziprasidone to any clinically significant extent.,(See Summary)
764,Glecaprevir/Pibrentasvir,Zofenopril,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zofenopril is a prodrug metabolised in the liver by a non-CYP mechanism to zofenoprilat, the active metabolite.",(See Summary)
765,Glecaprevir/Pibrentasvir,Zolmitriptan,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolmitriptan metabolism is complex with CYP1A2 involvement but this enzyme is not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
766,Glecaprevir/Pibrentasvir,Zolpidem,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zolpidem is metabolised by CYP3A4 and to a lesser extent by CYP2C9 and CYP1A2. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of zolpidem to any clinically significant extent.,(See Summary)
767,Glecaprevir/Pibrentasvir,Zonisamide,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Inhibition of P-gp by zonisamide is unlikely to have a clinically significant effect on glecaprevir/pibrentasvir due to the large therapeutic safety margins.,(See Summary)
768,Glecaprevir/Pibrentasvir,Zopiclone,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zopiclone is metabolised by CYP3A4 but glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect this pathway to any clinically significant extent. [Note, elimination of zopiclone may be reduced in patients with hepatic dysfunction and a lower dose of zopiclone nightly is recommended for these patients. Zopiclone is contraindicated in patients with severe hepatic insufficiency.]",(See Summary)
769,Glecaprevir/Pibrentasvir,Zuclopentixol,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zuclopentixol is predominantly metabolised by CYP2D6 which is not expected to be affected by glecaprevir/pibrentasvir.,(See Summary)
770,Glecaprevir/Pibrentasvir,Drospirenone/ethinylestradiol (COC),Do Not Coadminister,NA,"Coadministration with glecaprevir/pibrentasvir and ethinylestradiol is contraindicated. In interaction studies evaluating ethinylestradiol and glecaprevir/pibrentasvir in healthy female subjects, ALT elevations were observed in some subjects during coadministration. Based on increased ALT levels, coadministration of ethinylestradiol containing hormonal contraceptives or hormone replacement therapies is not recommended.","Co-administration of Maviret with ethinyloestradiol-containing products is contraindicated due to the risk of ALT elevations. Coadministration of ethinyloestradiol/norgestimate (35/250 µg once daily) and glecaprevir/pibrentasvir increased ethinyloestradiol Cmax, AUC and Cmin by 31%, 28% and 38%, respectively. There was no change in norelgestromin Cmax, but AUC and Cmin increased by 44% and 45%. Cmax, AUC and Cmin of norgestrel increased by 54%, 63% and 75%, respectively. Coadministration of ethinyloestradiol/levonorgestrel (20/100 µg once daily) and glecaprevir/pibrentasvir increased ethinyloestradiol Cmax, AUC and Cmin by 30%, 40% and 56%, respectively. Cmax, AUC and Cmin of norgestrel increased by 37%, 68% and 77%, respectively.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Coadministration of Mavyret may increase the risk of ALT elevations and is not recommended. Coadministration had no effect on glecaprevir or pibrentasvir concentrations but may increase the risk of ALT elevations and is not recommended. Coadministration of ethinyl estradiol/norgestimate (35/250 µg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 11 subjects. Ethinyl estradiol Cmax, AUC and Cmin increased by 31%, 28% and 38%, respectively. Cmax, AUC and Cmin of norgestrel increased by 54%, 63% and 75%, respectively. There was no change in norelgestromin Cmax, but AUC and Cmin increased by 44% and 45%. Coadministration of ethinyl estradiol/levonorgestrel (20/100 µg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 12 subjects. Ethinyl estradiol Cmax, AUC and Cmin increased by 30%, 40% and 56%, respectively. Cmax, AUC and Cmin of norgestrel increased by 37%, 68% and 77%, respectively.Mavyret Prescribing Information, AbbVie Inc., June 2019."
771,Glecaprevir/Pibrentasvir,Dydrogesterone/estradiol (HRT) ,Potential Weak Interaction,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Estradiol is metabolized by CYP3A4 and CYP1A2 and is glucuronidated. Dydrogesterone is metabolized to dihydrodydrogesterone (possibly via CYP3A4). Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect these pathways to any clinically significant extent. However, glecaprevir/pibrentasvir is an inhibitor of OATP and in vitro studies have shown estradiol to be a high-affinity OATP substrate: the clinical significance of this is unknown. An OATP-mediated interaction is possible, which may increase exposure of estradiol to a limited extent. This is unlikely to be clinically relevant with short durations of treatment for hepatitis C.",(See Summary)
772,Glecaprevir/Pibrentasvir,Mesna,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely. In vitro data suggest that mesna is a substrate of the OAT1, OAT3 and OAT4 renal transporters. Glecaprevir/pibrentasvir does not interact with these transporters. ",(See Summary)
773,Glecaprevir/Pibrentasvir,Medroxyprogesterone/conjugated estrogens (HRT),No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Medroxyprogesterone is metabolized by CYP3A4. The metabolism of conjugated estrogens is complex and involves CYP3A4 isoenzymes and glucuronidation in the liver. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect these pathways to any clinically significant extent. However, glecaprevir/pibrentasvir is an inhibitor of OATP and in vitro studies have shown conjugated estrogens are transported via OATP: the clinical significance of this is unknown. An OATP-mediated interaction is possible, which may increase exposure of conjugated estrogens to a limited extent. This is unlikely to be clinically relevant with short durations of treatment for hepatitis C.",(See Summary)
774,Glecaprevir/Pibrentasvir,Medroxyprogesterone/estradiol (HRT),No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Estradiol is metabolized by CYP3A4 and CYP1A2 and is glucuronidated. Medroxyprogesterone is metabolized by CYP3A4. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect these pathways to any clinically significant extent. However, glecaprevir/pibrentasvir is an inhibitor of OATP and in vitro studies have shown estradiol to be a high-affinity OATP substrate: the clinical significance of this is unknown. An OATP-mediated interaction is possible, which may increase exposure of estradiol to a limited extent. This is unlikely to be clinically relevant with short durations of treatment for hepatitis C.",(See Summary)
775,Glecaprevir/Pibrentasvir,Norelgestromin/ethinylestradiol (patch),Do Not Coadminister,NA,"Coadministration with glecaprevir/pibrentasvir and ethinylestradiol is contraindicated. In interaction studies evaluating ethinylestradiol and glecaprevir/pibrentasvir in healthy female subjects, ALT elevations were observed in some subjects during coadministration. Based on increased ALT levels, coadministration of ethinylestradiol containing hormonal contraceptives or hormone replacement therapies is not recommended.","Co-administration of Maviret with ethinyloestradiol-containing products is contraindicated due to the risk of ALT elevations. Coadministration of ethinyloestradiol/norgestimate (35/250 µg once daily) and glecaprevir/pibrentasvir increased ethinyloestradiol Cmax, AUC and Cmin by 31%, 28% and 38%, respectively. There was no change in norelgestromin Cmax, but AUC and Cmin increased by 44% and 45%. Cmax, AUC and Cmin of norgestrel increased by 54%, 63% and 75%, respectively. Coadministration of ethinyloestradiol/levonorgestrel (20/100 µg once daily) and glecaprevir/pibrentasvir increased ethinyloestradiol Cmax, AUC and Cmin by 30%, 40% and 56%, respectively. Cmax, AUC and Cmin of norgestrel increased by 37%, 68% and 77%, respectively.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Coadministration of Mavyret may increase the risk of ALT elevations and is not recommended. Coadministration had no effect on glecaprevir or pibrentasvir concentrations but may increase the risk of ALT elevations and is not recommended. Coadministration of ethinyl estradiol/norgestimate (35/250 µg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 11 subjects. Ethinyl estradiol Cmax, AUC and Cmin increased by 31%, 28% and 38%, respectively. Cmax, AUC and Cmin of norgestrel increased by 54%, 63% and 75%, respectively. There was no change in norelgestromin Cmax, but AUC and Cmin increased by 44% and 45%. Coadministration of ethinyl estradiol/levonorgestrel (20/100 µg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 12 subjects. Ethinyl estradiol Cmax, AUC and Cmin increased by 30%, 40% and 56%, respectively. Cmax, AUC and Cmin of norgestrel increased by 37%, 68% and 77%, respectively.Mavyret Prescribing Information, AbbVie Inc., June 2019."
776,Glecaprevir/Pibrentasvir,Norethisterone (Norethindrone)/ethinylestradiol (COC),Do Not Coadminister,NA,"Coadministration with glecaprevir/pibrentasvir and ethinylestradiol is contraindicated. In interaction studies evaluating ethinylestradiol and glecaprevir/pibrentasvir in healthy female subjects, ALT elevations were observed in some subjects during coadministration. Based on increased ALT levels, coadministration of ethinylestradiol containing hormonal contraceptives or hormone replacement therapies is not recommended.","Co-administration of Maviret with ethinyloestradiol-containing products is contraindicated due to the risk of ALT elevations. Coadministration of ethinyloestradiol/norgestimate (35/250 µg once daily) and glecaprevir/pibrentasvir increased ethinyloestradiol Cmax, AUC and Cmin by 31%, 28% and 38%, respectively. There was no change in norelgestromin Cmax, but AUC and Cmin increased by 44% and 45%. Cmax, AUC and Cmin of norgestrel increased by 54%, 63% and 75%, respectively. Coadministration of ethinyloestradiol/levonorgestrel (20/100 µg once daily) and glecaprevir/pibrentasvir increased ethinyloestradiol Cmax, AUC and Cmin by 30%, 40% and 56%, respectively. Cmax, AUC and Cmin of norgestrel increased by 37%, 68% and 77%, respectively.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Coadministration of Mavyret may increase the risk of ALT elevations and is not recommended. Coadministration had no effect on glecaprevir or pibrentasvir concentrations but may increase the risk of ALT elevations and is not recommended. Coadministration of ethinyl estradiol/norgestimate (35/250 µg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 11 subjects. Ethinyl estradiol Cmax, AUC and Cmin increased by 31%, 28% and 38%, respectively. Cmax, AUC and Cmin of norgestrel increased by 54%, 63% and 75%, respectively. There was no change in norelgestromin Cmax, but AUC and Cmin increased by 44% and 45%. Coadministration of ethinyl estradiol/levonorgestrel (20/100 µg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 12 subjects. Ethinyl estradiol Cmax, AUC and Cmin increased by 30%, 40% and 56%, respectively. Cmax, AUC and Cmin of norgestrel increased by 37%, 68% and 77%, respectively.Mavyret Prescribing Information, AbbVie Inc., June 2019."
777,Glecaprevir/Pibrentasvir,Norgestimate/ethinylestradiol (COC),Do Not Coadminister,NA,"Coadministration with glecaprevir/pibrentasvir and ethinylestradiol is contraindicated. In interaction studies evaluating ethinylestradiol and glecaprevir/pibrentasvir in healthy female subjects, ALT elevations were observed in some subjects during coadministration. Based on increased ALT levels, coadministration of ethinylestradiol containing hormonal contraceptives or hormone replacement therapies is not recommended.","Co-administration of Maviret with ethinyloestradiol-containing products is contraindicated due to the risk of ALT elevations. Coadministration of ethinyloestradiol/norgestimate (35/250 µg once daily) and glecaprevir/pibrentasvir increased ethinyloestradiol Cmax, AUC and Cmin by 31%, 28% and 38%, respectively. There was no change in norelgestromin Cmax, but AUC and Cmin increased by 44% and 45%. Cmax, AUC and Cmin of norgestrel increased by 54%, 63% and 75%, respectively. Coadministration of ethinyloestradiol/levonorgestrel (20/100 µg once daily) and glecaprevir/pibrentasvir increased ethinyloestradiol Cmax, AUC and Cmin by 30%, 40% and 56%, respectively. Cmax, AUC and Cmin of norgestrel increased by 37%, 68% and 77%, respectively.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Coadministration of Mavyret may increase the risk of ALT elevations and is not recommended. Coadministration had no effect on glecaprevir or pibrentasvir concentrations but may increase the risk of ALT elevations and is not recommended. Coadministration of ethinyl estradiol/norgestimate (35/250 µg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 11 subjects. Ethinyl estradiol Cmax, AUC and Cmin increased by 31%, 28% and 38%, respectively. Cmax, AUC and Cmin of norgestrel increased by 54%, 63% and 75%, respectively. There was no change in norelgestromin Cmax, but AUC and Cmin increased by 44% and 45%. Coadministration of ethinyl estradiol/levonorgestrel (20/100 µg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 12 subjects. Ethinyl estradiol Cmax, AUC and Cmin increased by 30%, 40% and 56%, respectively. Cmax, AUC and Cmin of norgestrel increased by 37%, 68% and 77%, respectively.Mavyret Prescribing Information, AbbVie Inc., June 2019."
778,Glecaprevir/Pibrentasvir,Norethisterone (Norethindrone)/mestranol (COC) ,Do Not Coadminister,NA,"Mestranol is rapidly and almost completely converted to ethinylestradiol by CYP2C9. Coadministration with glecaprevir/pibrentasvir and ethinylestradiol is contraindicated. In interaction studies evaluating ethinylestradiol and glecaprevir/pibrentasvir in healthy female subjects, ALT elevations were observed in some subjects during coadministration. Based on increased ALT levels, coadministration of ethinylestradiol containing hormonal contraceptives or hormone replacement therapies is not recommended.","Co-administration of Maviret with ethinyloestradiol-containing products is contraindicated due to the risk of ALT elevations. Coadministration of ethinyloestradiol/norgestimate (35/250 µg once daily) and glecaprevir/pibrentasvir increased ethinyloestradiol Cmax, AUC and Cmin by 31%, 28% and 38%, respectively. There was no change in norelgestromin Cmax, but AUC and Cmin increased by 44% and 45%. Cmax, AUC and Cmin of norgestrel increased by 54%, 63% and 75%, respectively. Coadministration of ethinyloestradiol/levonorgestrel (20/100 µg once daily) and glecaprevir/pibrentasvir increased ethinyloestradiol Cmax, AUC and Cmin by 30%, 40% and 56%, respectively. Cmax, AUC and Cmin of norgestrel increased by 37%, 68% and 77%, respectively.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Coadministration of Mavyret may increase the risk of ALT elevations and is not recommended. Coadministration had no effect on glecaprevir or pibrentasvir concentrations but may increase the risk of ALT elevations and is not recommended. Coadministration of ethinyl estradiol/norgestimate (35/250 µg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 11 subjects. Ethinyl estradiol Cmax, AUC and Cmin increased by 31%, 28% and 38%, respectively. Cmax, AUC and Cmin of norgestrel increased by 54%, 63% and 75%, respectively. There was no change in norelgestromin Cmax, but AUC and Cmin increased by 44% and 45%. Coadministration of ethinyl estradiol/levonorgestrel (20/100 µg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 12 subjects. Ethinyl estradiol Cmax, AUC and Cmin increased by 30%, 40% and 56%, respectively. Cmax, AUC and Cmin of norgestrel increased by 37%, 68% and 77%, respectively.Mavyret Prescribing Information, AbbVie Inc., June 2019."
779,Glecaprevir/Pibrentasvir,Norethisterone (Norethindrone) (POP),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely and contraceptive efficacy is unlikely to be affected. Norethisterone is metabolised by CYP3A4. Glecaprevir is only a weak inhibitor of CYP3A4 and is unlikely to affect these pathways to any clinically significant extent.,(See Summary)
780,Glecaprevir/Pibrentasvir,Norethisterone (Norethindrone) (depot injection),No Interaction Expected,NA,Coadministration with norethisterone as a depot injection has not been studied but based on metabolism and clearance a clinically significant interaction is not anticipated and contraceptive efficacy is unlikely to be affected. Norethisterone is metabolised by CYP3A4. Glecaprevir is only a weak inhibitor of CYP3A4 and is unlikely to affect these pathways to any clinically significant extent.,(See Summary)
781,Glecaprevir/Pibrentasvir,Norethisterone (Norethindrone)/estradiol (HRT),No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Norethisterone is metabolised by CYP3A4. Estradiol is metabolized by CYP3A4 and CYP1A2 and is glucuronidated. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect these pathways to any clinically significant extent. However, glecaprevir/pibrentasvir is an inhibitor of OATP and in vitro studies have shown estradiol to be a high-affinity OATP substrate: the clinical significance of this is unknown. An OATP-mediated interaction is possible, which may increase exposure of estradiol to a limited extent. This is unlikely to be clinically relevant with short durations of treatment for hepatitis C.",(See Summary)
782,Glecaprevir/Pibrentasvir,Norgestrel/ethinylestradiol (COC),Do Not Coadminister,NA,"Coadministration with glecaprevir/pibrentasvir and ethinylestradiol is contraindicated. In interaction studies evaluating ethinylestradiol and glecaprevir/pibrentasvir in healthy female subjects, ALT elevations were observed in some subjects during coadministration. Based on increased ALT levels, coadministration of ethinylestradiol containing hormonal contraceptives or hormone replacement therapies is not recommended.","Co-administration of Maviret with ethinyloestradiol-containing products is contraindicated due to the risk of ALT elevations. Coadministration of ethinyloestradiol/norgestimate (35/250 µg once daily) and glecaprevir/pibrentasvir increased ethinyloestradiol Cmax, AUC and Cmin by 31%, 28% and 38%, respectively. There was no change in norelgestromin Cmax, but AUC and Cmin increased by 44% and 45%. Cmax, AUC and Cmin of norgestrel increased by 54%, 63% and 75%, respectively. Coadministration of ethinyloestradiol/levonorgestrel (20/100 µg once daily) and glecaprevir/pibrentasvir increased ethinyloestradiol Cmax, AUC and Cmin by 30%, 40% and 56%, respectively. Cmax, AUC and Cmin of norgestrel increased by 37%, 68% and 77%, respectively.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Coadministration of Mavyret may increase the risk of ALT elevations and is not recommended. Coadministration had no effect on glecaprevir or pibrentasvir concentrations but may increase the risk of ALT elevations and is not recommended. Coadministration of ethinyl estradiol/norgestimate (35/250 µg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 11 subjects. Ethinyl estradiol Cmax, AUC and Cmin increased by 31%, 28% and 38%, respectively. Cmax, AUC and Cmin of norgestrel increased by 54%, 63% and 75%, respectively. There was no change in norelgestromin Cmax, but AUC and Cmin increased by 44% and 45%. Coadministration of ethinyl estradiol/levonorgestrel (20/100 µg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 12 subjects. Ethinyl estradiol Cmax, AUC and Cmin increased by 30%, 40% and 56%, respectively. Cmax, AUC and Cmin of norgestrel increased by 37%, 68% and 77%, respectively.Mavyret Prescribing Information, AbbVie Inc., June 2019."
783,Glecaprevir/Pibrentasvir,Conjugated estrogens (HRT),No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of conjugated estrogens is complex and involves CYP3A4 isoenzymes and glucuronidation in the liver. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect these pathways to any clinically significant extent. However, glecaprevir/pibrentasvir is an inhibitor of OATP and in vitro studies have shown conjugated estrogens are transported via OATP: the clinical significance of this is unknown. An OATP-mediated interaction is possible, which may increase exposure of conjugated estrogens to a limited extent. This is unlikely to be clinically relevant with short durations of treatment for hepatitis C.",(See Summary)
784,Glecaprevir/Pibrentasvir,Norgestrel/conjugated estrogens (HRT),No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of conjugated estrogens is complex and involves CYP3A4 isoenzymes and glucuronidation in the liver. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect these pathways to any clinically significant extent. However, glecaprevir/pibrentasvir is an inhibitor of OATP and in vitro studies have shown conjugated estrogens are transported via OATP: the clinical significance of this is unknown. An OATP-mediated interaction is possible, which may increase exposure of conjugated estrogens to a limited extent. This is unlikely to be clinically relevant with short durations of treatment for hepatitis C.",(See Summary)
785,Glecaprevir/Pibrentasvir,Influenza vaccine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. There is some evidence that vaccines may downregulate CYP3A4 but the clinical impact of this is unknown. No a priori dose adjustment of glecaprevir/pibrentasvir is recommended.,(See Summary)
786,Glecaprevir/Pibrentasvir,Adalimumab,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Adalimumab is a monoclonal IgG antibody. Elimination is similar to endogenous IgG and occurs primarily via proteolytic catabolism throughout the body. Glecaprevir/pibrentasvir is not expected to interact with this pathway.,(See Summary)
787,Glecaprevir/Pibrentasvir,Cyclophosphamide,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cyclophosphamide is activated (major pathway) to 4-hydroxycyclophosphamide by CYPs 2B6 (major), 2C9 and 3A4. Inactivation (minor, 10%) to the neurotoxic chloroacetaldehyde metabolite is performed mainly by CYP3A4. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect this pathway to any clinically significant extent.",(See Summary)
788,Glecaprevir/Pibrentasvir,Gestodene/ethinylestradiol (COC),Do Not Coadminister,NA,"Coadministration with glecaprevir/pibrentasvir and ethinylestradiol is contraindicated. In interaction  studies evaluating ethinylestradiol and glecaprevir/pibrentasvir in healthy female subjects, ALT elevations were observed in some subjects during coadministration. Based on increased ALT levels, coadministration of ethinylestradiol containing hormonal contraceptives or hormone replacement therapies is not recommended.","Co-administration of Maviret with ethinyloestradiol-containing products is contraindicated due to the risk of ALT elevations. Coadministration of ethinyloestradiol/norgestimate (35/250 µg once daily) and glecaprevir/pibrentasvir increased ethinyloestradiol Cmax, AUC and Cmin by 31%, 28% and 38%, respectively. There was no change in norelgestromin Cmax, but AUC and Cmin increased by 44% and 45%. Cmax, AUC and Cmin of norgestrel increased by 54%, 63% and 75%, respectively. Coadministration of ethinyloestradiol/levonorgestrel (20/100 µg once daily) and glecaprevir/pibrentasvir increased ethinyloestradiol Cmax, AUC and Cmin by 30%, 40% and 56%, respectively. Cmax, AUC and Cmin of norgestrel increased by 37%, 68% and 77%, respectively.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Coadministration of Mavyret may increase the risk of ALT elevations and is not recommended. Coadministration had no effect on glecaprevir or pibrentasvir concentrations but may increase the risk of ALT elevations and is not recommended. Coadministration of ethinyl estradiol/norgestimate (35/250 µg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 11 subjects. Ethinyl estradiol Cmax, AUC and Cmin increased by 31%, 28% and 38%, respectively. Cmax, AUC and Cmin of norgestrel increased by 54%, 63% and 75%, respectively. There was no change in norelgestromin Cmax, but AUC and Cmin increased by 44% and 45%. Coadministration of ethinyl estradiol/levonorgestrel (20/100 µg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 12 subjects. Ethinyl estradiol Cmax, AUC and Cmin increased by 30%, 40% and 56%, respectively. Cmax, AUC and Cmin of norgestrel increased by 37%, 68% and 77%, respectively.Mavyret Prescribing Information, AbbVie Inc., June 2019."
789,Glecaprevir/Pibrentasvir,Medroxyprogesterone (oncology),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Medroxyprogesterone is metabolized by CYP3A4. Glecaprevir is a weak inhibitor of CYP3A4 but is unlikely to affect this pathway to any clinically significant extent.,(See Summary)
790,Glecaprevir/Pibrentasvir,Cannabidiol (CBD),No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cannabidiol is mainly metabolized by CYP3A4 and CYP2C19. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect the exposure of cannabidiol to any clinically significant extent.,(See Summary)
791,Glecaprevir/Pibrentasvir,Procyclidine,No Interaction Expected,NA,Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Little is known about procyclidine metabolism but it is likely to be metabolised by P450 and glucuronidated. Glecaprevir/pibrentasvir does not interact with these pathways.,(See Summary)
792,Glecaprevir/Pibrentasvir,Clofazimine,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clofazimine is largely excreted unchanged in the faeces, both as unabsorbed drug and via biliary excretion. Glecaprevir/pibrentasvir does not interact with these pathways. [Note, the US Prescribing Information for clofazimine recommends to avoid clofazimine in patients with hepatic impairment (Child-Pugh Class A, B, and C) unless the benefit outweighs the risk.]",(See Summary)
793,Glecaprevir/Pibrentasvir,Alcohol,No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alcohol is metabolized by alcohol dehydrogenase and aldehyde dehydrogenase. Acute alcohol use inhibits CYP2E1. Chronic use may induce CYP2E1 and to a lesser extent CYP3A4 but this is unlikely to be clinically relevant. Glecaprevir/pibrentasvir does not interact with these pathways. Additionally, a study of over 15,000 veterans treated with DAAs found no association between alcohol use and SVR12, suggesting that alcohol does not affect the efficacy of DAAs.","A retrospective study of over 15,000 veterans found no association between alcohol use and SVR12 in HCV+ patients treated with sofosbuvir, ledipasvir/sofosbuvir, or ombitasvir/paritaprevir/ritonavir + dasabuvir. The authors conclude that DAA treatment should not be withheld on the basis of alcohol use.Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents. Tsui J, Williams E, Green P et al. Drug Alcohol Depend, 2016, 169:101-109."
794,Glecaprevir/Pibrentasvir,Carfentanil,Potential Interaction,NA,"Coadministration has not been studied but carfentanilconcentrations may be increased due to weak CYP3A4 inhibition byglecaprevir/pibrentasvir. The impact of weak CYP3A4 inhibition is unclear sincecarfentanil is only present at very low concentrations. However, even modestincreases of carfentanil levels may lead to an increased risk of severe toxicities,including potentially fatal respiratory depression. Since carfentanil is anextremely strong opiate, reported to be up to 10,000 times more potent thanmorphine, and multiple deaths have resulted from its use, we would advisepatients to avoid.",(See Summary)
795,Glecaprevir/Pibrentasvir,Drospirenone/estradiol (HRT),No Interaction Expected,NA,"Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Estradiol is metabolized by CYP3A4 and CYP1A2 and is glucuronidated. Drospirenone is metabolised in part by CYP3A4. Glecaprevir/pibrentasvir is only a weak inhibitor of CYP3A4 and is unlikely to affect these pathways to any clinically significant extent. However, glecaprevir/pibrentasvir is an inhibitor of OATP and in vitro studies have shown estradiol to be a high-affinity OATP substrate: the clinical significance of this is unknown. An OATP-mediated interaction is possible, which may increase exposure of estradiol to a limited extent. This is unlikely to be clinically relevant with short durations of treatment for hepatitis C.",(See Summary)
796,Glecaprevir/Pibrentasvir,Desogestrel/ethinylestradiol (COC),Do Not Coadminister,NA,"Coadministration of glecaprevir/pibrentasvir and ethinylestradiol is contraindicated. In interaction studies evaluating ethinylestradiol and glecaprevir/pibrentasvir in healthy female subjects, ALT elevations were observed in some subjects during coadministration. Based on increased ALT levels, coadministration of ethinylestradiol containing hormonal contraceptives or hormone replacement therapies is not recommended.","Co-administration of Maviret with ethinyloestradiol-containing products is contraindicated due to the risk of ALT elevations. Coadministration of ethinyloestradiol/norgestimate (35/250 µg once daily) and glecaprevir/pibrentasvir increased ethinyloestradiol Cmax, AUC and Cmin by 31%, 28% and 38%, respectively. There was no change in norelgestromin Cmax, but AUC and Cmin increased by 44% and 45%. Cmax, AUC and Cmin of norgestrel increased by 54%, 63% and 75%, respectively. Coadministration of ethinyloestradiol/levonorgestrel (20/100 µg once daily) and glecaprevir/pibrentasvir increased ethinyloestradiol Cmax, AUC and Cmin by 30%, 40% and 56%, respectively. Cmax, AUC and Cmin of norgestrel increased by 37%, 68% and 77%, respectively.Maviret Summary of Product Characteristics, AbbVie Ltd., April 2019.Coadministration of Mavyret may increase the risk of ALT elevations and is not recommended. Coadministration had no effect on glecaprevir or pibrentasvir concentrations but may increase the risk of ALT elevations and is not recommended. Coadministration of ethinyl estradiol/norgestimate (35/250 µg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 11 subjects. Ethinyl estradiol Cmax, AUC and Cmin increased by 31%, 28% and 38%, respectively. Cmax, AUC and Cmin of norgestrel increased by 54%, 63% and 75%, respectively. There was no change in norelgestromin Cmax, but AUC and Cmin increased by 44% and 45%. Coadministration of ethinyl estradiol/levonorgestrel (20/100 µg once daily) and glecaprevir/pibrentasvir (300/120 mg once daily) was studied in 12 subjects. Ethinyl estradiol Cmax, AUC and Cmin increased by 30%, 40% and 56%, respectively. Cmax, AUC and Cmin of norgestrel increased by 37%, 68% and 77%, respectively.Mavyret Prescribing Information, AbbVie Inc., June 2019."
